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Cell surface carbohydrates play a key role in cell-cell recognition, this occurs via lectin proteins 
from one cell interacting with terminal sugar molecules on another. These interactions are 
ubiquitous throughout life with roles ranging from fertilisation to bacterial invasion. However, 
the downstream effects of carbohydrate interactions are not fully understood, partly due to 
the difficulty in isolating interactions for study. Using well characterised non-toxic carbon dots 
(CDs) we developed probes towards the identification of cell surface carbohydrate profiles 
and to assess the multivalent lectin binding strength via Förster resonance energy transfer 
(FRET) between two non-toxic, fluorescent probes in solution. We developed an assay and 
probed the specific interaction of Concanavalin A (ConA) lectin in this system. 
 
Secondly, we explored the anti-cancer therapeutic potential of these glyco-carbon dots for 
improved chemotherapy drug – doxorubicin, delivery. Exploiting the enhanced permeability 
and retention (ERP) effect exhibited with nanoparticles for enhanced delivery as well as 
carbohydrate functionalisation for targeted delivery. We observe anti-cancer potential in this 
work and uncover a slow release mechanism for the delivery of doxorubicin to the site of 
action.  
 
Finally, we assessed the photothermal therapy (PTT) potential of a novel carbon dot for anti-
cancer treatment observing both cancer cell targeting and cytotoxicity. This work contributes 
to the development of non-invasive localised cancer treatments which involve a nanoparticle 
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1.1 Carbohydrates  
 
Carbohydrates are molecules defined as containing carbon, oxygen and nitrogen atoms in the formula 
Cm(H2O)n but often contain groups at different positions such as N-acetyl, carboxylic acid or sulfate in 
nature. They usually consist of a 5 or 6 carbon membered ring but can consist of only 3 carbons. The 
specific definition relates to the field and context but biochemically they are small molecule aldose or 
ketoses. They are referred to as saccharides and hence monosaccharides which form di-, oligo- and 
poly- saccharide. They are also referred to collectively as glycans and end in the suffix -ose. They exist 
as two enantiomers D- and L- which must be denoted to describe the molecule referred to1,2.  
 
1.2 Biological importance of carbohydrates  
 
1.2.1 Carbohydrates in nature 
 
Carbohydrates are a key component in cellular communication and act as the first interaction a cell 
has with its external environment. Their role is less well understood compared to proteins as the field 
of glycobiology is much newer and our understanding of their functionality is still developing3. Their 
complexity is not encoded directly in the genome, but occurs predominantly in the golgi body via 
numerous controlled steps to build complex macromolecules which play a role in protein folding, 
structure and function. Understanding glycosylation patterns and sequence to function relationship is 
much more complicated than seen in proteins4. They play a key role in immune response, disease 
pathways and pathogen mediation hence understanding the pathways they are involved in is crucial 
frontier to tackle to pave the way for new medicines5.  
 
Monosaccharides are the simplest component constituting polysaccharides. Glucose is a common 
monosaccharide which is broken down in the Krebs cycle to generate ATP. Monosaccharides have a 
complex signalling role when they are linked to form polysaccharides. A range of biologically common 
hexose monosaccharides including D-glucose, D-mannose, D-galactose, N-acetyl-D-glucosamine, N-
acetyl-D-galactosamine, L-fucose and D-glucuronic acid. Biologically important nine-carbon 
monosaccharides such as sialic acids also exist. Monosaccharides can be linked via biologically distinct 
alpha and beta linkages to produce branched or linear oligosaccharides which can have various 
covalent modifications at any of its carbon positions1. Appreciation of the potential diversity in 
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polysaccharide structure is apparent from the fact a hexasaccharide made from six distinct 
monosaccharides, linked by either an alpha or beta linage has 1 trillion possible combinations1. 
 
Carbohydrates are most commonly found as part of the extra cellular matrix (ECM) forming a 
glycocalyx which is integral to cellular health. In this structure carbohydrates are involved in a number 
of roles including acting as a protective barrier, modulating inter cellular interaction, maintaining cell 
matrix integrity and modulating cell-microbe interactions. Carbohydrates can be attached to soluble 
cytosolic proteins, commonly o-linked which is carried out in the cytosol6.  
 
Extracellular facing membrane bound polypeptides are glycosylated, and these form the basis for cell 
signalling. These glycoproteins are for the most part synthesised in the endoplasmic reticulum (ER) -
golgi pathways in Eukaryotes. These can be N- (asparagine) or O- (e.g. serine and threonine) linked. 
Before attachment to a peptide, a monosaccharide is linked to a nucleotide or lipid in an activation 
step to allow their crossing the endoplasmic reticulum (ER) or golgi membrane. Nascent polypeptide 
is synthesised directly into the ER lumen where folding is facilitated by carbohydrate attachment by 
glycosyltransferases. Once the glycopeptide is fully formed it is transported to the cis-golgi for 
carbohydrate remodelling and elaboration. It then exits the trans-golgi and is transported to and 
presented on the cell surface membrane7,8.  
 
1.2.2 Carbohydrate mediated communication in pathogens 
                           
 
Figure 1.1 Cell interactions are mediated by lectin-carbohydrate binding include inter-cellular, pathogenic, and toxin 
mediation interactions. In this figure the lectin receptor is attached to and presented on the cell membrane and binding as 
stated partners. On the cell, virus, bacteria and toxin carbohydrates (which are not presented in this figure) are attached and 




Glycans are the first line of communication between neighbouring cells, or toxins (Figure 1.1). Most 
commonly glycan binding proteins (GBPs) recognise carbohydrates and modulate cell to cell 
communication. Glycan binding proteins can be classed as lectins or glycosamineglycan-binding 
proteins.  
 
One example of carbohydrate function can be seen through their promoting the recirculation of 
lymphocytes through the bloodstream and lymphatic system. This is important for immune system 
function facilitated by L-fucose, D-mannose and fucoidan (fucose polysaccharide) carbohydrates. 
These line the post capillary venule and inhibit lymphocyte binding hence promoting circulation and 
improved chance of pathogenic encounter eliciting greater immune response. Another commonly 
referenced example is the carbohydrate mediated sperm and egg binding event9. The egg is heavily 
glycosylated existing as the zona pellucida (ZP) comprised of mainly glycosaminoglycan hyaluronan. 
The sperm surface contains O-linked hyaluronan binding proteins and cleavage proteins to navigate 
the ZP and fuse with the egg plasma membrane. Post fertilisation, the O-linked sugars are 
deglycosylated to prevent further sperm adhesion therefore conferring fertilisation by a single sperm.  
Carbohydrate recognition has been observed in certain diseases as the basis of pathogenic invasion 
of healthy cells and hence also immune response offering a good target for disease treatment. 
Examples of well-studied multivalent carbohydrate mediated pathogen invasion include Shiga toxin 
and cholera toxin diseases, FimH lectin mannose binding by E.Coli, HIV and Ebola can be bound by 
DCSIGN and DCSIGNR lectins with respective specificity, owing to their high mannose coating.10 
 
One example of viral glycan mediated infection is seen with Influenza A. The virus contains sialic 
binding haemagglutinin (HA) and sialic acid cleaving neuraminidase (NA) which work in tandem to 
mediate host cell invasion where replication can be hijacked. New viruses which have a mixture of the 
HA and NA antigenic receptors on the surface can then propagate further. Sialic acids (Sia’s) bound by 
HA include sialic acid 2,3- linked galactose (Sia𝛼-2,3Gal) and sialic acid 2,6 linked galactose (Sia𝛼-
2,6Gal) conformers. Sia𝛼-2,6Gal is the main carbohydrate of the two presented in human airways, 
hence, viruses with HA and NA which can bind terminal 2,6- linked SAs are able to infect humans. 
Avian cells present 2,3- linked sialic acid hence corresponding HA and NA can bind. Swine trachea 
presents both Sia𝛼-2,3Gal and Sia𝛼-2,6Gal hence, both influenza A strains are supported11. This 
allowed for new stains to develop which present both HA and NA types hence, avian flu became an 
epidemic in 2003, 2004 and swine flu a pandemic in 2009-2010 which had human to human 
pathogenicity. The most recent coronavirus disease 2019 (COVID-19) caused by the virus Severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), immediate animal host is currently not known, 
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finding the animal responsible could help develop a vaccine and minimise the spread of future 
outbreaks12.  
 
1.2.3 Multivalent carbohydrate binding & the cluster glycoside effect 
 
Often carbohydrate recognition occurs via the multivalent interaction between glycans and a given 
receptor as a means to enhance binding. Each individual binding events are too weak to confer 
association between carbohydrate and protein, however, when multiple binding event occur strong 
association is conferred (Figure 1.2). This is termed the cluster glycoside effect (CGE) as in nature 
carbohydrates are clustered together at the cell surface to promote multivalent binding13. Multivalent 
binding also confers selectivity. If multiple carbohydrates recognised by a particular protein are 
clustered together, they communicate a strong signal which cannot be accidental. Paradoxically, 
binding has also been observed to be diverse where one protein can bind more than one type of 
carbohydrate. For example, with the lectin Concanavalin A, binding of mannose is preferential, 
however, glucose binding also occurs. Binding affinity is based on subtle structural differences 
between carbohydrates such as the secondary carbon -OH position in this case and its implications in 
the binding pocket. Hierarchical binding confers selectivity, but also allows for binding affinity to be 
modulated.  
Figure 1.2 Multivalency is key to mediating lectin-carbohydrate interactions at the cell surface. Multivalent binding as seen 
on the right confers tighter binding between lectin and carbohydrate than the sum of the same number of individual 
interactions. Multivalent binding is defined as when both ligand and receptor exhibit multiple binding interactions. 14 
 
Binding affinity is often quantified in terms of a binding constant which is a measure of the strength 
of interaction. The binding constant can either be presented as the binding affinity (𝑘!), meaning how 
tightly a protein and carbohydrate are bound, or the dissociation constant (𝑘"), describing how likely 
the two components are to separate. They are both the reciprocal of each other and lectin affinity is 
most commonly described in terms of dissociation constant for comparison. The koff and kon are the 












Equation 1.1 Dissociation constant kd equation. L is ligand P is protein. The koff and kon are dissociation and association 
constants. Unit of kd is measured in molarity (M). 
 
In one study by Mori et al.15 the binding of Concanavalin A (ConA) to a mannotriose (3,6-Di-O-(𝛼-D-
mannopyranosyl)-D-mannopyranose) via quartz crystal microbalance (QCM) the 2:1 and 1:1 
(carbohydrate:Con A) binding stoichiometry was investigated (Figure 1.3). Carbohydrates were bound 
to the quartz microbalance and Concanavalin A was added in 10 mM HEPES buffer and allowed to 
bind. In the 1:1 ratio Concanavalin A was able to bind one terminal mannose of the mannotriose. In 
the 2:1 interaction, two terminal mannoses were bound by the same ConA protein at two different 
binding sites. The interaction was controlled by adding a galactose spacer to create the 1:1 interaction 
and no spacer in the 2:1 interaction. The 𝑘! of 2:1 stoichiometry was 10 times higher compared to the 
1:1 ratio evidencing the cluster glycoside effect.15 
 
Figure 1.3 Carbohydrate cluster glycoside effect was  measured through affinity contsants by Mori et al.15. Concanavalin A 
binding of terminal mannose of mannotriose in a 1:1 or 2:1 (carbohydrate:lectin) bound to a quartz crystal microbalance 
(QCM) via streptavidin:biotin functionalisation. The galactose terminated disaccharides act as spacers as Concanavalin A 
does not bind galactose.15  
 
Studies into the FimH lectin seen on the pili of E. coli is an interesting case where increased 
multivalency is not the basis for increased binding affinity. FimH has two domains, one which is for 
carbohydrate binding (FimHL) and the other for association with pili FimG protein (FimHP). It is known 
to bind high mannose type glycans mono- and divalently, which have a divalent (C3 and C6 linked) 
trimannoside domain. These glycans are presented on the urinary tract cell surfaces and one E. coli is 
able to exhibit up to 200 interactions to this surface. However, these individual binding interactions 
means that the E. coli is still relatively weakly bound to the urinary tract lining. The kd for divalent 
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binding to 𝛼-6Man2,  𝛼-2Man2 and 𝛼-3Man2 is 2.7 x 10-4, 7.0 x 10-5 and 2.8 x 10-5 M respectively owing 
to the fast off rate of the lectin. This allows for the E. coli to traverse the lining and imposes good 
invasiveness. Strong binding termed “catch-bonding” is induced through shear stress acting on the 
interaction. When urine is excreted the force pulls the E. coli and the FimHP domain dissociates from 
FimG, but it remains tethered. This improves the binding affinity 2000-fold and allows E. coli to evade 
removal from the urinary tract. Treatments for urinary tract infection is therefore desirable and 
targets to the FimH lectin must have better affinity than this trimannoside but importantly a slower 
off rate.16  
 
1.2.4 Concanavalin A lectin carbohydrate interactions 
 
Concanavalin A is a lectin of molecular weight 104-122 kDa isolated from Jack beans (Canaualia 
ensiformis) known to bind mannose and glucose seen to generate an immune response, agglutinating 
mannose presenting erythrocytes involved in conferring blood group types17, insulin receptor-
mediation18 and in mediating Escherichia coli pathogenesis19.  
                   
 
Figure 1.4 Concanavalin A structure with four homotetrimers which each have a binding site, circled in red. The binding of a 
terminal mannose residue is mediated by a Ca2+ ion and two glutamic acid residues.20 
  
ConA preferentially binds terminal 𝛼-D-mannose over 𝛼-D-glucose whilst 𝛼-D-galactose is used as a 
negative control experimentally as the axial 4-position hydroxyl means that it does not fit in the 
binding site.21 Concanavalin A has 4 binding sites one from each of its subunits which make up a 
homotetramer at pH 7.4, with a crystal structure determined size of 7x7x6 nm (Figure 1.4). At pH < 








ConA is known to favour polysaccharides over monosaccharides as it forms hydrogen bonds with 
carbohydrates which precede the terminal mannose both on the surface of the protein and within the 
binding site. Both branched and linear oligomannosides are preferred over monomannoside and 
evidence suggests increasingly branched oligomannosides confers tighter binding. For example, in a 
study by Munoz et al.23 dendrimeric presented mannose showed a non-linear binding affinity to ConA. 
As the generations of mannose increased so did the multivalent binding effect. Generation 1 (G1) – 3 
mannoses, G2 – 9-mannoses and G3, 27 mannoses were used in an SPR experiment and Kd was 
measured. G3 had a of 372-fold binding enhancement compared to methyl-mannose, whereas G2 has 
a 112-fold and G1 a 13.8-fold improvement This fits with the notion of greater clustering conferring 




Figure 1.5 Lectin glycodendrimer shows improved binding conferring the cluster glycoside effect, Munoz et al.23 
 
A multivalent effect is seen for ConA when the C-3-position hydroxyl is free to hydrogen bond with 
the protein, which is linked by a C-6-linkage to the preceding mannose which also has another 
mannose at the C-3-position creating a mannotriose (3,6-Di-O-(𝛼-D-mannopyranosyl)-D-
mannopyranose) as shown in figure 1.6. This was shown through a study with variable branched 
glycoproteins isolated from hen egg ovalbumin in a frontal affinity chromatography (FAC) experiment. 
Kd for this trimannoside was 0.24 𝜇M, when a mannose was linked at the C-3-position of the terminal 
C-6-linked mannose the Kd increased to 35 𝜇M. Also, in this study it was seen that introducing a C-2-
linked mannose on the C-3-position hydroxyl of the C-6-linked mannose promotes tighter binding 
likely by having additional hydrogen bonding with the protein. Kd decreased from 0.2 𝜇M to 0.029 
𝜇M.21 Hence, branching such as at the C-2-position of the terminal mannose induces tighter binding 
over linear mannosides. One final observation saw that modification of the C4 position of the C-3-






Figure 1.6 Concanavalin A binding of trimannose (3,6-Di-O-(𝛼-D-mannopyranosyl)-D-mannopyranose). Red indicates the -OH 
which should be accessible for ConA binding. Certain other changes either improve, reduce or remove binding. Changes may 
be far away from the binding site and still impact binding dramatically due to hydrogen bonding effects with Concanavalin.21  
 
Concanavalin A is known to exhibit weak hydrophobic affinity seem through binding of lipid vesicles. 
This fits with the role of Con A, a cell surface glycan bind protein, closely proximate to the lipid plasma 
membrane. These lipid interactions are weak, for example 7 x 102 M-1 between ConA and B-
indoleacetic acid a lipid analogous to tryptophan which is found in plants24.  
 
3,6-Di-O-(𝛼-D-mannopyranosyl)-D-mannopyranose is common to all glycopeptides and composes the 
first branching step after two sequential N-acetylglucosamines which are asparagine linked. This motif 
is known to be bound tightly by Concanavalin A and hence a good experimental control. From nature, 
structures with this trisaccharide have been observed to bind tightly with Concanavalin A including 
the branched mannose 9-mer called “high mannose” found in the endoplasmic reticulum, and other 
hybrid N-glycans composed of differing monosaccharides25. This 9-mer is important for protecting 
proteins from degradation and signalling a protein is ready for the next step in the glycosylation 
pathway26. If not added to a protein post translation, then the protein will not fold correctly27. Elevated 
levels of high-mannose have also been observed in breast cancer28. Therefore, investigating high-






1.2.5 Carbohydrates in Cancer 
 
During the progression of cancer, certain pathways are up and down regulated to allow the cancerous 
cell to grow, reproduce, form a tumour and become malignant and metastasise. This involves a lot of 
protein synthesis and elevated metabolic turnover which in turn impacts the glycosylation pathways. 
These glycosylation changes are reflected on the cell surface through the overall carbohydrate profile 
depending on the cell type and stage of tumour progression.  
 
Understanding the differences between cancer cells and healthy cells as well as how the glycocalyx 
profile changes with each stage of cancer progression is important for cancer diagnosis and treatment. 
Glycosylation changes in cancer can take the form of structure truncation, elongation and also 
structure modification. Also, certain epitopes may be over presented on the cell surface which for 
example may play a role in tumour endothelial escape and metastasis. A well-known example is that 
of the overexpression of terminal sialic acid on tumour cells in a number of cancers which was first 
observed through wheat germ agglutinin (WGA) agglutinating on the tumour. Sialic acids monitoring 
(down to picogram amounts) is carried out clinically during cancer treatments. Tumours benefit from 
having a high density of negatively charged sialic acids on their surface as this causes inter-cellular 
repulsion and promotes metastasis. Sialic acids are bound by siglecs and selectins which normally 
mediate immune response hence, hyper sialylation helps evade immune recognition.28  
 
Another example In this context can be found with mucin glycoproteins. These are heavily 
glycosylated glycoproteins which are found on mucosal surfaces and modified in cancer. The 
oligosaccharides are decorated with sialic acid and are able to traverse the epithelial cell layer and 
enter the blood vessel below. These changes can be detected using monoclonal antibodies and used 
as a diagnosis. Overexpression of Lewisx and Lewisa and sialyl Lewisx and sialyl Lewisa have also been 
observed on cancerous cells and have been linked to metastasis, which is mediated through binding 
endogenous selectins.29 In the case of N-acetyllactosamine the increase in sialic acid is 𝛼-2,6-linked 
rather than	𝛼-2,3-linked which experimentally can be distinguished by the Sambucus Nigra Lectin 







1.3 Synthetic platforms to mimic glycan presentation 
1.3.1 Glycoarrays  
 
Glycoarrays consist of a support to which carbohydrates can be covalently or electrostatically bound 
for subsequent investigation. Using arrays to immobilise either the lectin or carbohydrate offers 
certain advantages for measuring binding affinity such as high throughput, low material requirements, 
streamlining, repeatability and potential for commercialisation. They allow for a number of analysis 
techniques to be conducted to measure lectin-glycan interactions. Methods for conjugation are varied 
depending on the carbohydrate and linker involved, but most examples reported include click 
chemistry (e.g. Cu(I)-catalysed cycloaddition between an azido and alkyne), amide coupling, ionic 
interaction(with poly-L-lysine), fluorous based coupling and DNA-DNA based immobilisation30 (Figure 
1.7).   
 
Considering the multivalent nature of lectin-carbohydrate binding, the spatial organisation is an 
important consideration when developing carbohydrate arrays. Designing arrays with defined 
organisation allows for the investigation of multivalency as seen in the work by Mori et al.15 where 
they controlled the density of 3,6-Di-O-(α-D-mannopyranosyl)-1-amino-1-deoxy-D-mannopyranose 
with spacers to achieve either 1:1 or 2:1 protein-carbohydrate valency as seen in 2.3.1. 
 
By confining carbohydrates to a surface, a number of techniques can be used to probe them such as 
mass spectrometry, surface plasmon resonance, or quartz crystal microbalance (QCM). Furthermore, 
binding experiments can be conducted with a range of complimentary partners such as lectins, 
antibodies or pathogens. This is useful for the discovery of novel physical information and interactions 
which are not isolatable in solution.  
 
However, one major drawback of plate assays results from the fact they are 2 dimensional, whereas 
in nature lectin-carbohydrate interactions often occur in 3 dimensions. Concanavalin A for example 
has 4 binding sites which are arranged tetragonally to each other, hence, to utilise all binding sites it 
would need to encounter carbohydrates in 3 dimensions. The development of nanoparticles as glyco 
platforms overcomes this issue and provides glycan presentation that is more similar to that seen in 
nature. This is achieved through the fact nanoparticles provide a multivalent nanoscale 3D 
arrangement. The nanoprobes potentially mimic pathogens in terms of curvature and size providing 
a good model for multivalent pathogenic invasion mechanisms. Being on the sub-cellular size regime, 
nanoparticles are able to assimilate well offering potential as a drug delivery or diagnostic tool. They 
 26 
 
also offer programmable nanoscale functionality, presenting multiple types of carbohydrate 
multivalently in a spatially controlled way.  
 
 
1.3.2 Nanoparticle glycan presentation 
 
Nanoscale multivalent glyconanoparticles have been synthesised to mimic carbohydrate clustered 
presentation in 3D with the aim to develop synthetic platforms that enable the study of multivalent 
carbohydrate/protein interactions. A range of materials and methods have been explored as 
multivalent platforms that mimic glycan presentation in nature and that are generally non-toxic. In 
some instances, the platforms introduce novel properties such magnetism or incorporate a 
conjugated drug for therapeutic effects. In general, designing these particles from the bottom up 
allows for tighter control of the glycan presentation which allows for study of the principles 






























Figure 1.7 Glycoarrays involve the immobilisation of the carbohydrate of interest and then the  probing by either an 




Nanoparticles used for glycan presentation include metallic and polymeric particles, as well as carbon-
based dots and dendrimers. In addition, synthetic glycopolymers can be synthesised through block 
copolymer methods where self-assembly is controlled by the starting material properties to produce 
vesicles, micelles and rod-like shapes. Starting components can include glycan-functionalised 
monomers which following self-assembly present the sugar moiety on the surface in a highly ordered 
way31,32. Changing the starting copolymer structure can influence the glycan density, the nanoparticle 
shape and introduce multiple glycan moieties to create a synthetic glycocalyx.  
 
Metallic glyconanoparticles can be made from iron oxide, gold, or semi-conductor material to form 
quantum dots and quantum rods. In these cases the nanoparticle is synthesised before glycan 
functionalisation commonly through thiol group interaction or with quantum dots via metallic 
coordination. Gold coated iron oxide nanoparticles offer the potential for magnetic control and also 
surface plasmon resonance measurements. Gold nanoparticles also exhibit colour change properties 
as a result of clustering which can be used as a measure of interparticle interaction33. One example 
uses the photoluminescence (PL) properties of gold nanoparticles functionalised with mannose to 
probe binding with E.Coli.34 
 
Dendrimeric glyconanoparticles are often designed to have symmetry in their structure owing to their 
highly ordered arrangement which can be useful when studying the cluster glycoside effect. For 
instance, this is evident on probes based on a C60 fullerene scaffold, where highly branched structures 
could be prepared. In one example by Sánchez-Navarro et al.35 360 mannobioses were displayed on 
one particle. Therapeutically this system has potential to block the binding of pathogenic Dengue and 
Zika virus which share this carbohydrate in common and is known to bind to the dendritic cell-specific 
intercellular adhesion molecule-3-grabbing nonintegrin (DC SIGN) receptor in a multivalent manner 
on human dendrimeric cells36. Another glycodendrimer using a C60 fullerene scaffold, presented 12 
or 24 𝛼-mannoses as well as 𝛼-galactose as a negative control was used to assess the multivalent 
binding of Concanavalin A. Cu-assisted click chemistry synthesis methodology was employed and 
isothermal calorimetry (ITC) was used to measure the binding parameters. The 𝐾! of the 12-mer was 
421.6±21.2 M−1×10−4, the 24-mer was 137.5±25.4 M−1×10−4 and the galactose was reported as showing 
no binding. These values along with ∆𝐺 values and showed that the lower valency 12-mer has better 
binding to Con A likely due to high entropic value for the 24-mer meaning less binding occurred. This 
effect is interesting despite relatively high (and therefore poor binding) 𝐾! values. The authors suggest 
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that high entropy originates with the 24-mer binding as it has greater flexibility and 15 Con A proteins 
clustering compared to 6.5 for the 12-mer35.  
 
 
                    
 
Figure 1.8 Common glyconanoparticles; polymeric glyconanoparticles, example starting material polymers such as chitosan 
and diblock copolymers. Quantum dot based glyconanoparticle and dendrimeric glyconanoparticles which in this example 



























































































































































































1.3.3 Quantum Dot glycan presentation 
 
Quantum dots are semi-conductor crystalline nanoparticles which offer unique properties in that they 
exhibit the quantum confinement effect (QCE) and have size dependent fluorescence properties. Sizes 
are commonly between 2-10 nm but they can be larger at 200 nm when synthesised via electronic 
lithography routes37. CdSe quantum dots sized 2.1, 2.5, 2.9, 4.7 and 7.5 nm have blue, green, yellow, 
orange and red photoluminescence respectively38. In a semi-conducting material, an electron-hole 
pair (also known as an exciton) can be generated upon irradiation. When the exciton is confined to a 
particle smaller than its Bohr radius the energies become quantized into discrete energy levels. The 
energy levels are then related to the particle size. A photon is emitted when the electron-hole pair 
recombines39. QDs consist of a core and shell structure such as CdSe/CdS or CdSe/ZnS, where the shell 
material has a band gap that straddles the core band gap hence acting as a passivating layer (Figure 
1.9). QDs are used as they commonly are photostable and have a high quantum yield comparable with 
fluorescent proteins  and some commercial dyes used in bioimaging40. 
 
 
The glycan density on the QD surface can be controlled in a number of ways, for example by changing 
the conjugation method (CDI or EDC/NHS amide coupling agents)41, using spacers, or varying the 
length of linker between carbohydrate and nanoparticle surface42. Previous work in the Galan group 
investigated control over carbohydrate presentation by introducing molecules as spacers and also 
achieving bi-functionalisation with 2 different carbohydrates through ratio control during conjugation. 
Using these glyconanoparticles they were able to investigate the role of individual carbohydrates on 

















In their work, cadmium selenide (CdSe) QDs with a Zinc Sulfide (ZnS) shell were made and coated with 
a trioctylphosphine oxide (TOPO) corona which provides colloidal stability through Zn-O interaction. 
This was then exchanged with ligand of interest which contained a thiol which is able to coordinate 
with the ZnS. In this work the thiols used were either Mercaptoacetic acid (MAA) or dihydrolipoic acid 
(DHLA). MAA was used as a linker for the conjugation of dextran as a positive control, whilst DHLA had 
2 versions, a PEG linker terminated in either a carboxylic acid or a hydroxyl. The carboxylic acid was 
used as a handle to react with 1-aminoglycosides of interest in an EDC coupling reaction, and the 
unreactive hydroxyl acts as a spacer. By controlling the molar ratio of these 2 types of DHLA linkers 
the overall density of glycosylation could be controlled. Ratios of 100:0, 60:40, 40:60 and 0:100 
spacer:linker were used to generate 4 QDs with varying linker density. Furthermore, these carboxylic 
acids sites could either be reacted with 1 or 2 different aminoglycosides. Carbohydrates investigated 
in this system include, glucose, mannose, maltose, maltotriose galactose and lactose and dextran as 
a positive control (Fig.1.9). 
 
Initial cytotoxicity studies with HeLa and AS cell lines showed that there was no toxic effect with QDs 
coated in 60% lactose after a 24 hours incubation period compared to control without QDs. At the 
same concentration, capped QDs without glycan functionalisation were toxic under the same 
conditions. Hence, in subsequent cell studies the QD density was fixed at 60% carboxylic acid 
terminated DHLA linker and 40% hydroxyl terminated DHLA linker. In the case of hydroxyl, glucose, 
mannose, maltose and maltotriose functionalised QDs, no uptake was observed. In the case of dextran 
and galactose functionalised QDs, uptake was observed and early and late endosomal and some Golgi 
retention was observed, with slight variation between cell lines. After 24 hours the number of QDs 
had reduced, suggesting exocytosis of the QDs. Lactose functionalised QDs were taken up and 
retained in the endosomes, Golgi and endoplasmic reticulum (ER) in both cell lines evading exocytosis 
beyond 24 hrs. 
 
Bi-functionalised QDs with lactose and a carbohydrate which when mono-functionalised previous did 
not allow QDs entry into the cells, allowed QD uptake. In this way lactose was used as a “Trojan horse” 
to facilitate the uptake of bi-functionalised QDs seen with 1:1 functionalised lactose:mannose and 
lactose:maltotriose. Notably, these QDs had a different intracellular localisation to lactose-conjugated 
QDs, suggesting an intracellular targeting role of the mannose and maltotriose post internalisation. 





1.4 Synthesis of Carbon dots 
 
Carbon dots (CDs) were discovered in 2004 by Sun et al.43 during the preparation of single walled 
carbon nano tubes (SWCNT). In the last 15 years research developing syntheses and exploring the 
applications of CDs has become a huge field in its own right.  Carbon dots syntheses are categorised 
into two main approaches: top down where carbon-based materials with defined structure are broken 
down into nanoparticles retaining structure from the original material or bottom up where small  
 
Figure 1.10 Synthesis and glycan functionalisation of quantum dots as carried out by Benito-Alifonso et al.44 These materials 
were used in cancer cells and uptake depending on the glycan present was investigated. 
molecules are carbonised and dehydrated to form carbon-based particles. The Sun et al.45 synthesis 
can be classed as a top down approach. Bottom up methods are more accessible and allow for easier 
CD core manipulation through established doping effects although these are intrinsically less well 
defined and often less structured than those synthesised by top down methods. Top down methods 
include, electrolysis with graphitic electrodes, ultrasonication where soundwaves facilitate 



















































































































































oxidising a carbon source into particulate form. Common precursors include, graphene and graphene 
oxide (GO), soot, carbon nanotubes, fullerenes and activated charcoal (Figure 1.11). The structures 




Figure 1.11 Carbon dot synthesis route, top down from structured bulk precursor materials, or bottom up from small 
molecules without inherent structure. Commonly used methods are included, and the general resulting structure is drawn 
which results from these methods46. 
A wide range of techniques are available to probe the structure of carbon dots (Figure 1.11). Certain 
techniques are able to probe the core or shell i.e. surface independently, whilst the majority provide 
information on the whole structure. AFM, FTIR NMR and XPS probe the surface structure and provide 
useful information on the surface which is important when considering environmental interactions. 
TEM and Raman spectroscopy probe the core structure such as crystallinity. Overall properties such 
as size, elemental content, structural information and photoluminescence can be measured through 
fluorescence and UV-Vis spectroscopy, DLS, DOSY, TGA, Zeta potential, EDX and small angle x-ray 
scattering (SAXS). Refer to appendix for a brief explanation of the techniques used in this work. 



































































Figure 1.12 Venn diagram of the techniques available to characterise carbon dots. Relevant techniques are categorised as 
able to probe the core or shell independently or both. 
 
1.4.1 Top Down carbon dot synthesis 
 
1.4.1.1 Graphene containing carbon dots 
 
Carbon dots made via top down methods retain some graphene structure in their core which is 
hypothesised to be the basis for quantum confinement in material termed either carbon quantum 
dots (CQDs) or graphene quantum dots (GCDs)47. Bulk graphene itself has a band gap of 0 eV owing to 
its linear energy dispersion of the charge carriers. However, fragments of nanoscale graphene are 
known to exhibit quantum confinement in a size dependent manner due to 𝜋	conjugation electron 
delocalisation (and 𝜋 − 𝜋* transitions in the sp2 domain). Time dependent density function theory 
(TDDFT) can be used to determine the band gap and therefore emission wavelength of a graphene sp2 
domain of certain diameter (Figure 1.13). However, factors such as edge functional groups, 






Figure 1.13 Graphene sp2 domain size to fluorescence emission wavelength positive relationship Reproduced with permission 
from Sk et al.47 
The mechanism involves the carbon dot being similar in size to QDs where the Bohr radius of an 
exciton in the material is larger than the particle therefore exhibiting size dependent 
photoluminescence (PL). The size of the carbon dot correlates with the size of the sp2 domains within 
the core, and evidence suggests that the larger the sp2 domain, the smaller the energy gap, hence, 
lower energy (red-shift). Li et al. observed for 1.2 nm CQDs a 350 nm fluorescence peak, 1.5-3 nm 400-
700 nm peak, and for 3.8 nm core 800 nm. GCDs were synthesised via electrochemical means involving 
graphitic rods and separated on the basis of size post synthesis using silica-gel chromatography with 
petroleum ether/diethyl ether. Evidence for this effect was determined through predicting the highest 
occupied molecular orbital-lowest unoccupied molecular orbital (HOMO-LUMO) band gap for isolated 
graphene sp2 domains between 1.4-2.2 nm and observing that they match up with the PL energies 
observed in a size dependent manner.48  
 
Furthermore, another study observed the same size-PL dependence analogous to QDs. GCDs were 
synthesised from 3 coal based starting materials; anthracite, bituminous coal and coke, each of which 
has a different structure. Under top down synthesis conditions involving sonication in acid followed 
by heating to 100 – 120 oC before neutralisation with NaOH and filtration, a-GCD, b-GCD and c-GCD 
were afforded of diameters 29 ± 11 nm, 2.30 ± 0.78 nm, 5.8 ± 1.7 nm respectively. Each fit a size 
dependent PL profile where a-GCD fluoresced yellow, b-GCD blue and c-GCD green (𝜆ex 345 nm). 
Interestingly, individual b-GCD particles of 2.96 nm, 2.30 nm had different fluorescence emission 
peaks of 500 nm and 460 nm, further conferring quantum confinement effect. However, the evidence 
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does not exclude oxidative groups at the graphene edge as the mechanism for the photoluminescence 
observed49. 
 
Peng et al.50 developed CQDs synthesised from carbon fibres in acid before heating for 24 hours, with 
size dependent fluorescence profiles (Fig 1.14). 1.4 nm had blue fluorescence 405 nm ( 𝜆&' 318 nm), 
4-8 nm had green 500nm (𝜆&' 331 nm) and 7-11 nm had yellow 575 nm emission (𝜆&' 429 nm). These 
CQDs of different sizes were synthesised at three temperatures 80 OC, 100 OC and 120 OC respectively. 
The authors hypothesis that the temperature controls the size and the nature of the sp2 domains in 




Figure 1.14 Carbon Quantum Dots (CQDs) synthesised by Peng et al.50 at 80 OC, 100 OC and 120 OC via top down methods 
exhibit size dependent fluorescence and band gap energies. 50 
 
1.4.1.2 Graphene oxide containing carbon dots 
 
Graphene oxide derived CQDs exhibit similar size-dependent emission as graphene derived ones. The 
structure of graphene oxide contains some sp3 domains as epoxy and hydroxyl groups and also 
oxidated sites in the form of carboxyl and carbonyl groups commonly found at the particle edges.  Sp2 
domains exist within the graphene layer as smaller domains separated by sp3 regions (Figure 1.15). 
Larger graphene quantum dots (GCDs) contain larger and more sp2 domains which are responsible for 
their PL. Edge functional groups are good handles for manipulating the PL spectra and GCDs can also 
be doped in a similar way to non-sp2 containing carbon dots. Depending on whether electron enriching 
















Figure 1.15 The sp2 domains in graphene and graphene oxide (GO) act as chromophores/centres at which electron-hole pairs 
can recombine radiatively. The PL energy can therefore be tuned by controlling the amount of sp2 present in the graphene 
carbon dot (GCD).47 
Literature sometimes refers to the sp2 domain within GCDs as the conjugated domain and references 
the size dependent quantum confinement PL effect which is seen in GCDs. The larger the conjugated 
system, the more red-shifted the PL reported. For example, graphite was used to prepare CDs by Zhou 
et al.52 CDs were separated using filters of molecular weight cut-off (MWCO) <5 kDa and 5-10 kDa 
which yielded blue (1.9 ± 0.3 nm) and yellow (3.2 ± 0.5 nm) fluorescent particles. Filter sizes larger 
than this yielded particles which did not exhibit fluorescence. They proposed sp2 conjugate domain 
size as the basis for this effect FTIR peak at 1630 cm-1 shifted to 1620 cm-1 (C=C stretch) which is 
indicative of a larger conjugation system in the yellow CDs.52 
 
1.4.2 Bottom up synthesis of carbon dots 
 
A wide range of materials have been used to synthesis carbon dots as the single prerequisite is that it 
contains carbon. As previously mentioned, top down methods confer structural properties to the CD 
which are intrinsic to the starting material such as graphene producing CDs with sp2 conjugate core. 
For bottom up methods, the precursors can be small organic molecules including amino acids, sugars 
and DNA as well as polymers and waste biomass (termed green methods). With biomass-based 
syntheses, the starting material is often a mixture of precursors. Natural materials used include 
pomelo peel,53 watermelon peel,54 coffee grounds,55 egg,56 milk,57 seafood waste58 and urine.59 These 
are commonly conducted using hydrothermal or microwave methods and generate heterogenous 
materials which do not confer any PL, size or structural consensus with each other as the small 
molecules are polymerised and carbonised at different rates and to different extents depending on 

















Amino acids contain acid and amine groups. The acid group facilitates polymerisation, conjugation 
and aromatic formation and the amine group also facilitates polymerisation as well as N-doping and 
passivation potential. All-natural amino acids were compared as starting material for hydrothermally 
synthesised carbon dots at 180 OC for 12 hrs. The variable R-group of amino acids was found to be 
crucial, by stabilising surface defects and achieve N-doping and to differing extents which was seen 
through the QY and PL intensity. For example, serine and threonine have terminal hydroxyl groups 
which were thought to promote dehydration and carbonisation hence good photostability and QY of 
30 % and 22 % respectively.61 
 
DNA macromolecules or nucleotides have been used for CD synthesis which have in some cases been 
shown to retain the heterocyclic features of the starting material and retain phosphate groups. One 
study observed that purine bases induced better N-doping that pyrimidine in a synthesis involving 
nucleotide bases. Furthermore, the sugar component confers greater QY compared to synthesis 
involving the equivalent nitrogenous base.60 
 
1.4.2.1 Carbohydrate based bottom up carbon dot synthesis 
 
A number of small carbohydrate molecules including glucose, mannose, fructose and glucosamine 
have been used for carbon dot synthesis due to their wide availability and low cost as well as their 
ability to ring-open in water forming an aldehyde which is important in condensation reactions 
involved in carbon dot syntheses. Resulting from these reactions are polymers and small molecules 
which can have a number of fates. Commonly glucose has been used and has a relatively low 
carbonisation temperature, lending its use for greener synthesis methods62. A CD synthesis involving 
H2SO4 refluxing from glucose only yielded carbon dots with low QY (0.01) which could be improved 
with a second TTDDA passivation step (0.13). This supports literature examples where having a simple 
carbonaceous material such as soot, citrate or carbohydrate alone, yields a material with poor PL 
properties63. 
 
A secondary passivating agent is usually included in carbohydrate-based syntheses and a wide range 
of bottom up synthesis methods have been employed in the literature. This secondary molecule in 
combination with glucose will dictate the CD structure and PL properties. One study by Klinger et al.64 
showed that glucose reaction with ammonia (ammoxidation reaction) produced a huge number of 
pyrazines such as 2-pyrazinol, 2,5- and 2,6-fructosazine and 2,5- and 2,6-deoxyfructosazine. When a 
polysaccharide was used in its stead, lower yield was obtained showing that monosaccharide is 
preferred for carbon dot synthesis64. Other carbohydrates such as glucosamine have been used to 
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produce pyrazines as they contain an amine group. Glucosamine has also been observed to have a 
doping effect and red-shift CD fluorescence due to the N containing amine group. The formation of 
pyrazine containing molecules is also possible in a self-condensation reaction which is a common 
group in molecular fluorophores65.  
 
A fructose and maltose-based synthesis produce graphite-like sp2 core carbon dots. Using either NaOH 
or NaHCO3 base and both carbohydrates at 500 mM concentration (whilst under room temperature 
and pressure) synthesised a green fluorescent CD. However, this synthesis had a relatively low QY of 
2.2 %66.  
 
1.4.2.2 Photoluminescence and carbon dot structure relationship 
 
The structure to PL relationship of carbon dots is one of their most intriguing properties. The 
photoluminescence makes carbon dots useful for biological context and understanding the basis of 
this property and improving it is a main focus in the field. Synthesis and application should be 
considered in tandem when developing carbon dots. CD PL properties are influenced by starting 
materials and synthetic conditions through passivation, doping, molecular fluorophore generation 
and crosslink enhanced emission. Figure 1.16 summarises the structural basis for carbon dot PL.  
 
As previously mentioned, precursor molecules are very wide ranging and each influence the PL profile 
of the resulting CD. More than one PL centre can exist within a carbon dot owing to the multiple 
distinct structures that can exist in a single carbon dot. Commonly but not as a rule, top down synthesis 
methods confer conjugated sp2 structure in the core. These domains commonly absorb at lower 
wavelengths between 200-250 nm and exhibit blue-fluorescence as seen with graphene (Figure 1.16 
blue shaded area highlights core region). Bottom up methods confer more variability in the structure 
often with a mixture of sp3 and sp2 regions. Sp2 core domains generated from bottom up methods will 
show similar PL profiles to top down synthesised CDs. Sp2 hybridised O and N at the edge of crystalline 
domains are known as the “edge domain” and absorb between 250 – 350 nm with a correspondingly 
red-shifted fluorescence (Figure 1.16 green shaded area). Oxidised “surface domain” (Figure 1.16 
orange shaded area) groups such as pyrrolic, amine and carboxylic groups confer even more red-
shifted absorption and fluorescence, in the region above 350 nm into the visible region. Furthermore, 
surface groups can result in surface emissive traps which require passivation for good QY. Self-
absorption can occur when the PL profiles of different surface domains overlap so that the emission 
of one is the excitation energy of another causing a cascade excitation, this can be seen in both the 




Molecular fluorophores can be generated during synthesis and presented at the CD surface which may 
have their own PL profile independent from the main carbon dot. Polymeric content can confer 
improved PL if crosslinked polymer is present in the CD structure through the crosslink enhanced 
emission effect. Finally, the PL profile can be blue or red-shifted through heteroatom doping which 





























Figure 1.16 Carbon dot structure to photoluminescence relationship. Multiple contributing factors influence a carbon dots PL 
profile which are determined in synthesis and can be modified post synthesis. Three shaded areas indicate three areas 
fluorescence can originate from. Blue = core, green = edge domain, orange = surface domain. Blue molecules illustrate surface 
molecules on the CD surface with their own PL profile.  
 
1.4.2.3 Passivation for improved carbon dot quantum yield 
 
Passivation is well known as a mechanism to make emissive and improve the QY in CDs with highly 
oxidised surfaces.  The oxygen containing surface groups are known as surface defects and capture 
excitons and have associated red-shifted PL. Exciton trapping means that the QY of the CD is low and 















































inorganic materials which can be added in synthesis or conjugated to existing functional groups post 
synthesis. This feature gives carbon dots tunability and has facilitated improved QY from < 1% to over 
90 % in the best cases. Polyethylene glycol1500 (PEG1500) was one of the first passivating molecules, 
conjugated to CDs synthesised using laser ablation from graphite powder and cement in the presence 
of water. The initial material generated in this manner was not fluorescent however, after heating 
nitric acid (up to 2.6 M) treated CDs with PEG1500, the material exhibited excitation dependent 
emission between 400-694 nm (Figure 1.17). Interestingly, better QY was induced by subjecting this 
material to repeated PEG1500N functionalisation.43 
 
                                  
Figure 1.17 Passivation with PEG1500 of carbon dots synthesised from graphite powder and cement to reveal fluorescence 
upon 𝜆ex 400 nm shown by Sun et al.43 
 
Passivating molecules work by facilitating electron-hole recombination located at the surface of CDs. 
Carboxyl surface groups non-radiatively allow electron-hole recombination by acting as electron 
acceptors. Hydroxyl functionalisation facilitates radiative recombination due to its electron donating 
property conferring improved QY. Evidence for this was shown by Fe3+ detection through coordinating 
with hydroxyl terminated CDs which quenches fluorescence. Hydroxylation had been shown to induce 
CD fluorescence in the first instance.67 Similarly, amine and amide groups have been shown to induce 
improved CD QY due to electron donating properties. CD passivating molecules with terminal amine 
groups include polyethyleneimine (PEI), poly(2-ethyl-2-oxazoline (PPEI-EI, average MW ~ 5000) 
initially explored by Sun et al.43 A plethora of amine containing molecules have since been conjugated 
via simple N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) coupling to 
carboxylic acid groups on CDs to improve QY.  
 
Passivation through incorporating small molecules into the synthesis has been shown with numerous 
amine containing molecules such as 4,7,10-trioxa-1,13-tridecanediamine (TTDDA), 1,2-
ethylenediamine (EDA), diethylamine (DEA), 1,4-butanediamine (BDA), and triethylamine (TEA).68 
Through NMR and FTIR (C-N peak at 1580 cm-1 stretch) these functional groups have been seen to be 
conjugated onto the CD surface. Interestingly, primary amines were seen to improve QY more than 
secondary or tertiary amines in a comparative study. In a microwave synthesis amine containing 
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molecule was added to citric acid before 2-4 minute microwave pyrolysis. QY values obtained for 
primary amine EDA was 30.2% whilst secondary amine DEA was 4.2% and tertiary amine TEA was 3.2% 
all compared to unpassivated CDs of 2.2%.69 
 
One other key property which can be affected by passivation is PL, which can change from excitation 
dependent to excitation independent. This is the case if the PL originated from the surface group 
induced trapped states of differing energy levels which can be removed through passivation. In this 
case any excitation independent PL observed originates from the core, either from sp2 domains, or in 
the case of amorphous CDs the sp3 enriched domains.70 
 
 
Figure 1.2 Effect of passivating on the photoluminescence (PL) profile of carbon dots. Passivating agents include PEG, PEI and 
PPEI-EI as well as other small amine containing molecules. Zhai et al.71 show that primary amine EDA improved the QY of 
unpassivated CDs from 2.2 % to 30.2 % whilst secondary amine DEA and tertiary amine TEA only improve the QY to 4.2 % and 
3.2 % respectively.71  
 
1.4.2.5 Doping carbon dots changes the photoluminescence properties 
 
Doping is another one step way to modify CD properties. Doping allows for PL tuning based on the 
electronegativity of the atom incorporated and the introduction of new bands in the energy gap. 
Electron withdrawing elements (high electronegativity) such as S, N, Cl and F blue-shift the PL profile 
as they introduce lower energy bands, n-type doping. Whilst electron donating elements (low 
electronegativity) such as Se, B, Cu and Co confer more red-shifted emission introducing higher energy 
bands, p-type doping. This doping effect can influence the surface electronics of surface groups or the 















e.g. PEG, PEI or PPEI-EI,































It has been reported that N and B (heteroatom) doping of GCDs show a blue and red PL shift 
respectively compared to undoped GCDs.72 Core sp2 regions confer a 𝜋 − 𝜋* transition in an excitation 
independent manner, however, N or B doping introduce n −	𝜋* transitions which introduce a lower 
energy levels and therefore an excitation dependent PL peak. Generally speaking, electron rich 
nitrogen typically induces a blue-shift on the CD, while electron poor boron tends to cause a red-shift. 
However, this is not always the case. Another example describing the synthesis of yellow fluorescent 
carbon dots employs F, S (electron withdrawing) and Se (electron donating) as doping agents.73 In the 
synthesis of these CDs, Poly(o-phenylenediamine) was combined with either potassium hydrogen 
difluoride (KHF2), sodium hydrosulfide or sodium hydroselenide in a hydrothermal synthesis at 180 OC 
for 12 hrs. Resulting CDs had fluorescence peak maxima at 411 nm (𝜆ex 362 nm), 530 nm (𝜆ex 483 nm) 
and 594 nm (𝜆ex 541 nm) respectively whilst undoped was at 570 nm (𝜆ex 521 nm). Selenium red-
shifted the undoped fluorescence peak whilst fluorine blue-shifted to a greater degree than sulfur 
showing that doping can be tuned to a certain degree based on the known electron properties of the 
dopant properties73. 
 
Nitrogen is one of the most commonly used doping agents for carbon dot as it can be easily 
incorporated from a range of starting materials found in nature such as carbohydrates and amino 
acids and thought to be inherently non-toxic. It is also of a similar atomic size to and has good valency 
with carbon meaning for a good doping agent. Trialling a number of amino acids Yang et al.74 observed 
that temperature during synthesis played a role in incorporation of nitrogen into the CD. A single 
starting material, the amino acid of choice was used in a hydrothermal synthesis at 180 OC before 
dialysis purification. At longer times, up to 6 hrs, more nitrogen was incorporated seen through FTIR 
amide peaks and I (1700 cm-1) and II (1580 cm-1) forming as a result of carbonisation and 
polymerisation. XPS also showed the nitrogen percentage content increased to 13.67% with 
temperature and time. After 18 h complete carbonisation was observed. Interestingly, varying the 
reaction time allowed for the degree of passivation to be tuned also. They propose that the amino 
acids polymerise in the reaction and these longer molecules can act as the passivating coating as seen 
in other syntheses with TTDDA and PEG. The degree of passivation is seen to be greater for a shorter 
reaction time of 3 hrs, and decreases up to 6 hr reaction time when the peptide carbonises. Passivation 
is attributed to the amine and oxygen containing groups in protein74.  
 
Simultaneous co-doping with groups of varying electron withdrawing ability such as N and S 
respectively, can be achieved. Qu et al.75 carried out a solvothermal synthesis from citric acid and N 
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and S containing thiourea. They achieved CDs with 3 PL peaks at 340 nm, 440 nm and 540 nm which 
can be attributed to the N-doped and S-doped verses undoped influence on the PL profile. 
Furthermore, they observed an increased QY effect suggesting a passivation role of the dopants due 
to the introduction of new energy bands.75 
 
Red-shifting the PL profile of CDs has been shown to be, paradoxically, possible through fluorine 
doping. The electron-withdrawing property of fluorine is known to induce fluorescence red-shift in 
polyconjugate sp2 systems. Work by Yang et al.76 achieved this with CDs synthesised through 
microwave synthesis from citric acid, urea and sodium fluoride. They suggest the basis for this effect 
is that fluorine doping is extended to expand the conjugate system and also to include the surface 
electronic states. This larger sp2 conjugate system has lower energy levels explaining the red-shifted 
fluorescence. This is evidenced by an increase in the 𝜋 − 𝜋* transition peak in the absorbance spectra 
at ~220 nm and XPS confirming fluorine incorporation in the CD. Hence, the doping effect must be 
considered in the context of the CD structure i.e. sp2 core, alongside the intrinsic dopant properties.76 
 
Mondal et al.77 studied the effect of Boron B and Phosphorus P doping in relation to already nitrogen 
doped carbon dots. These carbon dots were synthesised from a 1:1:1 of citric acid and EDA at 1:4. A 
bathochromic shift is seen in the emission spectra of both B and P doped nitrogen containing carbon 
dots at 340 nm and 420 nm which corresponds to possibly two fluorescence centres causing dual 
fluorescence. This provides more evidence that both fluorescence centre resulting from sp2 core and 
surface states are affected simultaneously by the same dopant. Interestingly the quantum yield is 
reduced upon B and P doping from 95% and 11% for nitrogen only carbon dots, to 63% and 9% for B 
and 63% and 6% P doped versions at 340 nm and 420 nm emission respectively. The reduced QY they 
attribute to increased trapped states from the dopants rather than more emissive levels relieving 
trapped states. Hence, the relationship between dopant and passivation is not always clear cut. Worth 















1.4.2.4 Molecular fluorophores on carbon dots 
 
During bottom up CD syntheses, small fluorescent molecules can be generated which are then 
incorporated into the CD structure through carbonisation. If the molecule is not broken down or 
covalently attached to the surface, as in passivation as described earlier, they may associate onto the 
CD as well as be free within the product mixture (which persist despite certain purification techniques 
such as dialysis and centrifuge filtration). These molecules usually form in the initial reaction step at 
lower temperatures (~180 OC), before the carbonisation at higher temperatures (300-400 OC) where 
the carbon dot core forms. As a result, the CD PL profile can result from the combined contribution of 
the small fluorescent molecule and the CD itself78.  
 
This effect was first observed by Krysmann et al.79 where they found that at lower reaction 
temperatures only a small molecule was made and upon temperature increase CD was formed and 
became the main reaction component. Citric acid (CA) and ethanolamine (EA) were combined in a 
pyrolysis reaction for 30 minutes. At the lowest temperature of 180 OC, the excitation independent PL 
profile emission peak of 455 nm was attributed to a fluorophore termed PL-CNP180, this was 
generated during synthesis whilst no nanoparticle (by DLS and TEM) was generated. When the 
reaction temperature was increased to 230 OC, a CD was generated named CNP230, which showed a 
new excitation dependent PL feature red-shifted (ex > 400 nm) in relation to the PL-CNP180 peak. This 
new PL peak was found to be from the core of the new CD. Hence, this system was seen to exhibit 
dual fluorescence. At the highest temperature of 300 OC, the CD was the main component seen 
through XPS (carbon content increase), TEM, FTIR and the second luminescence peak when excitation 
> 400 nm (excitation dependent) is the main feature. At 400 OC full carbonisation predominated hence 
no fluorophore was observed79. 
 
These results were confirmed by direct heating of CNP180 at 300 OC which under the same conditions 
afforded the same material as the original synthesis. They also conducted the reaction between CA 
and EA under hydrothermal conditions at 140 OC which yielded the same products (Figure 1.12). 
Hence, different from doping, the dual fluorescence is a result of two PL centres which are 





Figure 1.12 Molecular fluorophore generation during a pyrolysis carbon dot synthesis by Krysmann et al.79 was temperature 
dependent from the starting materials citric acid (CA) and ethanolamine (EA). At 180 oC only fluorophore was generated (PL-
CNP180). At 230 oC and 300 oC fluorophore and carbon dot were generated. At 400  oC  only carbon dot was generated.79 
 
Similarly, Song et al.80 observed very similar temperature effects when using citric acid (CA) and 
ethylenediamine (EDA) in a 4:1 mmol ratio employing a hydrothermal process. In their report, small 
aromatic fluorophores were produced at lower temperatures 100-200 OC. Separation of the major 
component, imidazo[1,2-a]pyridine-7-carboxylic acid, 1,2,3,5-tetrahydro-5-oxo- (IPCA) from the CD 
using silica gel column chromatography allowed for the PL profiles of IPCA and CD core to be 
investigated in isolation. IPCA had excitation independent emission and a high QY of 36%. They 
appreciate that complete purification of IPCA from the CD core is not possible hence the core was 
synthesised from heating CA at 200 OC. The obtained CD showed excitation dependent PL and was 
weakly blue-fluorescent with lower than 1% QY. Comparing CD cores synthesised both ways showed 
the same characteristics hence it was suggested that CA forms the CD core. It is well known that CA 
forms large conjugate systems through dehydration upon heating which is the basis for CD structure 
and sp2 conjugate fluorescence. Et-EDA and Ac-EDA are two variants on EDA which contain an ethyl 
group and an acetyl group respectively which when substituted for EDA in the synthesis, derive 
molecules which are variants of IPCA with the respective functional group attached. This confirms that 
EDA and CA are the precursor for IPCA and tuning of the small molecule generated is possible80. 
 
Interestingly, oligomers of IPCA were fractionated during separation suggesting polymerisation occurs 
from IPCA (in this context considered a dimer) which can then either carbonise or they propose 









































syntheses containing polymers as the starting material, and if retained post synthesis to infer crosslink 
enhanced emission (CEE) on CDs. Crosslinked polymer CD cores are different from conjugated centres 
as they are aggregated structures. The amine-based PL centres of the polymer when restricted in 
vibration and rotation due to crosslinking, promote radiative exciton recombination and hence, 
improved PL is a known effect.81 
 
The difference between molecular state fluorescence or CEE and passivation or doping, is that the PL 
centre originates from the fluorophore in isolation to the CD which can have its own PL centre. Hence, 
doping and passivation are not features seen in any of the materials described in this section. This is 
supported by the fact red-shifting of fluorescence is not seen as would be for doping and QY does not 
improve with a greater degree of polymeric content which would be the case in passivation. 
 
Furthermore, fluorescence lifetimes were determined for the fractions post separation. Each fraction 
contained two decay lifetimes which were identified as from the IPCA molecule and the CD core. 
Having determined that later factions contained more CD core and earlier fractions contained more 
IPCA, they correlated the average lifetime of the mixture increasing with each sequential fraction as a 
result of the increased CD core content. Similar lifetime experiments were conducted by Schneider et 
al.82 who used the known molecular lifetimes to distinguish between cursory fluorophores made 
during CD syntheses hydrothermally from different starting material mixtures all with citric acid (5.5 
mmol) in common. Either ethylenediamine, hexamethylenetetramine or triethanolamine were added 
(5 mmol) which afforded e-CDs, h-CDs and tCDs respectively. E-, and h-CDs syntheses generated 
surface fluorophores IPCA as with Song et al.80 and citrazinic acid respectively whilst tCDs only 
generated the CD core. They were able to observe lifetimes from the CD surface states were 
influenced by the fluorophore generated in the synthesis by comparing with CD when no surface 




Figure 1.3 Polymerisation of IPCA generated from citric acid (CA) and ethylenediamine (EDA) generated during carbon dot 
synthesis, seen by Song et al.  Subsequent crosslinking of these polymers on the surface of carbon dots have been shown to 





















































































1.5 Thesis aims  
 
The aim of this work is to develop a novel carbohydrate-based cancer cell targeting nanoplatform 
which can be used for diagnosis and for drug delivery. Well studied changes associated with cancer 
commonly target protein transcription up or down regulation, caused by increased cellular growth 
and division and cell membrane remodelling. One other facet of the cell membrane is the glycocalyx. 
This highly dense multifunctional carbohydrate layer adopts changes which promote cancer cell 
invasion and metastasis. Hence, identifying and targeting these glycan interactions is one route to 
achieving successful tumour targeting. Targeted treatment leads to improved drug efficacy and 
selectivity which should lead to fewer associated treatment side-effects.  
 
Understanding carbohydrate multivalent binding by their protein receptors called lectins, is important 
for developing specific targeting technology. Studying these interactions using synthetic probes and 
in isolation from the complete cell allows these interactions to be measured independently and should 
provide a fundamental understanding. Towards this goal, we proposed to use nanoscale particles for 
glycan presentation. We aim to develop and evaluate carbon dots, a fluorescent and non-toxic 
nanoscale particle, to probe carbohydrate lectin interactions. Utilising their photoluminescence 
properties, we aim to develop a FRET assay to investigate lectin binding interactions.  
 
Full characterisation of glyconanoparticles must be conducted when developing a novel carbon dot-
based FRET assay to measure the binding affinity of carbohydrate lectin interactions. Structural and 
spectral information on the glyconanoparticles inform the parameters of the FRET assay and must also 
be considered when interpreting the data. First developing the assay using lectins with known binding 
specificity with the aim to apply this to less well studied lectins and novel carbohydrates. Through 
using a nanoparticle, the multivalency exhibited in nature will be mimicked and provide a reasonable  
approximation of binding information Glycan-coated quantum dot nanoparticles have been shown in 
previous work within the Galan group by Benito-Alifonso et al.44 to act as a targeting moiety 
specifically for cancer cells. Hence, we aim to work towards a non-toxic version for drug delivery. The 
non-toxic nature of the carbon dots thus offers the possibility of future in vivo application, which we 










2. Carbon dot synthesis for glycan presentation  
2.1 Aims 
 
The work described in this chapter is aimed at developing novel carbon-based glyconanoparticles for 
biological applications. Functionalisation with several carbohydrates of interest was carried out, and 
full characterisation of the novel materials conducted. Little is known of the carbohydrate 
presentation on these nanoparticles, to that end novel structural information was obtained to inform 
an updated model of our glyconanoparticles. Specifically, carbohydrate valency, conjugation and 
organisation on the carbon dot surface were investigated. This work was conducted with 
consideration of how these carbohydrates are presented for multivalent binding with lectin proteins, 
specifically the lectin Concanavalin A which binds terminal mannose. 
 
The carbon dots synthesised and functionalised were characterised using common nanoparticle 
analytical techniques including dynamic light scattering (DLS), zeta potential, several spectroscopic 
techniques (such as fluorescence and UV-Visible spectroscopy), transmission electron microscopy 
(TEM), atomic force microscopy (AFM). The materials were also characterised by techniques 
commonly used for carbohydrate analysis including nuclear magnetic resonance (NMR) and the 
Molisch’s test. This information was used to infer novel structural information on the glycan carbon 
dots synthesised and was also used to inform binding studies with Concanavalin A and Sambucus nigra 




2.2.1 Synthesis  
 
Carbon dots were synthesised according to a protocol developed in the Galan group using 
carbohydrate based starting material glucosamine.HCl with a passivating agent, in a carbonisation 
reaction.46,83 It has been shown that carbohydrate density on the carbon dot surface can be controlled 
by the length and functionality of linker used.44 Hence, two variants of this carbon dot were 
synthesised using two different types of linkers, an amino acid based-one and a PEG-containing chain. 
The two CD syntheses were conducted according to a protocol developed by Hill et al.46 in the group. 
“Short linker” CD synthesis involved the microwave-assisted thermolysis of 𝛽-alanine and 
glucosamine.HCl which afforded acid terminated CDs termed “AcCDala” 10 and could be directly 
functionalised by 1-aminoglycans 1-8 in an EDC coupling reaction84. The “Long linker” CD synthesis 
employed 4,7,10-Trioxa-1,13-tridecanediamine (TTDDA) in the microwave reaction with 
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glucoseamine.HCl to afford CDs termed “AmCD” 16 with a long TTDDA, amine terminated group on 
the surface. 16 could then be further functionalised with succinic acid to introduce acid groups and 
undergo the same EDC coupling with 1-aminoglycans 1-8 85. In each case NMR allowed for the 
confirmation of conjugation. These two materials were characterised at each step using a number of 
techniques and the glycan presentation investigated.  
 





Blue-fluorescent carbon dots were synthesised from glucosamine.HCl and TTDDA starting materials in 
a 3-minute domestic microwave synthesis on a gram scale following a modified reported procedure.46 
Carbohydrates was chosen as a precursor molecule for carbon dot synthesis due to their availability 
and low cost combined with their inherent biocompatibility making them non-toxic materials. 
Glucosamine.HCl (GluNH2.HCl) contains an amine group which has the potential to act as a doping 
Figure 2.1 Synthesis scheme of AmCD to AcCD “long linker” carbon dots and glycan functionalisation. 
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agent in addition to the two primary amine groups in TTDDA included here. Literature evidence for 
the passivating ability of TTDDA supports the inclusion of TTDDA for achieving a material with good 
QY as well as providing a linker for subsequent biomolecule conjugation. 
 
Starting from GluNH2.HCl (0.24 M) and TTDDA (1.1 equiv.) in 20 ml H2O, microwave-thermolysis 
(800W, 80% power) was conducted. The microwave time had been optimised to 3 minutes where an 
oil like dark brown fluorescent (under UV light) material was afforded which was soluble in water.46 
The material was purified using spin centrifugation through a cellulose membrane (10,000 MWCO was 
initially used), before dialysis on a cellulose membrane 1,000 MWCO  in H2O was conducted over 16 
hrs. Extraction of the CDs with DCM and H2O was conducted to separate material generated which 
was not water soluble from the water soluble CDs. The final material termed AmCD 16 was freeze 
dried before further use. 
 
AmCD 16 was functionalised with succinic anhydride 1:1 mass equivalents in a ring opening reaction 
to convert these amine terminated CDs to acid terminated CDs to form AcCD 17. 
 
2.2.1.2 Short linker carbon dot synthesis – AcCDala 10 
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A second blue-fluorescent carbon dot was synthesised from glucosamine.HCl and amino acid 𝛽-
alanine in a 3-minute domestic microwave synthesis on a gram scale following reported procedures.83 
The 𝛽-alanine was included in the synthesis as a means to directly introduce an acid functional group 
at the surface of the CDs. It was also reported that following this method higher biomolecule 
functionalization could be achieved as the CD appears to bear more acid groups on the surface when 
compared to acid-coated AmCD 16. In brief, sugar and amino acid reagents were microwaved at 800W 
in a domestic microwave at 80% power for 3 minutes. Purification involved H2O/DCM extraction as 
with the previous CDs followed by further purification using a 10,000 Da MWCO Vivaspin20 for 10 
minutes at 8,000 rpm to yield 10.  
 
2.2.1.3 Kochetkov amination 
 
Both AcCDala 10 and AcCD 17 were functionalised with 1-aminoglycans 1-8 which had been 
synthesised from starting carbohydrates: β-D-galactose, β-D-lactose, β-D-glucose, β-D-maltose, β-D-
mannose, 3,6-Di-O-(α-D-mannopyranosyl)-D-mannopyranose, 4-O-(α-D-Mannopyranosyl)-D-
mannopyranose and β-D-Mannopyranose-(1—4)-β-D-mannopyranose-(1—4)-β-D-mannopyranose in 
a Kochetkov amination reaction. This was carried out on a 10 g scale (5g scale for disaccharides) over 
5 days at room temperature in a saturated ammonium carbonate solution in H2O (1% w/v) to afford 
70-84 % yields, as shown in table 2.1. Data for 1-5 are shown in table 2.1. For mannose disaccharide 
and trisaccharides 6,7 & 8 calculating the yield was not appropriate as a number of side products 
which were not distinguishable from starting material or product were generated. It was hypothesized 
that only 1-aminoglycosides would react with the acid functionality on the CDs and thus we decide to 
look at the carbohydrate remaining post conjugation and purification to carbon dot. Aminated 










Table 2.1 Kochetkov amination reaction percentage yield as determined through NMR. 
 
Literature showed that a number of aminated products could result in this reaction alongside the 
desired glycosylamine. These include the glycosyl ammonium carbonate salt, the dimer di-
glycosylamine or the glycosyl carbamate which can exist as either the 𝛼 or 𝛽 conformations86. Coupling 
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with the carboxylic acid handle on the carbon dot can occur with any of the glycosyl amine, the glycosyl 
ammonium carbonate salt or the dimer di-glycosylamine. The % yield in table 2.1 is the calculated % 
glycosylamine calculated from the total starting carbohydrate anomeric and the glycosylamine 
anomeric integration in NMR. According to these % yields, the amount of 1-5 used in the conjugation 
was modulated.  
 
2.2.1.4 Carbohydrate conjugation  
 
In the Kochetkov amination, in all di and tri- mannose cases 6,7 & 8 there was an amide peak in the 
anomeric region for the conjugated carbohydrate which matched literature for general glycosylamide 
formation. Hence, modulation of these before conjugation was not possible. This was seen in the 13C 
NMR as a peak between 70-82 ppm smaller than that observed from unconjugated carbohydrate 
anomeric peaks which came between 105-82 ppm. 
 
In order to glycan functionalise CDs, AcCD 17 was reacted with 1-aminoglycans 1-8, 200 mg aminated 
monosaccharide (400 mg disaccharide, 600 mg disaccharide) in an EDC coupling reaction in 3 ml H2O 
having calculated the moles of acid handles available to react. In this reaction steric effects are most 
likely to be the limiting factor in conjugation. Unconjugated saccharide was removed through dialysis 
500-1000 MWCO membrane and NMR was used to confirm conjugation. 
 
For sialyllactose carbohydrates which contain a carboxylic acid, reductive amination with sodium 
cyanoborohydride was used to functionalise AmCDs 16 on a 10 mg scale for 3 hours to afford 26 & 27. 




2.2.2.1 NMR carbon dot characterisation 
 
NMR spectroscopy was used to characterise the synthesised carbon dots at each stage of synthesis 
and conjugation. NMR provides information on the surface chemistry of the carbon dot, which is 
useful for observing subsequent conjugation steps. It can be used to quantify the presence of different 
chemical moieties. D2O was used as the solvent owing to the good water solubility of carbon dots. 
Proton (1H), carbon (13C) and Heteronuclear single quantum coherence (HSQC) NMR was conducted 
as detailed to characterise carbon dots. Glycan carbon dots synthesised within this work (Figure 2.1 
and 2.2) were characterised by NMR and are presented in Figures A.11-A.15 of the appendix, for 




Figure 2.3 shows the 1H spectra of AmCD 16 post purification. The characteristic peaks of the TTDDA 
linker are observed in the region between 1.83 – 3.60 ppm. Aromatic features at 8.50 ppm are 
observed reflecting the presence of aromatic groups at the surface which were generated during the 
synthesis carbonisation process. Upon acid functionalisation with succinic anhydride two notable 
things occur in the 1H NMR spectra (Figure 2.4). Triplets corresponding to the methylene groups of 
succinic anhydride are seen at 2.38 ppm and 2.53 ppm and also the desymmetrisation of TTDDA occurs 
confirming conjugation of both TTDDA and succinic acid. This is seen through new peaks distinguishing 
the peaks labelled i, b, a & j in figures 2.4 and 2.5. From figure 2.3, b & i are at 1.83 ppm and a & j are 
at 2.97 ppm. In figure 2.4, upon succinic anhydride conjugation, these split into four peaks: i, 1.62 ppm 
b, 1.82 ppm, a, 2.89 ppm and j, 3.13 ppm. Peaks associated with carbohydrate ring structure usually 
seen between 3-4 ppm are not distinguishable, suggesting carbonisation of this structure. However, 
the disordered region between 3.5-3.6 ppm is a useful region to use as a carbon dot identifier in 1H 
NMR. 
 
1H NMR of AcCDala 10 is presented in figure 2.5. Identifiable key signals assigned to the methylene 
triplets from 𝛽-alanine were observed at 2.65 ppm and 3.15 ppm. These being distinguishable from 
each other suggests different environments and hence presentation on the carbon dot surface. Signals 
between 3.45-3.80 ppm were assigned to the carbon dot and used as an identifier for the presence of 
AcCDala 10.  
 
Glycan functionalisation of carbon dots was also supported by 1H NMR.  Distinct peaks corresponding 
to the carbohydrate ring structure between 3.2-4.1 ppm as well as anomeric peaks between 4.0-5.3 
ppm specific to each carbohydrate allowed for the identification and in some cases quantification of 
carbohydrate present (see section 2.4.1.5). HSQC was used to correlate proton and carbons to identify 
anomeric peaks according to literature where possible. This was dependent on the anomeric peaks 
not being overlaid with other peaks such as the H2O peak and the signal being strong enough to be 
detected.  
 
In many cases despite repeated dialysis, unconjugated carbohydrate and in some cases EDC was 
observed which appears to be non-covalently attached to the CD surface. Free carbohydrate 
observed, results from the Kochetkov amination of the 1-aminoglycan being incomplete as well as 
being hydrolysed in water. According to literature glycosylamide anomeric carbon peaks come 




D-mannopyranose and 4-O-(α-D-mannopyranosyl)-D-mannopyranose 11-13 and 18-20. However, 
other signals associated to unbound sugars were also observed and unfortunately, for all other CD-
carbohydrates no peak corresponding to an amide linked anomeric peak can be seen, which suggests 
no successful covalent conjugation is likely to have taken place.  
 
For example, figure 2.6 shows the 1H NMR spectra of CDala-1,4-mannotriose 12. This trisaccharide has 
six anomeric peaks (one under the H2O peak) in the anomeric region which correspond to two 
molecules, one of which is conjugated to the CD and the other free carbohydrate. Using an HSQC 
(Figure 2.7) to correlate these peaks with their carbons its apparent that the peak at 5.02 ppm 
correlates to a carbon signal at 71.32 ppm much smaller than usual for unconjugated anomeric peaks 
which usually come between 105-80 ppm. The other trisaccharide present in this NMR shows no 
evidence of being conjugated and peaks match those of the carbohydrate starting material identified 
in Figure A.8 at 5.04 ppm, 4.76 ppm and 4.59 ppm.  
 
The CD-glycans which have non-covalently associated carbohydrate only were investigated further to 
see if the amide linked carbohydrate has shifted upfield in the 1H NMR to come within the 
carbohydrate ring peaks between 3.2-4.1 ppm. Glucosyl amide 9 was synthesised and purified by 
another member of the Galan group. The 1H NMR of this molecule showed an anomeric peak shift to 
4.94 ppm from 4.57 ppm for 𝛽-D-glucose. Using HSQC NMR the correlated carbon shifted to 79.94 
ppm from 83.04 ppm for 𝛽-D-glucose. This suggests the signal of the amide should be observed within 
the anomeric region 4.0-5.3 ppm. However, when comparing the amide coupled glucose anomeric 
position to when it is carbon dot conjugated this anomeric peak is not visible. This suggests that in the 
case of glucose, mannose, galactose, maltose and lactose there is no covalent conjugation to the 
carbon dot 14-15 and 22-25. We therefore propose that the carbohydrate observed through NMR is 
electrostatically associated with the carbon dot surface. Figure 2.9 shows the conjugated (solid line) 
and non-covalently associated (dashed line) structure of CD-carbohydrates which were synthesised 






Figure 2.3 1H NMR of AmCD 16 (500 MHz, D2O): δ = 3.50-3.60 (m, c-h), 2.97 (t, J = 7.2 Hz a,j), 1.83 (q, J = 6.0 Hz, b,i). 
 
Figure 2.4 1H NMR of AcCD 17 (500 MHz, D2O): δ = 3.60-3.50 (d-g), 3.45 (t, J =8 Hz, c,h), 3.13 (t, J =8 Hz, j), 2.89 (t, J =8 Hz, 




























Figure 2.6 1H NMR of CDala-	𝛽-d-mannopyranose-(1—4)-	𝛽-d-mannopyranose-(1—4)-	𝛽-d-mannopyranose 11 (500 MHz, 
D2O): δ = 4.60 (s, 1H), 4.63 (1H, H1), 4.75 (s, 1H), 4.78 (d, J = 0.9 Hz, 1H), 5.02 (d, J = 2.3 Hz, 1H), 5.05 (d, J = 1.5 Hz, 1H) 
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Figure 2.7 HSQC NMR of CDala-𝛽-d-mannopyranose-(1—4)-	𝛽-d-mannopyranose-(1—4)-	𝛽-d-mannopyranose 11 (126 MHz, 
D20): δ = 93.77, 71.32, 93.68, 96.88, 100.06, 100.12 ppm 
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Figure 2.9 Scheme of synthesised glycan functionalised carbon dots.  Both CD-carbohydrate number and shortened name are 
included and used henceforth. Grey colour references that glyco carbon dots can be synthesised with both short and long 
linker CDs. Where two numbers are written the smaller number refers to AcCDala 10 syntheses and the larger refers to the 














































































































2.2.2.2 Glycan quantification -Molisch’s test 
 
The Molisch’s test allows for the quantification of any carbohydrate present on the carbon dot. It is a 
colorimetric test which uses sulfuric acid and phenol. The sulfuric acid dehydrates the carbohydrates 
which then condenses with two molecules of phenol to produce a yellow coloured product which 
absorbs at 490 nm. Using this test with our amide coupled carbohydrate-CD system it is necessary to 
appreciate the amide bond on the conjugated glycoside needs to be broken before the reaction can 
proceed. Hence, this method could underestimate the carbohydrate present on the CD. It also won’t 
differentiate between covalent and non-covalent bound carbohydrates. Indeed, comparing CD-
glycans which bear sugars non-covalently associated may report a more accurate signal of the 
carbohydrate present and correspondingly a higher amount compared to covalently linked CDs.  
Furthermore, comparing our system with other glycan functionalised nanoparticles in the literature 
which are commonly O-linked89,90, our N-linked glycans which are conjugated via a stronger amide 
bond could comparatively underestimate the carbohydrate present on our CDs. Therefore, producing 
a calibration curve from carbohydrates which contain an acetyl group at the anomeric position would 
perhaps be more accurate for our system.  
 
Figures S2.2 and S2.3 shows carbohydrate calibration data for all sugars used as well as absorption 
data for functionalised carbon dots, both long and short linked. Furthermore, background absorption 
was measured for unfunctionalised AmCD 16, AcCD 17 and AcCDala 10. Signal from which could 
originate from CD absorption at 490 nm or cleavable glucosamine on the CD surface originating from 




























sugar on CD 
15 2 0.969 303 ± 60 999.7 0.030% 
14 4 0.896 744 ± 201 999.3 0.074% 
12 14 0.966 4994 ± 1592 995.0 0.499% 
11 2 0.970 1118 ± 257 999.0 0.112% 
13 6 0.980 3461 ± 895 997.0 0.346% 
Table 2.3 Molisch test data for CD-carbohydrate synthesied from shorter linker synthesis. The carbohydrate measured is 
presented in terms of micromole (column 1) and micrograms (column 3). R2 represents the data goodness of fit, 1 being 
optimum fit (column 3). The amount of corresponding carbon dot is presented in terms of micrograms (column 4). The 
percontage mass of carbohydrate is calculated (column 5). 
 
The carbohydrate present (𝜇mol/g) the first column in tables 2.2 and 2.3 shows how many moles of 
carbohydrate are available for binding comparatively. Values range from 1 – 14 𝜇mol/g and do not 
show a trend based on either the carbohydrate present, whether covalent conjugation to the CD was 
seen, nor the type of CD (AcCD 17 or AcCDala 10) present. Carbohydrate functionalisation was also 
calculated in terms of mass (𝜇g/g) and in terms of percentage mass which composes CD-carbohydrate.  
Based on the above, this test cannot be used to elucidate the covalent or non-covalently attached 
carbohydrate nor can it reveal the specific sugar present as the test does not discriminate between 
carbohydrates. Tables 2.2 and 2.3 are therefore a measurement of the total amount of non-covalent 
bound carbohydrate and conjugated carbohydrate present in each sample.  
 
The carbohydrate mass percentage and the differences between them have been studied in AFM by 
Swift et al.91 Through AFM of CD-glucose 24, CD-mannose 22, CD-galactose 21, CD-maltose 23 and CD-
lactose 25, differences in adhesion between the tip and the glycan corona were observed92. These 









CD per CD-sugar 
μg/g 
Percentage mass 
sugar on CD 
24 2 0.988 373± 88 999.7 0.037% 
22 1 0.965 193 ± 43 999.8 0.019% 
23 1 0.926 421 ± 79 999.6 0.042% 
25 2 0.910 822 ± 229 999.2 0.082% 
21 5 0.997 890 ± 247 999.1 0.089% 
19 2 0.953 644 ± 207 999.4 0.064% 
18 3 0.970 1360 ± 486 998.6 0.136% 
20 2 0.840 1120 ± 485 998.9 0.112% 
26 2 0.910 1212 ± 229 998.8 0.121% 
27 5 0.961 3335 ± 1252 996.7 0.334% 
Table 2.2 Molisch test data for CD-carbohydrate synthesied from longer linker synthesis. The carbohydrate measured is 
presented in terms of micromole (column 1) and micrograms (column 3). R2 represents the data goodness of fit, 1 being 
optimum fit (column 3). The amount of corresponding carbon dot is presented in terms of micrograms (column 4). The 
percontage mass of carbohydrate is calculated (column 5). 
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carbohydrate mass 𝜇g/g is measured (Figure 2.10). Note that the same CD-carbohydrate batches were 
used to allow comparison between AFM and the Molisch’s test. 
 
As a mass percentage of CD-carbohydrate, carbohydrate values vary between 0.019 – 0.499 %. This 
range is much wider than that seen for the samples studied through AFM, 0.019 – 0.089 %. Hence, we 
would anticipate that the larger percentage carbohydrate masses of di- and tri- saccharides as well as 
sialyllactose cleavable conjugated onto the carbon dot we observe in the Molisch’s test would also be 
observed in AFM.  
 
Figure 2.10 a) Carbohydrate per CD (𝜇g/g) determined from the Molisch’s test. B) AFM adhesion studies92 of CD-carbohydrate 
from Swift et al92. 
CDs AmCD 16, AcCD 17 and AcCDala 10 have a carbohydrate signal which linearly increases with 
concentration (Fig S2.2). Negative control experiments with just water revealed a background level of 
absorption which is similar in absorption. Hence these measurements could be in error of the 
background. However, AcCD 17 and AcCDala 10 have a linear absorption greater than the background 
which is likely due to the glucosamine.HCl starting material used in the microwave synthesis of the 
CDs but also could reflect difference in their QY. This carbohydrate by inference must be present on 
the surface of the carbon dot and accessible for cleavage.  
 
Assuming the carbohydrate present is glucosamine we can calculate the amount of carbohydrate 
present on the surface of each of these materials per gram. Using literature values for the signal of 
glucosamine in the Molisch’s test93, we estimate the amount of sugar present on unfunctionalised 
CDs, see table 2.4. CDs (Figure S2.2) compared to CD-carbohydrate and CDala-carbohydrate the 
carbohydrate (Figure S2.3) absorption signal in the Molisch’s test is low as might be expected. 
However, it is important to note that glucosamine has a 30 times lower signal compared to mannose 
for the same concentration of carbohydrate in the Molisch’s test93. As both the short and long linker 















































Hence, the absorption could represent a significant carbohydrate amount when compared to that 
observed for carbohydrate functionalised carbon dots.  
 
 Table 2.4 Molisch test data for AmCD, AcCD and AcCDala 10. The carbohydrate measured is presented in terms of micromole 
(column 1) and micrograms (column 3). R2 represents the data goodness of fit, 1 being optimum fit (column 3). The amount 
of corresponding carbon dot is presented in terms of micrograms (column 4). The percontage mass of carbohydrate is 
calculated (column 5). 
When comparing the lower signal seen for glycan functionalised CDs and free CDs and taking into 
account that the Molisch’s test represents the cleavable and free carbohydrate present, it follows that 
the glucosamine on functionalised CD is mostly shielded sterically offering explanation for the reduced 
carbohydrate signal in functionalised CDs. 
 
2.2.2.3 Glycan quantification – using NMR  
 
In order to get a more accurate quantification of conjugated glycan functionalization. 1H and HSQC 
NMR measurements using imidazole as an internal standard were carried out. The same sample of 
CD-4-O-mannobiose which was used to assess carbohydrate conjugation in the Molisch’s test was 
used here (Figure A.19). 4-O-mannobiose anomeric peak at 5.04 ppm (1H) and 71.23 ppm (13C) and 
imidazole peak at 7.77 ppm (1H) were integrated and the moles of carbohydrate determined. In terms 
of mass, the carbohydrate mass was 51 mg per gram of CD-4-O-mannobiose 19 or 5.1 % content. 
Comparing this to the 0.064 % carbohydrate content determined through the Molisch’s test, NMR 
suggests a greater carbohydrate content than the Molisch’s test can measure. The carbohydrate 
quantified in NMR refers to only the conjugated carbohydrate, however, looking at the spectra Figure 
A.19 there is more unconjugated carbohydrate present than conjugated. Hence, the measure of 
carbohydrate content is suggested to be a gross underestimation in the Molisch’s test. Quantifying 
the total amount of carbohydrate using 1H NMR was not possible for CD-4-O-mannbiose 19 with 
imidazole as the anomeric peaks were not identifiable due to poor signal to noise resolution, resulting 
















sugar on CD 
16 6 0.475 2279 998 0.228% 
17 86 0.837 30848 969 3.085% 








Figure 2.11 FTIR of a) AmCD 16 b) AcCD 17 c) AcCDala 10 
FTIR was carried out on AmCD 16, AcCD 17 and AcCDala 10 in order to investigate the surface groups 
present on each carbon dot (Figure 2.11). All CDs had peaks at 3350 cm-1 (O-H stretch), 3332 cm-1 (N-
H stretch) and 2924 cm-1 (N-H stretch) which corresponds to the presence of amine and or alcohol. 
For AcCDala 10 this peak has combined with the peak at 2870 cm-1 (C-H stretch) which is seen 
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separately for AmCD 16 and AcCD 17. The other peak that all spectra share is the one at 1087 cm-1 (C-
O). Upon succinic acid ring opening reaction to convert AmCD 16 to AcCD 17 new peaks appear in the 
FTIR spectrum. 1638 cm-1 (HNCO stretch) amide, 1561 cm-1 (N-H stretch) amine, and 1400 cm-1 (O-H 
bend) carboxylic acid. The formation of an amide bond confirms conjugation of succinic acid which is 
also seen through the new carboxylic acid peak. For AcCDala 10, a carboxylic acid peak is also seen at 
1403 cm-1 (O-H), suggesting 𝛽-alanine is presented on the surface. Three additional peaks are also 
seen compared to AcCD 17 due to the different synthesis reflected on the carbon dot surface. These 
are 1714 cm-1 (C=O stretch), 1212 cm-1 (C-O stretch) and 611 cm-1 (C-Cl stretch).  These results match 
expected surface functionality.  
 
2.2.2.5 UV-Vis spectroscopy 
 
UV-Vis data of AmCD 16, AcCD 17, AcCDala 10 and example CD-carbohydrate, CD-, CDala-, 4-O-
mannobiose in H2O are presented in Figure 2.12. Common features include an absorption peak at 280 
nm corresponding to carbonyl and carbohydrate n à 𝜋* transition and also a large peak at < 200 nm 
corresponding to 𝜋 à 𝜋* transitions. The absorption tail seen towards longer wavelengths up to 600 
nm belong to the numerous optical sites which exist at the surface of CDs. Swift et al.91 investigated 
the absorption of CD-, glucose, mannose, maltose, galactose and lactose and through 2D fluorescence 
plots observed that at wavelengths greater than 300 nm the absorption varied between carbohydrate 
present. This suggests that the surface electronics are influenced by the carbohydrate present 
independent of the core,94 hence carbohydrates are not just passivating agents. 
 
The absorption peak at 280 nm varies in shape dependent on carbohydrate conjugated (independent 
of concentration intensity). For example, both CD-lactose and CD-maltotriose have smaller broader 
peaks compare to CD-4-O-mannobiose. The differences here may reflect the carbohydrate 
concentration on the CD. Interestingly, the AcCDala 10 spectra all have a more pronounced peak at 
280 nm in common, seen through comparing CD-mannose and CDala-mannose. Perhaps reflecting the 
different CD cores and the electronic characteristics they impose on the edge band emission. 
Furthermore, no difference can be concluded in the UV-Vis spectra between covalent and adsorbed 







Figure 2.12UV-vis absorption spectra for a) AmCD 16, b) AcCD 17, c) AcCDala 10, d) CD-4-O-mannobiose 19 and e) CDala-4-
O-mannobiose 14. 
 
2.2.2.6 Fluorescence spectroscopy 
 
The excitation and emission of AmCD 16, AcCD 17, AcCDala 10 and example CD-carbohydrate CD and 
CDala-, 4-O-mannobiose in water are presented in Figure 2.12. The excitation spectra has a peak at 
340 nm which is seen for all CDs synthesised. Swift et al.94 propose that the carbohydrate conjugation 
affects this region specifically which corresponds to the absorption peak seen at 340 nm. From our 
data it looks as though a substantially greater glycan dependent excitation change is seen for the peak 
at 290 nm. AcCDala 10 shows this starkly, where glycan presence has a much greater peak at 290 nm 
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in CD-4-O-mannobiose 19. Interestingly, for CD-4-O-mannobiose 19, the same peak at 290 nm is 
reduced compared to the starting AmCD 16 or AcCD 17. Hence, both the surface domain and edge 
band are influenced by the carbohydrate at the surface. 
 
These carbon dots have excitation-dependent emission similar to other carbon dots synthesised via 
bottom up methods, reflecting the variety of molecular states present in carbon dots. The peak 
emission upon excitation at 340 nm is 450 nm with a slight shoulder at ~ 525 nm. If carbohydrate is 
present this shoulder is more pronounced owing to the dual fluorescence of these carbon dots 
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Figure 2.13 Fluorescence spectra of a) AmCD 16 b) AcCD 17 c) CD-4-O-mannobiose 19 d) AcCDala 10 e) CDala-4-O-
mannobiose 12 f) and all CD-carbohydrate emission spectra overlapped. 
 
 
2.2.2.7 Quantum yield 
 
Quantum yield (QY or 𝚽) of a nanomaterial is an independent ratiometric assessment of its ability to 
emit photons of light based on the number of photons absorbed. This characteristic is important when 
considering bioimaging applications. Some of the brightest commercially available fluorophores have 
QYs up to 0.92 and QDs have good QY, greater than 0.5 in some cases which has been matched by 
recent carbon dot syntheses across the fluorescence spectrum based on improved passivation. 
Depending on the application QY may be considered sufficient. Using spectrophotometer 
instrumentation available to us, we are able to analyse materials of low QY down to 0.01.   
 
When calculating the QY, the excitation and emission wavelengths of a material must be considered, 
different dyes with known QY are used as a standard against which the material of interest is 
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compared. Two common dyes are Rhodamine B 𝜆&' 514 nm and Quinine sulfate (QS) 𝜆&' 350 nm. In 
this work quinine sulfate was used as its photoluminescence is similar to short and long linker carbon 
dots synthesised in this work, see section 2.4.9. Experimentally the standard must be run in 0.1 M 
H2SO4 at 22 oC. Experimentally, a calibration curve of fluorescence versus absorbance is made when 
the absorbance is less than 0.1 (see Figure S2.9, where there is a linear relationship can be observed 
bwhen abs <0.1). The gradient of the line is then used to calculate the QY. The QY was determined to 
be between 0.66-8.79 for all material to be used in further experiments. The QY was dependent on 









Equation 2.1 Quantum yield (QY or 𝛷) equation. Using quinine sulfate (QS) as a standard (QY = 0.54), the refractive index (𝜂) 
of H2O being 1.33 and using the gradient (𝑚) from the data generated measuring fluorescence against absorbance. 
 
Sample QY% R2 
Quinine Sulfate 54.60  0.99 
AmCD 3.87 ± 0.44 0.85 
AcCD 8.79 ± 0.16 0.74 
CD-glucose 3.92 ± 0.47 0.84 
CD-mannose 6.36 ± 0.19 0.99 
CD-galactose 7.05 ± 0.31 0.97 
CD-maltose 5.75 ± 0.69 0.84 
CD-lactose 6.26 ± 0.29 0.97 
CD-maltotriose 7.05 ± 0.31 0.97 
CD-1,3-1,6-manntriose 4.04 ± 0.79 0.99 
CD-1,4-manntriose 3.88 ± 0.07 0.99 
CD-4-O-mannobiose 2.39 ± 0.44 0.99 
AcCDala 6.29 ± 0.42 0.94 
CDala-mannose 0.66 ± 0.04 0.96 
CD-ala-galactose 3.50 ± 0.04 0.98 
CDala-1,3-1,6-mannotriose 4.50 ± 0.79 0.76 
CDala-1,4-manntriose 2.26 ± 0.19 0.91 
CDala-4-O-mannbiose 3.06 ± 0.44 0.74 
CD-3’sialyllactose 2.30 ± 0.19 0.87 
CD-6’sialyllactose 5.24 ± 0.34 0.94 
Table 2.5 Quantum yield (QY or 𝛷) data measured for the carbon dot materials synthesised. R2 is the goodness of fit with 1 
being the best fit.  
 
2.2.2.8 DLS and zeta potential  
 
Dynamic light scattering (DLS) and zeta potential (𝜁) were used to try and observe monodispersed 
carbon dots and determine their hydrodynamic size in HEPES buffer 0.1M concentration with 5 mM 
CaCl2 and 5mM MnCl2. This buffer is used in all later binding studies (see Chapter 3). TEM and AFM 
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reported size distribution of carbon dots between 1.54 – 3.69 ± 2.8 and 2.27 ± 0.89 (for AmCD 16) 
respectively. Hence, from DLS we expected a hydrated diameter larger than this, but of the same order 
of magnitude. Furthermore, previous work in the group measured monodispersed CDs using DLS in 
distilled H2O: 3.85 ± 0.8985 and MeOH: 3-4 nm92.  
 
Factors affecting carbon dot dispersion include the dispersant interaction, pH and particle 
concentration. In this work we were interested in the distribution of CDs in HEPES buffer, hence we 
did not change this parameter. 0.1 M HEPES buffer has a pKa of 7.48 at 25 oC, buffering over the pH 
range 6.8- 8.2. Amines on the surface of AmCD 16 at this pH are neutral and acids on the surface of 
AcCDs 16 are charged. However, for both types of acid functionalised CDs (AcCD 16 and AcCDala 10), 
electrostatic repulsion did not induce a monodispersed sample.  
 
Literature evidence shows that a size distribution trend exists for nanoparticles as a function of 
concentration. At high concentration the size distribution is distorted and at low concentration the 
data is too noisy. Where the size distribution is independent of the concentration, particle diameter 
can be measured. Optimisation with CD-galactose in 0.1M HEPES and comparing with H2O, MeOH and 
0.01M HEPES between 0.3 – 5 mgml-1, the particle size in each diluent was measured. Peak 1 data for 
both intensity and number measurements are shown in figure 2.14. Peak 1 refers to the first peak 
measuring the smallest size but greater than 1 nm, allowing for solvent peaks which fall below 1 nm 
to be omitted.  
 
In MeOH and H2O, the peak 1 diameter was measured between 100 – 500 nm and between 400 – 
1000 nm respectively, suggesting aggregation is the presiding form in both solutions, and data 
aggregation occurs in a concentration dependent manner. Number data did not reveal any particle 
size smaller than that observed from intensity data at these concentrations and conferred the same 
size distribution. In HEPES buffer at 0.1 M and 0.01 M smaller sizes were measured at the same order 
of magnitude as seen with other techniques, suggesting greater monodispersed sample. In the two 
buffers, diameters of 0.7 nm ± 0.2 and 1.2 nm ± 0.2 respectively for number data and 4.3 nm ± 0.6 and 
2.7 nm ± 0.6 respectively for intensity data are averages from data collected between 0.3 – 2.5 mgml-
1 where sizes are in the same regime.  
 
Looking at size distribution for CD-galactose 21 in 0.1 M HEPES only, peak 1 number data at 
concentrations 0.3 – 2.5 mgml-1 (Figure 2.14d) shows only one peak. This peak corresponds to solvent, 
shown by the green data points all below 1 nm. This is likely due to the proportion of particles in the 
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monodispersed form being very low. Looking at the intensity data of the same sample, larger particles 
4.278 nm ± 0.555 nm are measurable.   
   
  
   
Figure 2.14 DLS of CD-galactose 21 at concentrations 0.3125 – 5 mgml-1. Peak 1 % intensity (a&b) and % number (c&d) data 
are presented for CD-galactose in 0.1 M HEPES (green), 0.01 M HEPES (blue), MeOH (red) and H2O (purple). 
For each CD-carbohydrate the concentration in 0.1 M HEPES to measure particle hydrodynamic 
diameter, must be determined through the same optimisation process. However, to allow comparison 
of the degree of aggregation between CD-carbohydrates, DLS (% intensity data) and zeta potential 
were carried out, with sample concentration 0.4 mgml-1 in 0.1 M HEPES for all CD-carbohydrates 
(Figure 2.15). For these samples the reported sizes all report hydrodynamic diameters between 500-
1000 nm suggesting aggregation. This is likely due to electrostatic and hydrophobic inter carbohydrate 
and carbon dot surface group interactions.  
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Observing intensity data of CD-galactose 21 in 0.1 M HEPES best elucidates the CD hydrodynamic size 
is supported by zeta potential results. Generally speaking, more positive zeta potential is indicative of 
more monodispersed particles in a sample, hence by varying concentration of CD-galactose 21, it is 
possible to infer at which concentration the size should be measured using DLS. Within the 
concentration range measured, 0.4 mgml-1 in 0.1 M HEPES, was the highest zeta potential 
measurement of 7.0 ± 0.6 mV. Correspondingly in DLS, this concentration falls in the range where the 
particle size measured doesn’t vary with concentration. Hence, supporting the diameter for CD-
galactose 21 as 4.3 nm ± 0.6 nm. 
 
Figure 2.16 Zeta potential ( 𝜁) data for CD-galactose over a range of concentrations 0.1 – 0.5 mgml-1 . Data for CD-galactose 
in buffer 0.1 M HEPES (green), 0.01 M HEPES (blue), MeOH (red), and H2O (purple) are shown. 
 
At the same concentration of 0.4 mgml-1 in 0.1 M HEPES, the zeta potential was measured for all CD-
carbohydrates (2.17). For CD-carbohydrates with a AmCD 16 core the 𝜁 was between 5-15 mV. Apart 
from the CD-sialyllactose sample which is slightly negative reflecting the carboxylic acid group on the 
terminal sugar and hence presented on the CD surface. As zeta potential is a measure of difference in 
charge between particle surface and the diluent, this negative charge suggests that the carbohydrate 
is presented on the surface of the particle and is a distinct environment to the diluent.  
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AcCDala 10 data zeta potential values all suggest a slightly negative surface charge (but close to 0 mV) 
hence are likely aggregating. This reflects that these particles are made through a different synthesis 
and have a different structure and surface properties such as carboxylic groups seen from FTIR peak 
at 1403 cm -1. Comparing CD-carbohydrate and CDala-carbohydrate which have been functionalised 
with the same carbohydrate either having a positive or negative zeta potential depending on the CD, 
suggests that the carbon dot surface is highly exposed to the diluent. 
 
In summary, table 2.6 shows the hydrodynamic diameter and corresponding zeta potential for each 
sample at 0.4 mgml-1 in 0.1 M HEPES. This concentration of HEPES buffer is used in later experiments 
where binding is assessed through DLS hydrodynamic aggregate size measurements. Compared to 
previous size distributions for CD-carbohydrate materials46,92 measured in H2O and MeOH these sizes 
are much larger in 0.1 M HEPES.  
 
  
















































































































































































CD-sugar Intensity pk1 (d.nm) Zeta potential 
(mV) 
AmCD 590 ± 71 15.7 ± 3.5 
AcCD 611 ± 113 5.1 ± 0.8 
CD-glucose 827 ± 53 4.4 ± 1.6 
CD-mannose 726 ± 61 9.6 ± 2.5 
CD-galactose 927 ± 38 7.0 ± 0.6 
CD-maltose 428 ± 13 10.1 ± 6.0 
CD-lactose  719 ± 16 5.0 ± 2.2 
CD-maltotriose 385 ± 37 14.3 ± 3.0 
CD-1,4-mannotriose 717 ± 17 9.0 ± 1.3 
CD-1,3-1,6-mannotriose 628 ± 61 12.8 ± 1.7 
CD-4-O-mannobiose  650 ±79 11.0 ± 1.7 
AcCDala 923 ± 100 -1.9 ± 0.7 
CDala-mannose 536 ± 54 -2.1 ± 0.9 
CD-ala-galactose 1296 ± 11 -7.0 ± 2.1 
CDala-1,3-1,6-mannotriose 576 ± 47 -6.3 ± 1.4 
CD-1,4-mannotriose 893 ± 34 -0.1 ± 2.0 
CD-4-O-mannobiose 1012 ± 71 -8.7 ± 3.7 
CD-3’sialyllactose 716 ± 48 -5.0 ± 1.8 
CD-6’sialyllactose 484 ± 121 -3.3 ± 0.6 





Previous high-resolution transmission electron microscopy (TEM) work in the group with these CD-
carbohydrates show these have an sp3 crystalline diamond-like core evidenced by lattice spacing of 
0.21 nm and 0.25 nm for the (111) and (110) planes respectively. The diameter of AmCD 16 core was 
previously reported as 2.45 ± 0.54 nm83, agreeing with diameter range measured from samples in this 
work which are reported as between 1.54-3.69 ±	2.87 as seen in Figures 2.19, 2.20 and 2.21 
(histograms) and presented in table 2.7. 
 
TEM provides a diameter based on the contrast against a carbon background which is relatively 
difficult to achieve. Best contrast is achieved when using homemade carbon coated (4 nm coating) 
copper grids. Considering that the edge domain surrounding the core and the glycan coating may give 
poor contrast TEM usually reports a smaller diameter than DLS. High resolution images taken by Hill 
et al. show that AmCD 16 observed by TEM are wholly made up of sp3 region. Hence, the particle 
diameter seen through TEM is that of the sp3 core.  
 
Data presented in figure 2.19 are TEM images of AmCD 16, AcCD 17 and CD-carbohydrates; CD-
lactose, CD-glucose, CD-mannose, CD-galactose and CD-maltose 21-25 all made from long linker CDs. 
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Selected samples were chosen for TEM to allow for complete processing. Samples were prepared in 
MeOH at 5 mgml-1 before drop casting onto carbon coated copper grids and left to dry overnight 
before imaging. In each case the left-hand image shows the lowest magnification of each sample and 
magnification increases as you move right. From these images the carbon dots can be confirmed as 
quasi-spherical nanoparticles. Upon glycan functionalisation the high contrast cores observed for 
AmCD 16 and AcCD 17 are less well resolved owing to the glycan coating present. This coating is seen 
as a cloudy corona around the particles but also present separate from CD cores. This is most clearly 
seen in CD-galactose where a shadowy film covers the grid and is not correlated to the location of the 
CD cores. As TEM reveals the core sp3 domain, the diameter reported for each of AmCD 16, AcCD 17 
and CD-carbohydrate are all within error of each other. The large error is likely due to the highly 
heterogeneously sized population of particles known to result from bottom up syntheses. 
 
Scanning transmission electron microscopy (STEM) a form of dark-field microscopy was trialled for 
imaging AcCDs 17. This technique is good for imaging samples with low contrast as it collects scattered 
electrons from the sample and the background remains dark. The AcCDs 17 here are bright and more 
easily distinguishable from the background then in standard TEM. The diameters measured using this 
technique was 3.47 ± 2.79, within error compared to 2.84 ± 2.0 for standard TEM. 
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Figure 2.19  TEM images of long linker carbon dots; AmCDs 16; AcCDs 17; CD-lactose 25; CD-glucose 24; CD-mannose 22; 
CD-galactose 21 and CD-maltose 23. Increasing magnification from a to c. 
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Figure 2.21 Histograms of diameter from images in figure 2.19 for a) AmCD 16, b) AcCD 17, c) CD-lactose 25, d) CD-galactose 
21, e) CD-mannose 22, f) CD-glucose 24, g) CD-maltose 23 h) AcCD 17 (from STEM figure 2.20) Image J software was used to 
measure particle diameter using  thresholding 
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CD-sugar Diameter from TEM (nm) 
AmCD 16 3.69 ± 2.8 
AcCD 17 2.84 ± 2.0 
CD-glucose 24 1.54 ± 0.64 
CD-mannose 22 2.37 ± 0.77 
CD-galactose 21 2.81 ± 1.87 
CD-maltose 23 1.91 ± 0.93 
CD-lactose 25 2.88 ± 1.67 





Tapping mode atomic force microscopy (AFM) provides the most accurate size information with the 
possibility of atomic resolution in the height dimension. There are some caveats when considering CD 
AFM data; the sample is dry during imaging hence the height does not represent the hydrated 
diameter of the particle. As the AFM tip has a radius of 0.35 𝜇m (in these experiments) there is an 
overestimation of the size of the CD using this technique. AFM of AmCD 16 revealed a diameter of 
2.27 ± 0.89 nm which is similar to previous work in the group of 3.0 ± 1 nm. Comparing this to TEM 
data 3.69 ± 2.8 nm, 1.57 nm height of AmCD 16 is considerably smaller. This may reflect either an 
overestimate of size from the TEM data or an underestimation of the size from AFM. Considering that 
TEM data shows a smaller average size post carbohydrate functionalisation, suggests that the TEM 
data for AmCD 16 is an overestimation. 
 
AFM can also be used to probe the composition and heterogeneity of the CD-carbohydrates through 
adhesion studies as carried out by Swift et al.91 Through adhesion mapping the areas of high adhesion 
which can be thought of as “sticky” are carbohydrate and areas of low adhesion are the CD surface. 
This was determined from probing the surface of CD-carbohydrates and observing areas of high and 
low adhesion on one particle. Some particles had more sticky areas than others which showed 
variability and inhomogeneity between carbohydrates and between individual particles also. One 
consideration of this conclusion must be that the CD-carbohydrate linker is relatively long. When dried 
the TTDDA linker and carbohydrate may not represent the hydrated organisation of these molecules, 




2.2.2.12 Carbon dot structure and spectroscopic properties 
 
Publication by Swift et al.94 uses a number of techniques to conclude information about the CD 
electronics and structure relationship. Specifically, the influence of the presence of carbohydrate on 
the electronic and spectroscopic properties on the long linker carbon dots. Glucose, mannose, 
galactose, maltose and lactose were tested in this work. TEM images presented in this publication 
were carried out by myself. The main work in this paper involved the use of ultra-fast spectroscopy to 
elucidate the lifetimes of the long linker CDs.  
 
Transient absorption (TA) of carbon dots involves a pump and probe laser which are sent to the sample 
in femto or nanosecond succession to sequentially excite the sample from the ground state to the 
excited state and then the probe laser is sent to collect a snapshot of the exited energy profile at the 
set delay time point between pump and probe. This snapshot is based on how much the sample 
absorbs the probe laser energy. The delay is varied to build up an image of the sample excited states 







Figure 2.22 Atomic force microscopy images of AmCD 16 a) topography b) 3D height profile of AmCDs 16 c) histogram of 
particle height (error is SEM). 














Mean diameter: 2.27 nm ± 0.89





for non-radiative decay between energy levels within the molecule is called the excited state lifetime 
and a single molecule has as many lifetimes as it has energy levels in the conduction band. Apart from 
the fluorescence mechanism, the intrinsic lifetimes along with QY of a CD will determine the 
appropriateness of the material for bioimaging68.  
 
Bioimaging application of CD is advantageous if the intrinsic lifetime is greater than commercial 
fluorophores such as fluorescein 4.1 ±0.1 ns, Rhodamine B 17.4 ±0.02 ns, Alexafluro 488 4.1 ns and 
Alexafluor 647 1 ns. Commonly for CDs with dual fluorescence the core PL will have a relatively longer 
decay lifetime such as 14 ns compared to the lifetime of 1.3 ns originating from shell and surface PL 
centre. The lifetime of interest can be selected through either relatively blue or red shifting the 
excitation wavelength as the core has a fluorescence maxima blue shifted relative to the surface PL 
centre68. 
 
The excitation wavelength used is close to the excitation maxima of the sample in our case 340 nm 
pump wavelength and white light (CW) probe. This wavelength is known to excite both fluorescence 
mechanisms present in our material, hence, multiple lifetimes were observed. T1 lifetimes on the 
picosecond order between 4.2 - 15 ps (for both AmCD 16 and CD-carbohydrates) were attributed to 
core relaxation, dependent on solvent access to the CD surface groups below the inhomogeneous 
glycan corona. T2 had ps lifetimes which scaled with T1 hence, were also attributed to the core. Longer 
ns lifetimes T3 was thought to be from the surface groups. Exciton trapping here confers a longer 
lifetime and we propose the majority of the fluorescence91. 
 
2.3 Conclusions and future work  
 
In this chapter the CD structure and glycan functionalisation were investigated and characterised 
further when compared to previous work in the Galan group and the literature. Key findings include 
the need for better methods that can provide direct evidence of covalent functionalisation of carbon 
dots. Evidence of covalent linkage through an amide linked anomeric carbon was identified for 
mannose oligosaccharides on both short and long linker CDs, however it was also observed that non-
covalently attached sugar might also be present on the CD surface. This information must be used to 
inform any experiments involving these materials. The glycan presentation is known to impact lectin 
binding through the cluster glycoside effect. Hence, interpreting binding studies with these 
glyconanoparticles must be correlated to nanoparticle-based glycan conjugation and thus 




Furthermore, physical characterisation of long linker carbon dots was carried out to build up a full 
picture of the glyconanoparticle structure. Electronic properties of the carbon dot depend on the 
carbohydrate, changing the photoluminescence excitation in some cases, the fluorescence peak at 
500 nm (dual fluorescence) and the quantum yield. These spectroscopic properties were determined 
for the specific batch of carbon dots which are used in the following chapter. Having developed and 
characterised these materials in the same way from the same synthesis batch of carbon dots allows 
for relative comparison between these material.  
 
 
Figure 2.23 Summary figure of longer linker carbon dot functionalised with a generic carbohydrate (mannose in this case). 
Data from DLS and AFM from this chapter are used in combination with high-resolution TEM data from the thesis of S.Hill83. 
Surface functional group information informed through FTIR, the Molisch test and NMR.  
 
The conclusive structure of long linker CD-carbohydrate is summarised in Figure 2.23. Previous high 
resolution TEM work by Stephen Andrew Hill83 shows a core sp3 crystalline structure, with an average 
size of 1.3 ± 0.2 nm and an sp2 amorphous layer around that. AFM and DLS data show height and 
hydrated diameters of 2.27 ± 0.89 nm and 4.28 ± 0.56 nm respectively. These data can vary based on 
carbohydrate as shown by Swift et al.94 and also between batches. NMR data showed that the 
carbohydrate present can be quantified relative to the carbon dot in the sample hence allowing 
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comparison between CD-carbohydrates. This method allows for the quantification of all carbohydrate 
present on the carbon dot surface both covalently bound and non-covalently associated. The Molisch 
test quantification method is appropriate for O-linked carbohydrates as this is more readily cleavable 
than our N-linked carbohydrates. TEM and zeta potential data shows that carbohydrate exists 
associated to the surface of the carbon dot. TEM also shows that material of low density exists in the 
CD-carbohydrate samples but not AmCD 16 or AcCD 17 samples suggesting the presence of glycans. 
Work by Swift et al.94 shows that the glycan coating of the CD-carbohydrate is likely inhomogeneous 
as the surface of carbon dot is exposed post carbohydrate functionalisation. This makes sense as the 
structure of carbons dots is known to be quasi-spherical and the functional amine and acid handles 
are also likely inhomogeneously distributed on the CD surface.  
 
Caveats include that it can be difficult to determine the ratio of covalently bound and non-covalently 
bound carbohydrate in each CD-carbohydrate sample. Also, the presentation of these glycans cannot 
directly be inferred. The ratio of linked and associated carbohydrate will differ between CD-
carbohydrate samples; hence, binding studies would be specific to that sample. The long linker carbon 
dots would extend the carbohydrate away from the carbon dot surface if unfolded. However, with 
free carbohydrate associated through hydrogen, hydrophobic interaction this may not be the case. 
Indirect methods have been used to determine the lectin binding to these glyconanoparticles through 























2.4 Chapter 2 Experimental 
2.4.1 Synthesis 
 
1) Amine terminated CD core synthesis (AmCD 16) 
Amine terminated carbon dots (AmCDs) numbered 16 were synthesised in a microwave assisted 
reaction from Glucosamine.HCl (1 g) and TTDDA (1.35 ml) dissolved in 20 ml deionised H2O. Reaction 
was carried out in a 250 ml conical flask at the centre of an 800 W Wilkinson domestic microwave at 
80% power for 3 minutes. CDs were extracted using H2O/DCM and purified further using a Vivaspin 
20 ml column 10,000 Da MWCO filter (GE Healthcare Life Sciences) centrifuged for 10 mins at 8,000 
rpm. CD were lyophilised before further use. AmCD 16 synthesis was also scaled up using a 
hydrothermal method. Glucosamine.HCl (6 g) was heated in H2O (8 ml) to 100 oC before TTDDA (8 ml) 
was added for 30 minutes. After synthesis, the same extraction and purification was carried out.  
 
2) Acid terminated FCD functionalisation (AcCD 17) 
AmCDs 16 (200 mg) were functionalised with a terminal acid group - AcCDs numbered 17 using 
succinic anhydride (200 mg) in 1:1 EtOH:H2O overnight. CDs were purified using dialysis in a 500-1000 
MWCO membrane (Biotech Spectra/Por dialysis membrane) overnight.  
 
3) Kochetkov sugar amination  
β-D-glycosylamines 1-8 were synthesised using the Kochetkov amination method to allow for 
conjugation onto the AcCD 17. Reaction mix consisted of 15 g trisaccharide 6 & 8, 10 g disaccharide 
2,4 & 7 or 5 g for monosaccharides 1,3 & 5  (1% w/v) in saturated (NH4)2CO3 stirred for 5 days at RT, 
over which solid (NH4)2CO3 was added at 40 mg per mg of saccharide to ensure the reaction remains 
in excess. After the reaction the solution was lyophilised to remove excess (NH4)2CO3 encouraged by 
re-dissolving in warm aq. MeOH as required. β-D-glycosylamines 1-8 were stored at -4 °C.  
 
4) AcCD-saccharide functionalisation – EDC coupling 
AcCD 17 (60 mg) was reacted with aminated saccharide (250 mg for monosaccharides) accounting for 
the Kochetkov amination yield in each case (Table 1) in 3ml H2O with a 2-fold amount of EDC overnight. 
Unreacted material was removed through dialysis against deionised H20 using a 500-1000 MWCO 






4b) AcCD-sialyl-D-lactose functionalisation – Reductive amination 
AcCD 17 (10 mg) was dissolved in 1 ml deionised H2O before either 3’-sialyllactose or 6’-sialyllactose 
(100 mg) was added to the solution and finally sodium cyanoborohydride (13 mg). The reaction was 
stirred for 3 hours. Unreacted material was removed through dialysing against deionised H2O using a 
5000 MWCO membrane overnight.  
 
5) AcCDala synthesis84 
“Short linker” acid terminated CDs – AcCDala numbered 10, were synthesised from glucosamine.HCl 
and 𝛽-alanine in a 3 minute domestic microwave synthesis. Glucosamine.HCl (1.00 g, 4.63 mmol) was 
dissolved in 20 ml deionised H2O before the addition and dissolving of 𝛽-alanine (0.45 g, 5.09 mmol). 
The reaction was carried out in a 250 ml conical flask at the centre of an 800 W Wilkinson domestic 
microwave at 80% power for 3 minutes. CDs were extracted using H2O/DCM and purified further using 
a Vivaspin 20 ml column 10,000 Da MWCO filter centrifuged for 10 mins at 8,000 rpm. CD were 
lyophilised before further use. 
 
6) AcCDala-saccharide functionalisation 
AcCDala (30 mg) was dissolved in 3 ml deionised H2O before the addition of coupling agent EDC (60 
mg) and finally the aminated saccharide of interest (125 mg for monosaccharides). The reaction was 
left stirring for 16 h. Unreacted material was removed through dialysing against deionised H2O using 
a 500-1000 MWCO membrane overnight.  
2.4.2 Post Kochetkov amination characterisation of glycosylamines 1-8.  
 
NMR was used to determine reaction yield for glycosylamines 1-5 using diagnostic 𝛽-anomeric peak 
shift as seen in table 1. The product and starting material anomeric peaks and 𝛼 and 𝛽 anomer signals 
are clearly distinguishable according to literature seen in 1H NMR between 4.0-5.3 ppm and in 13C 
between 82-105 ppm hence these are assigned. Where signals can be identified they are denoted as 
either starting material † and aminated product of interest *. Where possible, using literature 
references other proton and carbon signals have been assigned. For novel glycosylamines 6-8 the 
anomeric proton and carbon signals have been assigned. Remaining starting material anomeric peaks 
are also identified †. Molecule 9 is also fully assigned in this section. 
 
Notes on NMR assignments - * notates anomeric aminated product. † notates anomeric starting 
material. C1 and H1 refers to the 1st carbon position on the carbohydrate ring, moving around the ring 
clockwise to position 6. C1’ refers to the second and C’’ the third monosaccharide in an oligosaccharide 
beginning at the reducing end of the molecule. See Appendix for NMR spectra.  
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 1 1-Amino-1-deoxy-β-D-galactopyranoside95 
1H NMR (400 MHz, D2O): α-D-Galactopyranose δ = 5.25† (d, H1, 1H, J = 3.6) ppm. β-D-Galactopyranose 
δ = 4.61† (d, H1, 1H, J = 9.1) ppm. 1-Amino-1-deoxy-α-D-galactopyranose δ = 3.47 (dd, 2H, J = 9.6, 8.3). 
1-Amino-1-deoxy-β-D-galactopyranose δ = 4.25* (d, H1, 1H, J = 8.7), 3.38 (dd, 2H, J = 9.8, 8.7) ppm.  
13C NMR (126 MHz, D2O): 1-Amino-1-deoxy-β-D-galactopyranose δ = 87.55* (C1), 75.85 (C5), 73.53 
(C3), 71.90 (C2), 70.45 (C4), 61.15 (C6) ppm. 1-Amino-1-deoxy-α-D-galactopyranose δ = 68.96 (C4), 
68.78 (C2) ppm. α-D-Galactopyranose δ = 92.41† (C1) ppm. Mass ES+ prediction: 179.156 MW 
Measured mass ES+ : 202 and 364.1 MW.  
 
2 1-Amino-1-deoxy-β-D-lactopyranoside96 
1H NMR (400 MHz, D2O): α-D-Lactose δ = 5.22* (d,H1, 1H, J = 3.8) ppm. β-D-Lactose δ = 4.45 (d, 1H, J 
= 7.8), δ = 4.66 (d, 1H, J = 8.0) δ = 5.2 (d, 1H, J = 3.8) ppm. 1-amino-1-deoxy-β-D-lactose δ = 4.44* (d, 
1H, J = 7.8), 4.11 (d, 1H, J = 8.8), 3.92 (d, 1H, J = 3.4), 3.96 (d, 1H, J = 2.4), 3.85-3.55 (m, 9H), 3.22 (m, 
1H) ppm. 
13C NMR (126 MHz, D2O): β-D-Lactose δ = 102.47 (C1) ppm. 1-amino-1-deoxy-β-D-lactose δ = 102.47, 
84.42, 68.41, 68.62, 73.57 ppm. Mass ES+ prediction: 341.3 MW Measured mass ES+: 364.1 MW. 
 
3 1-Amino-1-deoxy-β-D-glucopyranoside97 
1H NMR (400 MHz, D2O): α-D-Glucopyranose δ = 5.18† (d, 1H, H1 J = 3.8) ppm. β-D-Glucopyranose δ = 
4.59† (d, 1H, H1 J = 7.9), 3.85 (s, 1H), 3.73 (s, 1H), 3.56 (d, 1H, J = 3.7), 3.49 (s, 1H), 3.43 (s, 1H), 3.27 
(t, 1H J = 8.6) ppm. 1-Amino-1-deoxy-β-D-glucopyranose δ = 4.24* (d, 1H, H1 J = 8.9), 3.60 (d, H6a, 1H, 
J = 6.0), 3.78 (d, H6b, 1H, J = ),  3.14 (t, H2, 1H, J = 9.0) ppm.13C NMR (126 MHz, D2O): α-D-
Glucopyranose δ = 91.84 (C1) ppm. β-D-Glucopyranose δ = 95.66 (C1), 75.67, 74.06, 72.60, 71.32, 
71.32 69.54 ppm. 1-Amino-1-deoxy-β-D-glucopyranose δ = 84.85* (C1), 72.41 (C2) 60.49 (C6) ppm. 
Mass spectroscopy ES+ prediction: 179.156 MW Measured mass: 202, 364, 381 MW.  
 
4 1-Amino-1-deoxy-β-D-maltopyranoside96 
1H NMR (400 MHz, D2O): β-D-maltopyranose δ = 4.59 (d, 1H, H1 J=8.0) ppm.  α-D-maltopyranose δ = 
5.16† (d, 1H, H1 J=3.8), 5.34† (d, 1H, H1’ J=3.8) ppm. 1-amino-1-deoxy-α-D-maltose δ = 5.28† (d, 1H, 
H1’, J = 5.5) ppm. 1-amino-1-deoxy-β-D-maltose δ = 4.64* (d, 1H, H1 J = 9.1), 4.23* (d, 1H, H1’, J= 8.9), 
4.04* (d, 1H’, J =8.8) ppm.13C NMR (126 MHz, D2O): β-D-maltopyranose δ = 95.47 (C1) ppm. α-D-
maltopyranose δ = 78.94 (C1), 99.69 (C1’) ppm. 1-amino-1-deoxy-α-D-maltose δ = 71.52 (C1) ppm. 1-
amino-1-deoxy-β-D-maltose δ = 82.75 (C1), 84.00 (C1’), 86.61 (C1’) ppm. Mass spectroscopy ES+ 




5 1-Amino-1-deoxy β-D-mannopyranose98 
1H NMR (400 MHz, D2O): β-D-mannose δ = 4.88† (d, 1H, H1 J= 1.1 ppm. α-D-mannose δ = 5.16 (d, 1H, 
H1 J=1.9) ppm. 1-amino-1-deoxy-β-D-mannose δ = 4.32* (d, 1H, H1 J=1.1) 3.93 (dd, 1H, J = 1.1), 3.40 
(d, 1H, J = 2.2) ppm.13C NMR (126 MHz, D2O): β-D-mannose δ = 82.01† (C1) ppm. α-D-mannose δ = 
80.30† (C1) ppm. 1-amino-1-deoxy-β-D-mannose δ = 82.36* (C1) ppm.  
 
6 3,6-Di-O-(α-D-mannopyranosyl)-1-amino-1-deoxy-D-mannopyranose 
1H NMR (500 MHz, D2O): δ = 4.38 (d, 1H, H1 J = 1.1) ppm δ = 4.90 (d, 1H, H1 J= 1.7) ppm δ = 5.14 (d, 
2H, H1 J= 1.7) ppm. All product, no sm.13C NMR (126 MHz, D2O): δ = 85.75 (C1), 102.50 (C1’), 105.30 
(C1’’) ppm. MS ES+ found m/z: 504.1916 527.1586, 528.1605. 
 
7 4-O-(α-D-Mannopyranosyl)-1-amino-1-deoxy-D-mannopyranose 
1H NMR (500 MHz, D2O): 4-O-(α-D-Mannopyranosyl)-1-amino-1-deoxy-D-mannopyranose δ = 4.20 (d, 
1H, H1 J = 1.1), 4.22 (d, 1H, H1 J = 1.1), 4.39 (d, 0.25H, H1), 4.42 (s, 0.39H), 4.62 – 4.59 (m, 2H), 5.04 
(dd, J = 6.2, 2.0 Hz, 1H), 5.12 (dd, J = 4.4, 1.8 Hz, 2H) ppm.13C NMR (126 MHz, D2O): 4-O-(α-D-
Mannopyranosyl)-D-mannopyranose δ = 101.43, 93.97 ppm. 4-O-(α-D-Mannopyranosyl)-1-amino-1-
deoxy-D-mannopyranose δ = 100.11, 85.24, 82.48 ppm. MS ES+ found m/z:  365.1099 
 
8 β-D-Mannopyranose-(1—4)-β-D-mannopyranose-(1—4)-1-amino-1-deoxy-β-D-mannopyranose  
1H NMR (500 MHz, D2O): Product: δ = 4.36 (d, 1H, H1 J = 1.1, C1), δ = 4.56 (s, 0.39H), δ = 4.92 (d, 1H, 
H1 J= 1.1) δ = 4.73 (d, 1H, H1) ppm. SM: δ = 4.62 – 4.59 (m, 2H) δ = 5.04 (dd, J = 6.2, 2.0 Hz, 1H) δ = 
5.19 (dd, J = 4.4, 1.8 Hz, 2H) ppm. 13C NMR (126 MHz, D2O): Product δ = 82.46 (C1), 84.98, 100.16 ppm. 
SM: δ = 93.72, 93.88 ppm. MS ES+ found m/z: 504.1916, 505.1911 
 
9 1-amino-(4-oxobutanoic acid)-𝜷-D-glucopyranose (synthesised by another member of the Galan 
group) 1H NMR (500 MHz, D2O): δ = 4.94 (1H, d, H1, J = 9.1 Hz), 3.85 (1H, dd, H6a, J = 2.2 Hz), 3.6  (1H, 
dd, J = 12.4 Hz, H6b, 5.3 Hz), 3.56-3.46 (2h, m, H3, H5) 3.43-3.34 (2H, m, H2, H5) 2.70 – 2.58 (4H, m, 










2.4.3 Post synthesis and purification characterisation of carbon dots 10, 16 & 17 
 
 
10 AcCDala  
1H NMR (400 MHz, D2O): δ = 2.65 (t, 2H, J= 6.5, b) δ = 3.15 (t, 2H, J= 6.5, a) ppm. 13C NMR (126 MHz, 
D2O): δ = 35.24 (a), 31.37 (b) ppm. 
 
16 AmCD 
1H NMR (500 MHz, D2O): δ = 5.09 (s, 1H) 3.50-3.60 (m, c-h), 2.97 (t, J = 7.2 Hz a,j), 1.83 (q, J = 6.0 Hz, 
b,i) ppm. 13C NMR (126 MHz, D2O): δ = 27.82, 37.50, 68.31, 69.27 71.37 ppm. 
 
17 AcCD 
1H NMR (500 MHz, D2O): δ = 5.10 (d, 1H, J = 2.3 Hz), 3.60-3.50 (d-g), 3.45 (t, J = 8 Hz, c,h), 3.13 (t, J = 8 
Hz, j), 2.89 (t, J = 8 Hz, a), 2.53 (t, J = 8 Hz, l), 2.38 (t, J = 8 Hz, k), 1.82 (p, J = 8 Hz, b), 1.65 (p, J = 8 Hz, 
i) ppm. 13C NMR (126 MHz, D2O): δ = 26.53, 28.29, 29.46, 30.24, 36.29, 37.66, 68.32, 69.49, 71.45 ppm. 
 
2.4.4 Post purification characterisation of CD-carbohydrates 11-15 and 18-27. 
 
Presented is the NMR characterisation of all CD-carbohydrates 11-15 and 18-27 synthesised in this 
work. For 11-13 (short linker) and 18-20 (long linker) where an amide linkage can be indirectly inferred 
through 13C NMR between 70-82 ppm this is identified with a *. For glycan functionalised carbon dots 
where the conjugated anomeric cannot be seen, where possible the starting material and 
aminoglycosyl anomeric peaks are identified. For sialyllactose conjugated carbon dots 26 and 27 the 
anomeric peaks are identified. No sialyllactose conjugation is observed through NMR as the anomeric 
proton next to the amide bond is not seen in the 13C in the region 82-105 ppm.   
 
11 CDala-1,4-mannotriose 
1H NMR (500 MHz, D2O): δ = 4.60 (s, 1H), 4.63 (1H, H1), 4.75 (s, 1H), 4.78 (d, J = 0.9 Hz, 1H), 5.02* (d, 
J = 2.3 Hz, 1H), 5.05 (d, J = 1.5 Hz, 1H) ppm. 13C NMR (126 MHz, D2O): δ = 93.77, 71.32*, 93.68, 96.88, 
100.06, 100.12 ppm. 
 
12 CDala-4-O-mannobiose 
1H NMR (500 MHz, D2O): δ = 4.61 (s, 1H), 4.73 (s, 1H), 4.75 (d, 1H, J = 1.1 Hz), 4.78 (d, 1H, J = 1.1 Hz), 
5.06 – 5.01* (m, 3H), 5.12 (t, 1H, J = 2.5 Hz) ppm. 13C NMR (126 MHz, D2O): δ = 71.25*, 93.71, 93.51, 
100.16, 101.33 ppm. 
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13 CDala-1,3-1,6-manntriose  
1H NMR (500 MHz, D2O):δ = 4.60 (s, 1H, H1), 4.63 (1H, H1), 4.75 (s, 1H, H1), 4.78 (d, 1H, H1 J= 0.9), 
5.03* (d, 1H, H1 J= 2.3), 5.05 (d, 1H, H1 J= 1.5) ppm. 13C NMR (126 MHz, D2O): δ = 93.79, 71.34* (C1), 
93.64, 96.90, 100.07, 100.15 ppm. 
 
14 CDala-galactose 
1H NMR (400 MHz, D2O): δ = 4.25 (d, 1H, J = 8.8), 4.60 (d, 1H), 4.89 (s, 1H), 5.28 (d, 1H, J = 3.7) ppm. 
13C NMR (126 MHz, D2O): δ = 70.39 (C1), 94.90, 91.51 ppm. 
 
15 CDala-mannose 
1H NMR (500 MHz, D2O): δ = 5.04 (s, 1H), 4.76 (s, 1H), 4.41 (s, 1H) ppm. 13C NMR (126 MHz, D2O): δ = 
85.02, 93.81, 93.42 ppm. 
 
18 CD-1,4-mannotriose 
1H NMR (500 MHz, D2O): δ = 5.05 (d, 1H, J= 1.5 Hz), 5.02* (d, 1H, J = 2.3 Hz), 4.78 (s, 1H), 4.76 (s, 1H) 
ppm. 13C NMR (126 MHz, D2O): δ = 71.45* (C1), 93.71, 93.71, 96.84, 100.16, 100.16 ppm.  
 
19 CD-4-O-mannobiose 
1H NMR (500 MHz, D2O): δ = 5.12 (d, J = 2.5 Hz, 1H), 5.05 (d, J = 2.0 Hz, 1H), 5.02* (d, J = 2.0 Hz, 1H), 
4.78 (s, 1H), 4.75 (s, 1H), 4.61 (s, 1H) ppm. 13C NMR (126 MHz, D2O): δ = 71.23*, 93.71, 93.71, 93.71, 
100.16, 101.33 ppm.  
 
20 CD-1,3-1,6-mannotriose 
1H NMR (500 MHz, D2O): δ = 5.05 (d, J = 1.,6 Hz, 1H), 5.02* (s, 1H), 4.78 (s, 1H), 4.76 (s, 1H) 4.60 (s, 2H) 
ppm. 13C NMR (126 MHz, D2O): δ = 71.35*, 93.81, 93.61, 96.84, 100.06, 100.16 ppm. 
 
21 CD-galactose 
1H NMR (400 MHz, D2O): δ = 5.12 (d, J = 3.8 Hz, 1H), 4.44 (d, J = 7.9 Hz, 1H) ppm. 13C NMR (126 MHz, 
D2O): δ = 92.20, 96.35 ppm. 
 
22 CD-mannose  
1H NMR (400 MHz, D2O): δ = 5.10 (d, J = 1.6 Hz, 1H), 4.82 (d, J = 1.2 Hz, 1H) ppm. 13C NMR (126 MHz, 




1H (Presat) NMR (500 MHz, D2O): β-D-maltose δ = 3.24 (m, 1H), 3.38 (t, 1H, J = 9.4), 4.68 (d, 1H, J = 7.9) 
ppm.  𝛼- D-maltose δ = 5.21 (d, 1H, J = 3.7), 5.36 (d, 1H, J = 3.8) ppm. Amino-1-deoxy-β-D-maltose δ = 
4.11 (d, 1H, J = 8.9), 4.17 (d, 1H, J = 8.8) ppm. Other new significant peaks δ = 4.26 (d, 1H, J = 8.9), 4.87 
(d, 1H, J = 5.4) ppm. 13C NMR (126 MHz, D2O): β-D-maltose δ = 69.22, 72.39, 95.60 ppm. 𝛼- D-maltose 
δ = 91.56, 99.30 ppm. Amino-1-deoxy-β-D-maltose δ = 86.73, 86.73 ppm. Other new significant peaks 
δ = 85.41, 86.34 ppm.  
 
24 CD-glucose 
1H (Presat) NMR (500 MHz, D2O): β-D-glucose δ = 3.25 (t,1H, J = 8.9), 4.62 (dd, 1H, J = 8.0) ppm. Amino-
1-deoxy-β-D-glucose δ = 3.14 (t, 1H, J = 9.0) ppm. Other new significant peaks δ = 4.30 (d, 1H, J = 8.9) 
ppm. 13C NMR (126 MHz, D2O): β-D-glucose δ = 73.27 ppm. Amino-1-deoxy-β-D-glucose δ = 95.79 ppm.  
Other new significant peaks δ = 86.82 ppm.  
 
25 CD-lactose  
1H (Presat) NMR (500 MHz, D2O): β-D-Lactose δ = 4.68† (d, 1H, J = 7.8), δ = 4.46† (d, 1H, J = 7.9). 𝛼-D-
Lactose δ = 5.23 (d, 1H, J = 3.8). amino-1-deoxy-β-D-lactose δ = 4.45* (d, 1H, J = 7.9) 4.16* (d, 1H, J = 
9.0) 3.98 (d, 1H, J = 2.8) 3.94 (d, 1H, J = 3.4) ppm. 13C NMR (126 MHz, D2O): β-D-Lactose δ = 102.80†, 
95.57† ppm. 𝛼-D-Lactose δ = 91.66 ppm. amino-1-deoxy-β-D-lactose δ =102.98*, 86.8*, 68.61, 59.99 
ppm. 
 
26 CD-3’-sialyllactose  
1H (Presat) NMR (500 MHz, D2O): δ = 5.09 (d, J = 3.8 Hz, 1H), 4.53 (d, J = 7.9 Hz, 1H), 4.40 (d, J = 7.8 
Hz, 1H) ppm.13C NMR (126 MHz, D2O): δ = 102.61, 95.77, 91.86 ppm. 
 
27 CD-6’-sialyllactose  
1H (Presat) NMR (500 MHz, D2O): δ = 5.10 (d, 1H, J = 3.8 Hz) 4.54 (d, 1H, J = 8.0 Hz), 4.30 (d, 1H, J = 7.9 












2.4.5 Molisch’s Test  
 
In a proposed mechanism of the Molisch’s test99,100 the mono-, di- or tri- saccharide is first dehydrated 
using H2SO4 to the hydroxymethylfurfuryl via intermediates of type X and Y. Subsequently the 
hydroxymethylfurfuryl reacts with 2 equivalents of phenol in a condensation reaction to form a 
product which is oxidised to chromophore Z which absorbs at 490 nm. In this method irrespective of 
sugar structure or functional groups around the ring the same enol form intermediate X is formed and 
subsequently chromophore Z. However, this reaction efficiency is known to depend on the initial 
carbohydrate hence a calibration curve must be produced in each case (Figure S.2a). In this way the 
carbohydrate conjugated onto a nanoparticle can be quantified in terms of 𝜇mol or ug per gram of 
CD-carbohydrate. Other methods involve using anthrone, ornicol, resorcinol for the condensation 
step. However, these methods are reported to be less sensitive as well as less convenient in that the 
molar absorptivity varies greatly between carbohydrates in these methods93,101. 
 
 
Supplementary Figure 2.1 Molisch’s Test Mechanism. Carbohydrate is dehydrated with H2SO4 and then chromophore Z is 
made by reacting with two molecules of phenol with the hydroxymethylfurfural.99,100 
Method according to Masuko et al.93 CD-carbohydrate at stock concentration 600 µgml-1 in H2O (50 
µL) was placed in a 96-well plate well and 5 subsequent 2-fold serial dilutions were made. 150 µL of 
concentrated H2SO4 was added to each well and plate was shaken for 30 min. Then 30 µL of phenol 
solution 5% w/v in water was added to each well and plate was heated to 90 oC in a static water bath 
for 5 min, before cooling to RT in another water bath for 5 min. Absorption at 490 nm was measured 





































             
                                                         
                         
Supplementary Figure 2.2 Molisch's test graphs. a) calibration curve for carbohydrate absorption at increasing concentration. 
b) Unfunctionalised carbon dot, AmCD (blue line), AcCD (red line) and AcCDala (green line) was measured as a function of 
concentration. Negative control of H2O was measured and shown as a black dotted line on the graph. 
 













































          
 
Supplementary Figure 2.3 Molisch's test graphs. a) CD-carbohydrate (long linker CD) results. b) CDala-carbohydrate (short 
linker CD) results. Using the calibration curve (Figure S2.2a) the absorption measured experimentally was used to determine 
the carbohydrate present. 
 
2.4.6 NMR experimental  
 
50 𝜇g of Imidazole was dissolved in D2O along with 0.5 mg CD-4-O-mannobiose before 1H NMR was 
carried out to quantify the moles of carbohydrate conjugated to the carbon dot through having 
identified the anomeric carbon close to the amide linkage to the carbon dot. The imidazole singlet at 
7.18 ppm and the anomeric peak at 5.04 ppm (identified using HSQC Figure A.19) from the CD-4-O-
mannobiose were integrated, (assuming that the conjugated sugar was 4-O-mannobiose), the moles 
of sugar was determined to be 7.47 x10-8 moles in 0.5 mg or 51 mg/g CD-4-O-mannobiose. This is 5.1 
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Supplementary Figure 2.4 UV-Vis data for all longer linker carbon dots and CD-carbohydrates synthesised. 
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Supplementary Figure 2.5 UV-Vis data for all shorter linker carbon dots and CDala-carbohydrates synthesised. 
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Supplementary Figure 2.6 Fluorescence spectra for all longer linker carbon dots and CD-carbohydrate synthesised. 
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Supplementary Figure 2.8 Quantum yield standard quinine sulfate (QS) absorbance and fluorescence profile. Calibration curve 
generated from experimental data, plotting fluorescence v. absorbance when absorbance was > 0.1. The gradient of this line 
was used to determine the QY of carbon dot samples using the QY equation. 
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Supplementary Figure 2.9 Quantum yield curves for both shorter and longer linker carbon dot samples. Curve generated from 
experimental data, plotting fluorescence v. absorbance when absorbance was > 0.1 a.u. Gradient from each curve was used 
in the QY equation to determine the quantum yield.  
 
CD-carbohydrate Line gradient Y-intercept QY error  
Quinine sulfate 1.357x106 ± 45776 -65377 ± 3673  
AmCD 16 96321 ± 20223 -7880 ± 2094 0.44 
AcCD 17 218424 ± 64168 -3095 ± 3875 0.16 
CD-galactose 21 175150 ± 14230 -286 ± 1112 0.31 
CD-glucose 21 97371 ± 21590 3126 ± 517 0.47 
CD-mannose 22 158145 ± 8825 -9678 ± 804 0.19 
CD-maltotriose 175150 ± 14230 -286 ± 1112 0.31 
CD-maltose  142898 ± 31803 1791 ± 1581 0.69 
CD-lactose  156707 ± 13377 758.3 ± 666.8 0.29 
CD-4-O-mannobiose 19 59496 ± 3695 1201 ± 201 0.08 
CD-1,4-mannotriose 18 96555 ± 3073 -249 ± 150 0.07 
CD-1,3-1,6-mannotriose 20 100406 ± 6027 51 ± 338 0.13 
AcCDala 10 156275 ± 19133 1755 ± 840 0.42 
CDala-galactose 14 23395 ± 1627 -92 ± 137 0.04 
CDala-mannose 15 19828 ± 1979 414 ± 167 0.04 
CDala-4-O-mannobiose 12 76110 ± 20031 -3682 ± 1674 0.44 
CDala-1,4-mannotriose 11 56291 ± 8633 -635 ± 499 0.19 
CDala-1,3-1,6-mannotriose 13 111922 ± 36175 1387 ± 1839 0.79 
CD-3’-sialyl-D-lactose 57919 ± 8997 -1228 ± 879.3 0.19 
CD-6’-sialyl-D-lactose 130244 ± 15328 -185.8 ± 1559 0.34 
Supplementary Figure 2.10 Quantum yield curve data and QY error summary table. 
 
2.4.10 DLS experimental 
 
DLS experimental: Malvern Zetasizer Nano-S Dynamic Light scattering instrument was used to record 
the hydrodynamic diameter of CDs. Samples were diluted to concentrations between 0.3125 – 5 mg 
ml-1 in (0.2 µm Minisart filter) filtered H2O, MeOH, 0.1 M or 0.01 M HEPES buffer (supplemented with 
5 mM CaCl2 and 5 mM MnCl2 ions) and measured in a 70 𝜇L volume Malvern disposable plastic cuvette 
at 25 oC. Minimum ten repeats were conducted in triplicate and averaged. 





























2.4.11 Zeta potential experimental  
 
Zeta potential experimental: Malvern Zetasizer Nano-S Dynamic Light scattering instrument, was used 
to record the seta potential of CDs. Samples were diluted to concentrations between 0.1 – 5 mg ml-1 
in the same diluents as in DLS. 750 𝜇L of sample was placed in a DTS1060 Malvern folded capillary cell. 
Minimum 100 repeats were conducted in triplicate and averaged.  
 
2.4.12 TEM experimental  
 
TEM was performed on either the Jeol 2100 (200 kV) for AmCD and AcCD or Jeol 1400 TEM Voltage 
(120 kV) for all other carbohydrate functionalised CD samples. In all cases, samples were prepared at 
5 mg ml-1 in MeOH before drop casting (20 𝜇L) onto 4 nm carbon-coated copper grids (non-glow 
discharged) and left to dry for 24 hr before imaging. 
2.4.13 AFM experimental  
 
On a clean surface 100 𝜇L of sample was drop cast onto freshly cleaved mica (1.5 cm2) and left for 2 
minutes. Angling the mica at 45o N2 was used to remove excess solution from the mica. Samples were 
left to dry overnight. Samples were imaged using a Bruker Multimode with Quadrexed Nanoscope 3D 
controller in tapping mode using NuNano AC mode silicon scout 350 probes, spring constant 42 N/m 



















3. Glyco-carbon dot lectin interactions 
 
This chapter explores work with the aim of developing a FRET based assay in vivo where the delivery 
of a drug can be measured via a FRET signal output. FRET has been used as a molecular ruler in cell-
based experiments involving the cell membrane and protein binding. This is owing to its sensitive 
distance dependence under 10 nm. The glycan functionalised CDs from chapter 2 are used with a 
commercial fluorophore to explore the capacity of this nanomaterial towards a FRET assay. Physical 
characterisation including DLS, AFM and TEM is carried on the same system to probe the structure 
and size of these aggregates formed as a result of binding between the CD-carbohydrate-lectin pair.  
 
3.1 FRET  
 
Förster resonance energy transfer (FRET) occurs when there is emission and excitation overlap 
between two fluorophores (Figure 3.1). 
 
Figure 3.1 FRET donor and acceptor photoluminescence example spectra with overlap between donor emission and acceptor 
excitation allowing for non-radiative energy transfer.  
 
This process involves non-radiative energy transfer from one molecule to another with reduced 
fluorescence from the donor (S1 to S0) which can be reabsorbed by the acceptor (Figure 3.2). Instead, 
the donor molecule donates energy to the acceptor molecule through a dipole-dipole coupling 
interaction.102 The energy transfer between the molecules is distance (𝑟) dependent, with an inverse 





Figure 3.2 Jablonski diagram of FRET from donor molecule to acceptor molecule. FRET involves non-radiation energy transfer 
between molecular excited states and results in red-shifted fluorescence energy to that of the absorbed energy.   
Overlaying a donor and acceptor fluorescence emission excitation profile of two given molecules can 
reveal if there is potential for FRET to occur when the molecules are in close proximity. FRET is used 
in biology as a molecular ruler first shown by Stryer104 and Clegg105, and has since been used as a tool 
to probe many types of biomolecule-biomolecule interactions106. The acceptor excitation and 
emission spectra should be Stokes shifted compared to the donor. This can be determined through 
the emission of the donor overlapping with the excitation of the acceptor (J). Optimal conditions 
would also have a peak within the donor spectra at a wavelength which the acceptor is not excited, 
as well as a peak in the acceptor fluorescence which the donor does not fluoresce. This does not 
exclude certain FRET pairs being used together, however, deconvoluting these spectra must be carried 
out in order for FRET quantification. Other conditions of FRET include good donor QY, donor and 
acceptor within 10 nm of each other (Figure 3.3) characterised through R0 and good dipole-dipole 




Figure 3.3 Distance dependence of FRET interaction between a donor with excited energy and acceptor with accepts this 
energy non-radiatively when < 10 nm away and emits red-shifted energy radiatively.  
 
3.1.1 FRET efficiency  
 
The FRET efficiency is defined as the QY of the FRET interaction and can be defined using the 
theoretical FRET equation below (Equation 3.1), where 𝑘./  is the rate of FRET, 𝑘$ is the radiative decay 






Equation 3.1 The FRET efficiency (E) as shown in terms of rates.  
 
It is possible to calculate the average distance (𝑟) of a FRET interaction. However, this requires 




[1 + ( 𝑟𝑅1	
)2]
 
Equation 3.2 FRET efficiency (E) relationship to the average distance between the donor and acceptor (r) with an inverse r 6 
power law as shown where R0 is the Förster radius.  
 
The FRET efficiency can be measured experimentally. There are several ways this can be carried out, 
including ratiometrically, fluorescence lifetimes or through measuring the change in fluorescence 
intensity of one species as a function of the starting signal. Depending on the fluorophores being used 





Ratiometric FRET provides a relative FRET efficiency (𝐸3&4.). However, this means that using the Erel. 
value to determine r is not feasible. 𝐼6 is the fluorescence from the acceptor at the acceptor 
fluorescence wavelength and 𝐼) is the donor fluorescence at the donor florescence when both have 
been excited at the donor excitation wavelength (in our case) 430 nm. This readout would require 
linear unmixing of the signal at (in our case) 525 nm to obtain 𝐼6 from 𝐼)6 and of the signal at 430 nm 
to obtain 𝐼)from 𝐼)6. This is unless the emission at 525 nm contains no directly excited donor emission 
i.e. 𝐼6 = 𝐼)6 and the emission at 430 nm contains no directly excited acceptor signal 𝐼)= 𝐼)6. Using 







Equation 3.3 Ratiometric FRET efficiency (Erel.) equation. 
 
Guo et al.90 developed a novel ratiometric FRET readout method which reduces the impact of certain 
problems such as low signal readout, instrument laser variability and signal fluctuation (termed self-
calibration). This was used to extract an apparent kd binding values which are comparable to each 
other. The acceptor fluorescence at 626 nm and donor fluorescence at 554 nm as 𝐼2-2/	𝐼778 were 
calculated having subtracted the direct acceptor excited background signal. The data was fitted using 
Hill’s equation as follows where 𝑛 is the Hill’s coefficient, 𝐾"  is the apparent binding dissociation 




= (𝑅9!'		[𝐶]%)/(𝐾"% +	[𝐶]%	)	 
Equation 3.4 Hill's equation used by Guo et al.90 to plot novel ratiometric FRET and extract an apparent kd. 
 
Excited state lifetime of the donor by itself (𝜏&), and when the acceptor is present (𝜏&%), can be used 
to probe the energy transfer to acceptor. As more energy transfer occurs to the acceptor the donor 
lifetime will decrease. This method is devoid of crosstalk from the acceptor as the lifetime can be 
donor independently measured. However, if multiple lifetimes exist for the donor then adaptations of 
equation 3.6 are required. Lifetimes are independent of donor concentration hence are less sensitive 
to experimental error. They can also be used as FRET readout to compare different environments 
which is useful for in vivo study.108–110 
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Equation 3.5 Donor lifetime FRET efficiency equation. 
 
FRET efficiency (𝐸) can be measured at one wavelength corresponding to the donor i.e. 430 nm in the 
presence (𝐼)6 =	 𝐼430) and absence (𝐼) =	 𝐼4300) of acceptor, to find the proportion of excited state 
energy transferred from the donor to an acceptor molecule. This is used when the acceptor molecule 
is non-fluorescent or not fluorescent at the donor emission wavelength. For more accurate 
measurements avoiding signal fluctuation the integral over a range of donor emission wavelengths 
better quantifies 𝐼) and 𝐼)6. Caveats of this method include that the emission peak wavelength must 
remain consistent upon acceptor addition.109 
 







Equation 3.6 Donor Fluorescence to measure FRET efficiency (E) equation. 𝐼430 refers to the donor emission intensity upon 
ConA-F addition (𝜆em 430 nm) and 𝐼4300  refers to the donor emission with no ConA-F addition.  
 
Measuring the acceptor emission is possible for measuring FRET efficiency (𝐸) and requires the 
absorption of the acceptor to be included in the equation. Either absorption of the acceptor when 
there is no donor (at both donor and acceptor excitation wavelength) is included or the absorption of 
acceptor at a wavelength where the donor does not absorb.  
 
The three-cube FRET method is commonly used in live cell imaging where bleed-through and crosstalk 
are harder to correct for. It involves collecting fluorescence at three filter sets or cubes; the donor 
filter set (𝐼))) which measures at the donor excitation and emission, the acceptor filter set (𝐼66) which 
measures at the acceptor excitation and emission and the FRET filter set (𝐼)6) which measures  at the 
donor excitation and acceptor emission111. Obviously within these measurements lies crosstalk and 
bleed-through, with the aim of isolating the donor fluorescence, direct acceptor excitation and the 
sensitised (FRET) acceptor intensity there are many methods as outlined by Gordon et al.112 and Zeug 
et al.113 which use correction factors to obtain a FRET efficiency value. These correction factors can 
include fluorophore coefficients, QY or filter set percentage transmission. Often this is referred to as 






3.1.2 Experimental ways to measure FRET  
 
Experimentally there are a number of types of experiments which can be used to put information into 
the equations in section 3.1.1 to obtain (𝐸). These include sensitised emission, photobleaching, 
lifetime imaging which are applicable in biology and chemistry. Furthermore, bioluminescence 
resonance energy transfer (BRET), fluorescence polarisation and homo-FRET can be used if these other 
techniques are not appropriate114.  
 
Sensitised emission refers to an experimental method where the donor and acceptor molecule 
fluorescence is measured as the variable is changed. From this the donor fluorescence, acceptor 
fluorescence or a ratiometric fluorescence change can be used to calculate (𝐸). Associated crosstalk 
is a major drawback of this method, however it is efficient for looking at systems where (𝐸) changes 
rapidly such as protein conformation studies.115 
 
Photobleaching is useful to measure FRET in vivo as it is relatively non-invasive although it can only be 
used once per cell. This involves having a FRET pair where the donor is transferring energy to the 
acceptor. Then the acceptor is permanently photobleached whilst the donor is unaffected. This causes 
the donor fluorescence to increase in relation to the amount of FRET that was occurring before 
photobleaching.115,116 
 
Fluorescence lifetime imaging looks at the inherent nanoscale lifetime or decay pattern of the donor 
species only. When the donor’s environment changes such as when it is transferring energy to an 
acceptor, its lifetime decreases. This method is commonly used in live cell imaging in a process called 
fluorescence-lifetime imaging microscopy (FLIM). This technique is vulnerable to artefacts from other 
cellular environmental impacts on the donor.115 
 
Single-molecule FRET is a growing area of research aiming to look at a single FRET interaction in order 
to measure specific interactions of interest in a complex environment and observe transient states. 
Commonly this is desired for in vivo application where interactions can involve sub-nanometer distinct 
states. Methods commonly used are similar to bulk population in that fluorescence intensity or 
lifetime are used.117 
 
Bioluminescence resonance energy transfer (BRET) involves most commonly luciferase being the 
source of light and also the donor partner in a FRET pair and can be used with other commercial FRET 
acceptor molecules. The luciferase protein being the sole acceptor excitor and not requiring an 
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external illumination source means that no direct excitation of the acceptor molecule occurs. This 
means one direction of crosstalk is eliminated from the experiment and quantification become easier. 
Other benefits of the source of light not being from an external source include removal of non-specific 
in vivo background autofluorescence and photobleaching of the donor molecule, however, one 
drawback is the low fluorescence of luciferase compared to some commercial fluorophores.118 
  
Homo-FRET makes use of a molecule’s self-absorption properties as it is seen in carbon dots as well. 
When two identical molecules are within 10 nm of each other, they have the capacity to transfer 
energy from excited donor to acceptor molecule. This occurs on a nanosecond timescale whereas 
rotation of the molecule is much slower. Hence, using a detector which only observes light polarised 
parallel to the linearly polarised excitation light, the signal of the originally excited molecules can be 
measured as a function of time. If a donor is transferring energy via homo-FRET, then its signal will 
decrease over time.115 
 
Fluorescence polarisation involves the excitation of a fluorophore in solution at one linear 
polarisation. After a certain amount of time the excited fluorophores are detected at two 
perpendicular linear polarisations. Based on the diffusion coefficient of the molecule and hence their 
size, polarisation will either remain the same if large, or depolarise if they are small and fast diffusing. 
Using fluorescence polarisation, binding can be quantified as a fluorophore will diffuse slower if bound 
and depolarise less quickly than if free in solution.119  
 
Any of these methods can be used to measure biological and chemical distance dependent 
phenomena. Commercial fluorophores are often used in this work as they have narrow and sharp 
fluorescence peaks and a narrow absorption band. In biology fluorescent proteins such as green 
fluorescent protein, yellow fluorescent protein and mCherry can be used for the precise sequence 
specific tagging of proteins120, an important advantage considering the distance dependence in FRET. 
This has allowed for protein conformational change to be monitored as well as binding interactions 





Figure 3.4 Experimental ways to measure FRET summary. Donor (and) acceptor are shown if present in the experiment. 




3.1.3 Caveats of FRET measurements 
 
By choosing a suitable nanoparticle it is possible to minimise problems associated with FRET 
experiments as outlined in section 3.1.2. However, it is important to be mindful of certain issues and 
recognise them in data e.g. artefacts can result from ions in a titration experiment which may be 
overlooked.126 Outlined are the most common problems of experimental FRET measurements. 
 
3.1.3.1 Crosstalk  
 
Crosstalk refers to the acceptor being directly excited by the donor excitation wavelength. This is a 
result of the fact that the absorbance and excitation of a fluorophore will be likely be non-zero. Also, 
even though the acceptor will be Stokes shifted, the width of its spectral peaks will be wide in 
comparison to the shift. The crosstalk can be estimated for a FRET pair by finding the intensity ratio 
between the emission upon donor and acceptor excitation when a sample of acceptor only is present. 





Another effect of spectral overlap is bleed-through, which refers to the donor signal which is seen at 
the wavelength measured as acceptor fluorescence i.e. acceptor channel. The severity of bleed-
through is judged in comparison to the intensity of acceptor in the acceptor channel. If significant it 
should be subtracted from the total intensity in the acceptor channel. However, this is difficult 
because isolating the donor bleed-through from the acceptor fluorescence in the overall acceptor 
channel during FRET cannot be done.127 
 
3.1.3.3 Non-specific FRET  
 
Non-specific FRET can result if the concentration of acceptor is very high or non-specific aggregation 
occurs between the donor and acceptor fluorophores inducing false positive FRET signal. This can be 
observed as the case if the FRET readout is linearly dependent on the concentration of acceptor 
fluorophore measured through its intensity.  Furthermore, at high donor and or acceptor 
concentrations or large sample volume, the donor molecule can emit a photon which is absorbed by 






3.1.3.4 Mixture of fluorophore populations 
 
In some cases, a single donor and acceptor do not interact in isolation, a donor can be bound by 
multiple acceptors or vice versa. In this it is assumed that there is a distinct donor to acceptor FRET 
interaction which occur independently, and the overall average FRET interaction is observed from 
each of these individual interactions. Generally speaking, FRET models follow kinetic assumptions as 
such. It is proposed that additional energy transfer pathway can exist but are not well understood.127  
 
With multivalent binding mixtures of fluorophore populations must be considered. A multivalent 
interaction can mean multiple binding events between two molecules which in turn have a single 
donor and acceptor molecule associated. Or if the multivalent binding occurs across multiple 
molecules then more than a 1:1 donor:acceptor interaction occurs. In this situation we assume that 
FRET transfer occurs as discrete events between the donor and multiple acceptors or vice versa.127 
 
3.1.3.5 Change in fluorescent properties upon binding 
 
Upon binding of the donor and acceptor structural changes, or environmental changes such as 
temperature and ionic strength can impact the donor or acceptor fluorescence, potentially having a 
quenching effect or shifting the fluorescence peak.127   
 
3.1.4 Nanoparticle FRET systems  
 
Nanoparticles have certain spectroscopic and physical properties which mean they could potentially 
become more popular for research than commercial molecular fluorophores and fluorescent proteins 
and hence be used in FRET experiments. Associated problems with dyes include in some cases weak 
signal, photobleaching, too short lifetimes for FRET, poor stability and huge toxicity issues. Issues 
associated with fluorescent proteins include that they are very labour intensive to produce, suffer 
from spectral crosstalk, and are very large in some cases for the length scale of FRET. 
 
QDs128–130, gold nanoparticles (AuNPs)131, graphene oxide nanoparticles132, upconverting 
nanoparticles133 have all been used in the context of FRET. The functional handles for modification on 
their surface means that any toxicity issues associated can be avoided by conjugation of biocompatible 
material. They are known to have comparatively good photostability which can be extended through 
passivation. Their photoluminescent properties can be tuned in some cases with high precision during 
synthesis such as size with QDs offering greater flexibility and tunability for bespoke FRET needs. QDs 
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also have narrow and symmetric emission peaks of many colours which allow for multiplexing134.  
AuNPs and graphene oxide nanoparticles have been used as efficient FRET quenchers also. Their small 
size allows for FRET scale (<10 nm) interaction as well as tightly controlled conjugation of molecules 
of interest for highly controlled FRET experiments.135,136  
 
 
3.1.5 Nanoparticle FRET for measuring lectin binding 
 
Not many nanoparticle FRET assays to measure lectin carbohydrate binding have been developed as 
of yet. The work by Guo et al.90  have shown QDs as an effective platform upon which to test 
multivalent lectin interactions involved in disease pathways. This could be extended to investigate 
binding in rare or unusual carbohydrates but also base novel nanoparticle FRET systems for lectin 
binding. Other work combining nanoparticles and lectin binding studies include using QDs to 
investigate maltose binding protein (MBP) affinity for maltose.137 MBP was bound covalently to QDs 
and through a fluorophore attached to maltose the binding was measured through FRET. In a similar 
system QDs were again used to measure MBP affinity for maltose, but through a competition assay. 
MBP was conjugated onto the QD and a maltose analogue, 𝛽-cyclodextrin which was quencher 
conjugated was added hence FRET-based quenching QD fluorescence. Once free maltose was 
introduced this analogue was displaced and a QD fluorescence signal was observed which was used 
to quantify binding.138 
 
Subsequently, work by Guo et al.90 developed a QD based ratiometric FRET assay to investigate the 
carbohydrate lectin interactions which mediate the pathogenic invasion seen in HIV and Ebola viruses. 
The binding affinity of lectins DC-SIGN and DC-SIGNR which mediate virulence were investigated in 
relation to multivalency. Results showed DC-SIGN binds > 100-fold tighter than DC-SIGNR to 
glyconanoparticles, which supported observed pathogen transfection in nature. Using QD 
glyconanoparticles they were able to elucidate novel structural binding information and assess the 
synthetic platforms suitability to intervene in pathogen lectin binding.   
 
In order to investigate the effect of multivalency both the lectin and carbohydrate valency was varied. 
Two lectins DC-SIGN and DC-SIGNR which have similar structure with 4 carbohydrate recognition 
domains (CRDs) but different special presentation were used. The carbohydrate density on the QD 
was controlled so that the inter glycan distance was either 0.98 ±	0.11 or 1.29 ± 0.36 nm and the 
number of glycans per QD was 330 ± 70 and 222 ± 62. Two types of QDs were made using ethylene 
glycol (EG) linker lengths with 3 or 11 carbons (C3 & C11) whilst using an inert DHLA linked zwitterionic 
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spacer to modulate glycan density further. Finally, either a monosaccharide or disaccharide was 
presented on the QD. Glycan density was calculated theoretically from the QD hydrodynamic radius 
and the number of carbohydrate molecules per QD. This was determined using the Molisch’s Test, a 
colorimetric assay. The unbound carbohydrate detected was used to infer the conjugated 
carbohydrate. 
 
A ratiometric FRET assay was used to measure the strength of binding between the lectins DC-SIGN, 
DC-SIGNR and an isolated CRD to specific carbohydrates mannose and dimannose. The dye Atto-594 
was attached to the lectin which is a spectrally suitable FRET acceptor for the QD and the 𝜆em ratio 
I626/I554 was used to monitor acceptor fluorescence/donor quenching. Experimentally an interaction 
was inferred if titration of acceptor into donor solution induced a stepwise increase in I626/I554. This 
signal then plateaus once all the donor sites have been saturated.  
 
Interaction between QD-dimannose and DC-SIGNR produced the largest FRET signal whilst QD-
mannose and DC-SIGNR produced poor signal similar to that with CRD only. CRD experiments show 
that monovalent interactions are not measurable in this assay and any interactions with mono 
mannose were also too weak to be measured. This suggests multivalent interaction between DC-
SIGNR and QD-dimannose. Secondly, DC-SIGN and QD-dimannose had an even greater FRET ratio 
suggesting DC-SIGN binds dimannose via more interactions that DC-SIGNR. The binding fit between 
DC-SIGNR and QD-mannose and QD-dimannose is positively cooperative which was not the case for 
DC-SIGN which showed no cooperativity. From this work DCSIGN was suggested to have all 4 CRDs 
facing upwards which allowed it to bind multivalently whilst DC-SIGNR CRDs face sideways and binds 
cooperatively and multivalently.  
 
Observations show that crowding, seen by dye saturation, induces a FRET signal decrease for DC-SIGN 
only with QD-dimannose for both C3 and C11 EG linker. This is removed when spacer is introduced to 
reduce to 25% glycan coating suggesting that the dimannose binding above saturation level causes 
CRD rearrangement.  
 
By keeping the ratio of QD-carbohydrate and lectin constant but varying the concentration  in solution 
they were able to see when the fluorescence ratio I626/I554  saturated and hence, when the QD-
carbohydrate were fully bound by lectin. From this data they were able to extract the apparent 




From the apparent Kd values they were able to compare lectins, linker length, carbohydrate mono- 
and di- saccharides and therefore investigate multivalency. The best binding they saw was with 
DCSIGN and the QD-dimannose with the shortest linker C3 where a low kd of 610 pM was observed. 
This fit with the binding mode seen from previous data and observations in nature where DCSIGN is 
able to exhibit secondary interactions with the dimannose to promote enhanced multivalent binding. 
They then tested QD-dimannose, when EGn = 3 and 11, as an inhibitory vector to prevent 
pathogenicity.  
 
A model system was set up with a murine leukaemia virus (MLV) virus which had the luciferase gene 
inside and an Ebola virus glycoprotein (EBOV-GP) presented on the surface which is bound by 
DCSIGN/R. A human embryonic kidney cell line (293T) was transfected so that they presented the 
DCSIGN/R lectin. The MLV was taken up and the luciferase gene expressed to confirm uptake. To test 
the QD-dimannose for inhibitory effect, the 293T cells were first predisposed to the QD-dimannose 
before the MLV virus was introduced. Through the removal of luciferase detection, it was observed 
that the inhibition in DCSIGN 293T cells by CD-dimannose with ethylene glycol linker (EG linker C3) had 
an IC50 (inhibitory concentration) of 0.7 ± 0.2 nM. This is comparable with the best synthetic 
glyconanoparticles available36,139,140. 
 
3.2 Physical characterisation for lectin binding  
 
3.2.1 DLS, zeta potential and TEM 
 
DLS is a relatively easy experiment to run to assess the size distribution of particles in solution. In a 
binding interaction, size distribution can be assessed to show new aggregates including the proportion 
of aggregation occurring. In one study liposomes were used where ConA and a mannosylated 
glycodendrimer linked porphyrin were embedded in the surface of two populations of liposome 148 
nm and 146 nm respectively.141 This was investigated to model the mannose receptor on retinal cell 
membranes as a drug target in retinoblastoma. Upon mixing they observed a new aggregate size as a 
function of ConA-mannose binding. The first was similar in size to the original liposomes 157 nm 
(representing the unbound liposomes) and a large aggregate 5180 nm was observed where ConA had 
specifically bound the terminal mannose causing aggregation. They anticipate that ConA can bind 




Figure 3.5 Liposome aggregation bridged by ConA- terminal 𝛼-D-mannose binding. Copied with permission from Makky et 
al.141  
 
Zeta potential was also used in this work to observe ConA functionalisation onto the liposome surface. 
Liposome by itself had a zeta potential of − 66.8 ± 2.9 mV, free ConA was − 14.2 ± 0.3 mV and 
conjugated − 79.4 ± 2.5 mV. Mixing alone did not show this same additive decrease in zeta potential 
− 62.2 ± 2.5 mV. Hence conjugation was inferred from zeta potential measurements.141 
 
DLS was used to observe aggregation induced between QDs functionalised with 𝛽-N-
acetylglucosamine (GlcNAc) and Wheat germ agglutinin (WGA) lectin. Hydrodynamic diameter 
increased from 14-16 nm to 240-260 nm. QDs have very high contrast owing to the metallic content, 
hence these 240-260 nm aggregates were imaged in TEM and confirmed to consist of GlcNAc 
conjugated QDs with WGA tightly aggregated compared to free GlcNAc conjugated QDs, indicating 
GlcNAc-WGA interaction.142  
 
Guo et al.90 use physical evidence for the interaction between their QD-carbohydrate and DCSIGN-R 
lectin, whilst DCSIGN had a smaller aggregate size. This provided supporting data for the FRET result 
they observed. They were able to isolate distinct size distributions from the raw data to infer 
multimodal distribution with aggregate diameters of 124 and 205 nm. Showing two distinctly different 
aggregate sizes existed in one sample. Guo et al.90 also observe aggregates for DCSIGNR with QD-
dimannose in TEM and STEM, whilst DCSIGN showed QDs were isolated suggesting a lack of 
aggregation. This result was quantified using nearest neighbour particle distance and matched data 





3.2.1 AFM  
 
AFM can be used not just as an imaging tool, but also as a means to probe force measurements. Single 
binding events can be measured using AFM down to pN forces. These experiments are usually labour 
intensive and require specialist AFM knowledge. They have been used to probe lectin interaction with 
carbohydrate. The AFM tip is functionalised with either the lectin or carbohydrate of interest and the 
binding partner is functionalised onto a mica, silicon or gold surface. The tip is brought within nm 
distance from the surface (depending on the linker length) and binding can occur in solution between 
the AFM tip and the substrate. Via feedback loops the force required is measured and a force-distance 
curve is generated. In one study the tip was functionalised with hexasaccharide and ConA was 
functionalised on a gold substrate. Hexasaccharide was used so that the terminal mannose was more 
accessible than in the monosaccharide form. Unbinding force was determined to be 96 ± 55 pN. This 
technique can also be used to probe whole cells. In one study AFM force interactions were used to 
map the glycocalyx on a whole bacterium (Bacillus cereus). A force map was built up across the whole 
cell using known force interactions characteristic of a lectin with various terminal N-
acetylglucosamine, mannose and glucose molecules.143 
 
AFM has been used to characterise AmCD 16, CD-glucose 24, CD-mannose 22, CD-galactose 21, CD-
maltose 23 and CD-lactose 25 is work carried out by Tom Swift et al.92 From 6 images of each CD-
carbohydrate the radius was calculated as seen in figure 3.6 Table 3.1 summarises the radii of the 
particles and the number in brackets shows the maximum radius from the core of the glycan 
functionalised CDs. Topography images show that the glycan corona is inhomogeneously distributed 
around the core. Figure 3.7 shows phase contrast images of AmCD 16 CD-glucose 24. The dark area 
corresponds to an individual CD whilst the lighter corona (in contrast to the background) in CD-glucose 




Figure 3.6 AFM topography image reproduced from Tom Swift’s thesis,92 images produced by Rob Harniman.  A) AmCD, B) 
CD-glucose, C) CD-mannose, D) CD-galactose E) CD-maltose E) CD-lactose. Images reproduced from Tom Swift’s  thesis.92  
CD sample Radius (nm) 
AmCD 3.03±0.05 
CD-glucose 5.69  




Table 3.1 AFM reported CD-carbohydrate radius for glycan functionalised CDs,  from AFM as measured by Swift et al.94 Table 
reproduced from Thomas Swift thesis.92 
 
 
Figure 3.7 Phase contrast image of the same carbon dot as shown in figure 3.5 A) AmCD 16 and B) CD-glucose 24  Reproduced 





3.3 Aims  
 
In this chapter we aimed to investigate carbohydrate lectin binding using a FRET readout mechanism. 
The work presented are experiments towards developing a carbon dot FRET assay which can be 
applied to investigate more complex lectin binding. The results in this work we aim to correlate with 
those seen in other systems in the literature, hence we use ConA, a well-studied lectin. The materials 
synthesised and characterised in chapter 2 were used as the donor partner in this work owing to the 
blue fluorescent properties of the carbon dots AcCD 17 and AcCDala 10. For ease we use commercial 
fluorescein bound ConA as the acceptor partner in this work. Binding interaction was also investigated 
through physical aggregation probing via DLS, TEM and AFM. We aimed to develop a ratiometric assay 
as seen in a number of literature examples. Specifically, we look to Guo et al.42 who develop a 
ratiometric FRET assay using QDs to probe DCSIGN and DCSIGNR lectin binding.  
 
3.4 Results and discussion 
 
Work in this chapter was conducted by myself and is unpublished. 
3.4.1 CD-carbohydrate Concanavalin A binding – physical characterisation  
 
In vitro physical characterisation of multivalent lectin binding interactions is made possible using a 
glyconanoparticle. Observing the aggregation of a glyco-nanoparticle as a function of binding protein 
allows for the interaction to be imaged and quantified. ConA which is tetravalent and can bind four 
terminal mannose residues in a tetrahedral organisation was used as the model system. We proposed 
this would induce 3-dimensional quasi-spherical aggregation which would increase in diameter as a 
function of lectin concentration. In figure 3.8, a 2D illustration of the proposed structure is presented 
to aide in visualisation of the CD-mannose 22 and the ConA seen in green. By using DLS the 
hydrodynamic size of these aggregates can be measured, whilst TEM can reveal the structure of the 
aggregates, distinguishing carbon dots from the background through their crystalline core. AFM 
provides accurate height information of the aggregates which can be correlated to the known size of 
carbon dots to determine the composition versus size of these aggregates. Each technique has 
associated caveats such as TEM and AFM being conducted on dried samples. However, combining the 
information from these three techniques confers aggregate structural information which can be 





Figure 3.8 2D illustration of how the ConA (green) and CD-mannose may interact to form an aggregate. The ConA and CD-
mannose are shown as ordered as a result of the ConA specificity for mannose rather than forming a CD-mannose aggregate 
with a corona of protein.  
3.4.2 Concentration range measured 
 
CD-glycans used in this work were CD-mannose 22 and CD-galactose 21. The CD contain the longer 
TTDDA-type linker and their synthesis and characterization have been described in detail using a 
variety of techniques such as DLS and TEM (chapter 2) and by Swift et al.91 𝛼-D-mannose is the specific 
terminal glycan that ConA binds in its binding site. The equivalent 𝛼-D-galactose is not bound by ConA 
at its binding site due to unfavourable interactions from the C-4 position hydroxyl of galactose 
preventing hydrogen bonding.21 ConA was allowed to bind to CD-mannose and CD-galactose in 0.1 M 
HEPES buffer pH 7.4, which contained 5 mM CaCl2 and 5 mM MnCl2 which dissociate into Mn2+ and 
Ca2+ ions in solution which play a role in ConA binding. All references of 0.1 M HEPES refer to this 
buffer with ions. The concentration of CD-mannose 22 and CD-galactose 21 were kept the same at 1 
mg ml-1, and the mass of ConA varied from an equivalent mass down to 0.00625 mg ml-1. The 





ConA (mg ml-1) ConA(μM) 
1:1 1 9.62 
1:0.2 0.2 1.92 
1:0.1 0.1 0.962 
1:0.05 0.05 0.480 
1:0.025 0.025 0.240 
1:0.0125 0.0125 0.120 
1:0.00625 0.00625 0.060 




A range of CD:ConA ratios were chosen as the moles of carbohydrate per CD could not be determined. 
Hence, to observe an interaction a wide range of mass ratios was used. Using DLS and zeta potential, 
these samples were all investigated. For TEM and AFM the ratio 1:0.025 was used having determined 
from DLS and zeta potential that an interaction was induced by ConA addition.  
 
3.4.3 CD-carbohydrate ConA interactions monitored using DLS 
 
CD-mannose 22 and CD-galactose 21 were investigated as multivalent glycan platforms for ConA 
binding. Considering the 𝛼-D-mannose specificity of ConA, CD-mannose was anticipated to have 
greater binding that CD-galactose 21. Through DLS the binding was investigated in terms of 
aggregation, hence CD-mannose 22 was expected to show greater aggregate sizes than CD-galactose. 
All DLS experiments were carried out in 0.1 M HEPES buffer. ConA was added to CD-carbohydrate in 
an Eppendorf tube and vortexed to promote disaggregation of any self-assembly and allow for lectin-
carbohydrate binding.  
 
Previous data in chapter 2 (section 2.2.2.8) the hydrodynamic diameter (peak 1 % intensity data) for 
CD-mannose 22 was 725.90 ± 60.85 nm and CD-galactose 21 was 926.50 ±38.05 nm. This size was 
larger than TEM and AFM, and therefore proposed to be the result of self-aggregation. These samples 
are the same material as suggested in the aggregation DLS studies. Hence the disassembly of CD-
carbohydrate is a prerequisite for specific ConA binding.  
 
We also carried out DLS on ConA by itself at concentrations 0.00625-1 mg ml-1, the same concentration 
as used with CD-carbohydrate. This showed that the lectin also self-aggregates with diameters 
between 200-325 nm between 9.62-0.060 𝜇M. This is shown by the fact than the literature reported 
size of ConA 7x7x6 nm15 which is 2 orders of magnitude smaller than the aggregates. ConA aggregates 
in a slight concentration dependent manner, where greater concentration reports smaller sizes down 
to ~ 200 nm and lower concentrations report larger sizes up to ~ 300 nm (figure 3.8). However, the 




Figure 3.9 DLS data (peak 1) intensity of ConA at concentrations between 9.62-0.060 𝜇M. The same concentrations used in 
binding experiments with CD-carbohydrate 
 
Interaction between the CD-glycan and ConA in solution reported different size aggregates than either 
the CD-carbohydrate by itself or the ConA by itself (0.060-9.62 𝜇M). This was seen for all CD-
carbohydrate samples as a function of increasing ConA concentration (figure 3.9). At the highest ConA 
concentration of 9.62 𝜇M aggregate size reaches 2248 nm for CD-galactose 21 and 3308 nm for CD-
mannose 22 (peak 1 size). For comparison, this is much larger than ConA by itself at 9.62 𝜇M of 200 
nm. However, the inverse result is seen between 0-1.92 𝜇M ConA concentration where CD-galactose 
21 has the greatest aggregate size. Hence, from this data it is difficult to conclude whether there is a 
specific or non-specific basis for aggregation.  
 
Raw data seen in supplementary figures S.3.1 & S.3.2 of the CD-glycan and ConA samples show that 
there are sometimes multiple peaks in the data showing multiple aggregate sizes exist in solution. The 
size of these peaks does not correspond to the size of either the CD-glycan or ConA (at the same 
concentration as the sample) in any case as far as we can see. Hence, the new aggregates must be 


























C o n A  D L S  In te n s ity  p k 1












Figure 3.10 DLS data (peak 1) intensity of ConA at concentrations between 9.62-0.060 𝜇M with 1 mg ml-1 CD-mannose 22 
and CD-galactose 21 in the sample.  
 
To analyse our data, we applied the  analysis methods reported by Guo et al.42 In their work, 
functionalised QDs are employed in binding studies, which are more easily monodispersed for DLS 
characterisation hence, the percentage size increase reflects the percentage size increase as a function 
of the diameter of one particle. We use this method in a similar manner, however as our glycan-CDs 
are aggregated to start with, our results show a disassembly of aggregates to form a new aggregate 
of distinctly larger size in a concentration dependent manner.  
 
The increase in diameter of the aggregate upon the addition of ConA as a function of CD-carbohydrate 
starting diameter is plotted in Figure 3.11. This data shows that as a function of CD-mannose 725.90 
± 60.85 nm (self-aggregated) which was smaller than CD-galactose 21 926.50 ±38.05 nm, the 
aggregate size upon ConA addition has increased more. CD-galactose 21 reaches 232 % increase and 
CD-mannose 22 reaches 946 % aggregate diameter increase. The initial size difference between CD-
galactose and CD-mannose 22 (CD-galactose 21 is 200.6 nm larger) could explain why there is a large 
% increase for CD-mannose 22. If ConA is non-specifically interacting with the CD-carbohydrate 
surfaces, then ConA addition will cause a greater % increase for a smaller aggregate. However, if CD-
carbohydrates do disaggregate, then the greater aggregate diameter reported for 9.62 𝜇M ConA 
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Figure 3.11 The ∆𝐷/𝐷$ (percentage increase) DLS data from figure 3.9  of aggregate size for CD-mannose 22 and CD-
galactose 21. 
 
3.4.4 Zeta potential of CD-carbohydrate concanavalin A binding  
 
Zeta potential was used as a measure of CD-galactose 21 and CD-mannose 22 binding with ConA 
between 0.00625 – 9.62 𝜇M i.e. the same samples used in DLS. Zeta potential is a good measure of 
nanoparticle surface charge and can be used as a means for measuring surface functional change in 
CDs.144 Hence in this context an overall change is CD surface charge would indicate ConA interaction.  
 
Firstly, ConA between the concentration range 0.06 – 9.62 𝜇M was measured by itself in zeta potential 
measurements. The values did not vary with concentration, mean value of 9.99 ± 0.36 (SEM) mV 
observed (Figure 3.12). ConA is fairly consistent in surface charge over the concentration range used 







































Figure 3.12 Zeta potential of ConA as a function of concentration between 0.06 – 9.62 𝜇M in 0.1 M HEPES buffer.  
 
Starting with 1 mg ml-1 CD-mannose 22 and CD-galactose 21 in 0.1 M HEPES the zeta potential are -
6.28 mV and -4.40 mV respectively. For CD-carbohydrate + ConA 9.62-0.060 𝜇M, the zeta potential 
increases as a function of ConA looking as though it is reaching a plateau at higher concentration in 
both cases (Figure 3.13). This plateau occurs before 10 mV even though the concentration of ConA 
reaches 9.62 𝜇M, a relatively high concentration. 10 mV being the charge of a ConA only aggregate 




Figure 3.13 Zeta potential of CD-mannose 22 and CD-galactose 21 upon the addition of ConA over the range 0.06 – 9.62 𝜇M 
in 0.1 M HEPES buffer. 
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This suggests that the aggregates are not fully coated in ConA and the negative influence of both CD-
carbohydrates is present on the surface. DLS data suggests that a distinct aggregate diameter was 
observed for CD-carbohydrate + ConA. Zeta potential data of the aggregates further supports the 
presence of CD/lectin aggregates showing that the complex has both protein and CD-carbohydrate. 
This suggests that the two components are distributed through the aggregate rather than a “core” 
CD-carbohydrate with a corona of lectin. This fits with the idea that the lectin carbohydrate interaction 
mediates the aggregate formation. However, it is not clear still whether this is a specific interaction or 
not. Non-specific hydrogen bonding between the carbohydrate and protein could be the reason for 
aggregation. However these results, do not rule out specific binding occurring within the CD-mannose 
22 + ConA aggregate either. 
3.4.5 AFM 
 
AFM was used to further investigate ConA binding of CD-carbohydrate in an effort to observe the 
aggregates and structural features which would reveal differences in binding mode between CD-
mannose and CD-galactose. DLS and zeta potential data show that both these carbohydrates induce 
an interaction between the carbon dot and ConA hence no specific binding can be concluded between 
CD-mannose and ConA. Based on the fact a strong ConA dependent interaction was observed in zeta 
potential over the mass ratio range (CD:ConA) 1:0.00625 - 1:0.1  the ratio 1:0.025 was chosen for 
further AFM studies. AcCD 17 was used as a control in these experiments, at the same mass ratio ConA 
was added to AcCD 17 and all 3 samples were prepared for AFM in the same manner. AFM involved 
the drying of aggregates onto mica with the aim to probe their surface and obtain information on how 
the aggregate is organised when in solution.  Accurate (dried) height and adhesion information can be 
obtained through AFM which provided structural aggregate information. 
 
Sample preparation is highly important for obtaining reliable AFM images. Cleanliness was optimised 
to produce artefact free samples which involved preparing the samples in a clean room. The sample 
preparation procedure was optimised iteratively, variables explored were deposition method, sample 
concentration, buffer concentration and drying rate. Successful imaging was possible through the 
following method. The samples of AcCD 17 and CD-carbohydrate + ConA with ratio 1:0.025 was diluted 
1000-fold in 0.1 M HEPES buffer. Mica was cleaved using Scotch tape and the sample was drop 
deposited on the freshly cleaved surface and left for two minutes. Then the solution was wicked away 
from the corner of the mica using white roll with minimal interference to the mica surface. The 
samples were left overnight to dry before AFM imaging was carried out. All AFM imaging presented 
in the results chapter 3.5.4 was carried out by AFM technician Dr. Rob Harniman using a Bruker 
Multimode AFM.  
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Topography and adhesion AFM images are shown for each of 0.1 M HEPES only, AcCD 17 + ConA in 
0.1 M HEPES (Figure 3.14), CD-mannose 22 + ConA in 0.1 M HEPES (Figures 3.15 and 3.16) and CD-
galactose 21 + ConA in 0.1 M HEPES (Figure 3.17). Topography reveals sub nm resolution in the Z-
domain (height). Adhesion measures the AFM tip’s interaction with the sample surface in mV, the 
lighter the shade of colour on the image the greater the interaction and vice versa.  
 
AcCD 17 AFM images are shown in figure 3.13. Key features include large structures up to 10.8 nm in 
height which were seen throughout the sample. These structures were attributed to HEPES buffer 
aggregating, possibly containing AcCD 17 and ConA material. The concentration of 0.1 M HEPES is 
much greater than the AcCD 17 or ConA which has been diluted 1000-fold, hence it is not surprising 
that HEPES buffer makes up a large proportion of deposited material.  
 
In AcCD 17 + ConA between these large structures, small particles of mean height 5 nm were observed 
which are within the same radius size range of  2.7 – 5.69 nm as measured of CDs by Swift et al.94 
Phase contrast image 3.14b maps the adhesion of the AFM tip with the sample. These smaller particles 
are dark which indicates that the AFM tip has lower adhesion to these than to the mica background. 
This low adhesion for “bare” carbon dots was described again by Swift et al.91 The HEPES buffer 
structure is lighter in this image indicating higher adhesion. This image also shows that the AcCD 17 
do not have light corona around the particle which is seen for CD-carbohydrates and was determined 
to be the carbohydrate corona as shown by Swift et al.91  and presented in figure 3.7. Hence, it can be 




Next CD-mannose 25 + ConA and CD-galactose 21 + ConA samples were imaged. In both samples, at 
the micron scale, large structures which we can attribute to HEPES buffer were observed. These can 
be seen in figure 3.15a. Magnification of the space around these structures revealed features of a 
different structure on the nm scale (Figure 3.15b). Between 50-200 nm, these structures had a height 
  







of ~ 10 nm and were not seen in any images of AcCD 17 + ConA. These were magnified further, and 
high-resolution images were taken for both CD-mannose 25 + ConA and CD-galactose 21 + ConA 
samples.  
 
Figure 3.15c,d show these 50-200 nm structures for CD-mannose 22. Structurally they have a denser 
core which has a greater height compared to the surrounding material. These CD-mannose + ConA 
aggregates vary in size and have an irregular edge shape. Following discussion with Dr. Rob Harniman 
(AFM specialist), we concluded that the CD-mannose 22 + ConA aggregates resulted from a drying 
effect. During the sample preparation, the aggregates dry onto the mica surface from the outside in 
towards the centre. As the water dries, material including CD-mannose 22 and ConA are dragged to 
the middle hence when the water finally evaporates, a “core” structure results in the middle of a 












Figure 3.15 CD-mannose and ConA 1:0.025 mass ratio. A-D) Topography images. 
Looking at figure 3.16 in more detail and rendered in 3D (figure 3.16b) shows more information on 
the aggregate structure. Height and phase information of CD-carbohydrates reported before was used 
to identify substructure of the aggregate. The aggregate is 120 nm in diameter in the AFM image from 
figure 3.16. Topographical image shows quasi-spherical particles within the aggregate which can be 
better distinguished in the 3D image. Within the “core” of the aggregate there seem to be CD sized 
particles which fits with our drying effect suggestion. Hence, we propose that the aggregate in figure 
3.16 contains CD-mannose 22. Furthermore, we can observe from phase contrast images (Figure 
3.16c) in blue, that the CD-mannose particles are dark blue, having low adhesion to the AFM tip, 
characteristic of CD91. There is a lighter area around each of these particles which is again more 
apparent in the 3D map corresponding to areas of higher adhesion as would be the case for 
carbohydrate, protein or as we have seen with HEPES buffer. Hence, we propose there is order within 
these aggregates were the CD-mannose 22 and ConA are distributed within the aggregate in a manner 
indicative of CD-mannose 22 to ConA interaction. This is not indicative of specific binding of ConA in 
itself. 
 
For CD-galactose 21 + ConA these “fried egg-type” structures were also observed. However, these 
were not the only nm scale structures observed. Figure 3.17 shows an image where both structures 
were seen. CD-galactose 21 + ConA also had aggregates of the same size but without this dense “core” 
structure. This suggests a smaller aggregate in solution hence a faster drying time, meaning that the 
dense core effect does not occur. One of these structures is magnified in Figure 3.17b,c. In this 
aggregate carbon dot sized particles can be observed. In the blue phase contrast image (Figure 3.17c) 
a lighter blue corona is observed which could be carbohydrate and/or ConA and HEPES buffer. 
However, interestingly this looks to be more loosely associated and less densely packed. This indicates 






This difference in structure occurrence between CD-carbohydrates + ConA could be a manifestation 
of ConA specificity for 𝛼-D-mannose and is non-specific for 𝛽-D-galactose. In order to determine this, 
quantification of these two discrete structures should be performed over a greater number of images 
















































Figure 3.16 AFM images of CD-mannose 22 + ConA. A) shows a wide field of view. White structures are aggregates of CD-


























Figure 3.17 AFM images of CD-galactose 21 + ConA. A) shows a wide field of view. White structures are aggregates of CD-









A 0.1 M HEPES control sample was prepared and imaging revealed large aggregates with height 40 nm 
(figure 3.18). These having the same height and adhesion properties as the large structures in other 
samples showed that 0.1 HEPES was the material composing these aggregates. In this sample no 
smaller nanometer structures were seen on the mica suggesting them to be the CD-carbohydrate and 
ConA material. 
 
Figure 3.18 AFM topography image of 0.1 M HEPES only on mica. Large micron structures observed. 
Efforts to remove some 0.1 M HEPES buffer for better visualisation of 50-200 nm structures were 
carried out. The sample CD-mannose 22 + ConA sample (as used for figure 3.15) was dialysed with 
H2O before deposition. The assumption was that the aggregates in solution would not disassemble at 
lower HEPES concentration and through this the large aggregates could be removed before imaging. 
However, a complete disaggregation of HEPES and nanoscale structures was induced. Figure 3.19 
shows the images of CD-mannose post dialysis with H2O. Individual carbon dots can be clearly 
observed in both topography and phase contrast images and no agregation at the micro or nanoscale 
was observed. Phase contrast images show that the CDs lie in an area of high adhesion which could 
be carbohydrate, protein or HEPES buffer. Hence, this was not a viable means for improving sample 
aggregate distribution. 





3.4.6 TEM  
 
TEM was carried out on both CD-mannose 22 and CD-galactose 21 + ConA with the aim of observing 
aggregates. The carbon dots are known to be between 1.54 – 3.69 nm in diameter in TEM and this 
was used as a means for identifying CDs in these images. Aggregates were not observed in CD-
galactose 21 + ConA as was the case in AFM. CDs were identified and were monodispersed suggesting 
no ConA induced aggregation was seen (Figure 3.20). During sample preparation the aggregates which 
exist in solution must disassemble. Sample preparation involves drop depositing 20 𝜇L of sample 
undiluted onto a 4 nm carbon coated copper grid and drying overnight before imaging. The same is 
not seen in CD-mannose 22 + ConA. Here no monodispersed CD-mannose was observed and there 
were aggregates between 30-50 nm, hence, smaller than the aggregates seen in AFM. From these 
images there were not enough aggregates to conduct statistical significance calculation. These were 
imaged via TEM and STEM as shown in figure 3.21. High-resolution TEM was conducted on one of 
these aggregates and within the aggregate CDs can be seen through their density and crystalline core. 
The areas around the CDs do not have crystallinity implying that this is material associate with the 
carbon dots which have no crystallinity, potentially ConA or carbohydrate. This result suggests that 
something in the TEM preparation process causes differential effect on the aggregates. This could be 
a result of tighter binding of ConA to CD-mannose 22 which is the result of specific binding.  
 














Figure 3.21 A) TEM and B) STEM image of CD-mannose + ConA low. C) High resolution TEM showing CD particle crystal      
lattice core. 
 
3.5 FRET Results 
 
In developing a novel carbon dot FRET assay for measuring lectin carbohydrate binding, nanomaterials 
synthesised and characterised in chapter 2 were used. The photoluminescence properties and full 
structural characterisation of these materials means that interpreting the meaning behind the results 
seen in this chapter can be discussed. As is the case with other nanomaterial-based FRET assays the 
material properties should be included as part of a correction factor which allow the variants in the 
assay to be comparable. These include QY and spectral overlap between donor and acceptor. The 
means for assessing the FRET efficiency can be conducted in a number of ways such as ratiometrically, 
by measuring the fluorescence increase or decrease in one fluorophore, through a 3-cube method – 
which measures in three channels with the aim of removing crosstalk signals. Often this means that 
the result of the assay is apparent to that assay only and an apparent kd is extracted. This means raw 
results from this assay cannot be compared with others, but rather trends can be compared. In this 
work we explore the two carbon dots synthesised, CDala-carbohydrate and CD-carbohydrate from 
chapter 2 as well as using FCD-3 from chapter 5 as a FRET acceptor. The effect of having a longer or 
shorter linker is explored. Some literature evidence shows that having a longer linker allows the 




favourable. However, in the context of a distance dependent FRET readout, a small increase in 
distance could result in a removal of FRET altogether. Figure 3.22 shows the relationship between 
distance and propensity for FRET to occur with our system. Theoretical R0 was calculated for the CD 
with fluorescein to determine the maximum distance at which FRET would be possible. Vice versa, the 
measured FRET signal indicates that the donor and acceptor must be within measurable distance 
hence can inform on the binding distance and conformation102.  
 
 
Figure 3.22 CD-carbohydrate binding by specific lectin in this case ConA attached with fluorescein allows distance dependent 
FRET interaction to occur.  
 
3.5.1 FCD-3 and AcCD 17 FRET experiment   
 
Initial efforts were made using long linker AmCD 16 synthesis carbon dots as the donor and using 
green fluorescent carbon dots FCD-3 as the acceptor partner. This would allow for two 
functionalisable platforms for multivalent presentation. By having the lectin presented on a carbon 
dot this would be more closely sterically similar to how the interaction occurs in nature. The spectral 
excitation and emission profiles are shown in figure 3.23a. The excitation spectra of AcCD 17 and FCD-
3 are shown on the same graph. Using these spectra optimal excitation of the AcCD would occur at 
320-340 nm where FCD-3 has low excitation. This is important to ensure minimal direct acceptor 
excitation. The fluorescence of FCD-3 peaks at 525 nm, at which AcCD 17 has minimal emission. This 
indicates good potential for FRET.  
 
A preliminary experiment was conducted to observe whether any FRET occurred between the two 
nanoparticles without the carbohydrate or lectin conjugated to either substituent. FCD-3 was titrated 
into a stock solution of AcCD 17 and the 𝜆em 525 nm measured as a function of  𝜆ex 340 nm. The raw 
fluorescence data is shown in figure 3.23. The blue line shows the emission of AcCD 17 (1 mg ml-1) in 
0.1 M HEPES buffer. Upon each addition of FCD-3 (each aliquot was 8 𝜇L of 5 mg ml-1) the emission at 
 141 
 
430 nm corresponding to AcCD 17 decreased but the fluorescence at 525 nm did not increase. This 
indicates no FRET occurred from blue CD to green. The decrease at 430 nm indicates energy transfer 
or quenching of AcCD 17 as a result of the addition of FCD-3, and any type of non-FRET energy transfer 
cannot be inferred. This decrease could be used as a measure of nanoparticle interaction, however, 
as it is not FRET it is not r6 distance dependent and will not be able to sensitively measure lectin-
carbohydrate interaction. Evidence from chapter 5 on the characterisation of FCD-3 shows that this 
material is composed of a small molecule coating a nanoparticle. Hence, this small molecule could be 
dissociating from the nanoparticle surface during the assay and inducing quenching. This was 




Figure 3.23 Graphs relating to AcCD 17 and FCD-3. A) Absorptionand emission spectra for AcCD 17 and FCD-3 overlaid. AcCD 
17 𝜆ex 340 nm and 𝜆em 430 nm. FCD-3 𝜆ex 430 nm and 𝜆em 525 nm. Overlap between AcCD 17 emission and FCD-3 absorption 
profiles is indicative of potential energy transfer via FRET. B) Shows the FRET assay raw data of 10 aliquots of FCD-3 titrated 



















AcCD 17 + FCD-3
AcCD 17 em (ex 340 nm)
AcCD 17 abs
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3.5.2 FRET pair Förster radius (R0)  
 
A consideration of FRET is the spectral overlap between the donor emission and acceptor excitation. 
This is usually shown through overlaid spectra as seen in figure 3.23. With CD-carbohydrate it has been 
shown that the conjugated carbohydrate can affect the electronic properties of the CD so that the 
emission shoulder ~ 520 nm differs between CD-carbohydrates synthesised from the same AcCD 17. 
We have seen differences between carbohydrate functionalised AcCDala 10 too. Hence, we calculated 
the difference in integral of each of CD-carbohydrates and CDala-carbohydrates with the acceptor 
fluorescein. Fluorescein conjugated ConA can be commercially purchased and was used in subsequent 
FRET assays. The spectral overlap (J) nm4 cm-1 M-1 is shown in table 3.3. The integrated area was 
calculated according to equation 3.7 in the program 𝑎|𝑒, where 𝑃𝐿)(;) is the donor emission integral 
when the area is normalised to 1 and 𝜖6 is ConA’s extinction coefficient. 
 





Equation 3.7 Equation used by software 𝑎|𝑒 to generate integrated area overlap between emission of CD-carbohydrate and 
CDala-carbohydrate and fluorescein (J) nm4 cm-1 M-1. Data obtained is summarised in table 3.3.  
The spectral overlap data were similar ranging between 1.476 - 1.787 x 1012 nm4 cm-1 M-1. This small 
range suggests that this would not have a large effect on the FRET potential. However, some methods 
for analysing FRET include this as part of a correction factor113 when calculating apparent FRET values. 
 
In order to determine the R0 of the CD-carbohydrate and CDala-carbohydrate with ConA-F equation 
3.8 found in Guo et al.90 was used. The equation provides the R0 in Angstrom (Å) however, this is often 
reported in nanometers for relevance. Where 𝑛3= 1.33 the refractive index, 𝐾- = 2/3 and is the 
random dipole moment orientation of free fluorophore, 𝑄+=	is the QY of the donor and 𝐼 is the integral 
of the spectral overlap (J) nm4 cm-1 M-1. 




Equation 3.8 Förster radius (R0) equation. Data obtained is summarised in table 3.3. 
The R0 values are presented in table 3.3 and show a range of values from 1.995-2.925 nm. This is 
relatively short compared to the 10 nm distance that FRET can potentially occur over. However, this 
means that up to 3.99-5.85 nm FRET can be measured using these materials as synthesised all be it 




Sample Spectral overlap (J) 
x1012 / nm4 cm-1 M-1 
R0 with 
Fluorescein (nm) 
AmFCD 1.623 2.55 
AcFCD 1.593 2.93 
CD-glucose 1.559 2.55 
CD-mannose 1.597 2.77 
CD-galactose 1.546 2.81 
CD-maltose 1.587 2.72 
CD-lactose 1.610 2.77 
CD-maltotriose 1.608 2.82 
CD-1,3-1,6-manntriose 1.719 2.60 
CD-1,4-manntriose 1.740 2.59 
CD-4-O-mannobiose 1.787 2.40 
AcCDala 1.491 2.74 
CDala-mannose 1.763 2.00 
CDala-galactose 1.748 2.03 
CDala-1,3-1,6-mannotriose 1.543 1.93 
CDala-1,4-manntriose 1.604 2.55 
CDala-4-O-mannbiose 1.614 2.60 
CD-3’sialyllactose 1.476 2.34 
CD-6’sialyllactose 1.634 2.46 
Table 3.3 Spectral overlap of CD-carbohydrate and ConA and calculated R0 values using equation 3.8. Errors could not be 
calculated in from this data as repeats were not conducted. 
 
3.5.3 Theoretical FRET distance using physical information 
 
Using the R0, and structural information we have for CD-carbohydrate and CDala-carbohydrate donor 
and ConA-fluorescein acceptor whether there is a physical barrier to FRET can be thought about. We 
observe aggregation when donor and acceptor are in buffered solution together and DLS reports 
aggregate sizes between 200-1000 nm. However, thinking about a donor and acceptor pair in 
isolation, FRET distance (r) can be thought about.  
Generic CD structure proposed in the conclusion of chapter 2 (section 2.3) shows the overall 
hydrodynamic size to be 4.28 ±	0.56 nm. If the CD fluorescence were to originate from the centre of 
the CD, the distance to the CD surface (i.e. the radius) is 2.14 nm. This calculated hydrodynamic radius 
includes the TTDDA linker which is ~ 2.13 nm long when extended (based on theoretical calculations 
where one C-C bond is 0.14 nm). Hence this likely means that the linker is not fully elongated at the 
surface. It is not known whether the carbohydrate on the CD surface is covalently or non-covalently 
bound. Assuming that both the TTDDA linker has a carbohydrate molecule covalently bonded and 
becomes fully extended in solution then this adds ~2.13 nm for the linker ~0.42 nm for succinic 




Furthermore, the short linker synthesis does not have the TTDDA linker or succinic anhydride on the 
surface hence this means a greater theoretical likelihood of FRET. Assuming specific binding occurs, 
the carbohydrate will be bound within the binding site on the ~7x7x6 nm ConA which is at the surface 
of the protein. Finally, the fluorescein acceptor is conjugated onto the protein in a 4.5:1 
fluorophore:protein ratio. This means it is likely that there is a fluorophore less than 7 nm from the 
carbohydrate.  
The minimum distance between the CD fluorescence centre (donor) and fluorescein molecule 
(acceptor) is therefore 0.84 nm. This is based on the fluorescence of the CD originating at the surface, 
a succinic acid linker (~0.42 nm) and carbohydrate molecule (~0.42 nm) and the fluorophore being 
next the carbohydrate in certain orientations, total 0.84 nm. This is nearer than the R0 for all CD-
carbohydrates reported hence, FRET is possible with these materials. However, the further possible 
distance between donor and acceptor is 12.11 nm. This is greater than the FRET distance possible as 
well as much greater than the R0 value seen for our donors in table 3.3. Hence it is feasible FRET could 
occur with these values. 
3.5.4 FRET between ConA and CDala-carbohydrate (Shorter linker)  
 
The shorter linker spectral profile was overlaid with that of ConA conjugated fluorescein (ConA-F) to 
assess the FRET potential, data is presented in figure 3.22. The excitation and emission spectra for 
AcCDala 10 are shown in blue and red respectively. CDala-carbohydrate spectra are similar enough 
that AcCDala 10 is a good indication of the FRET potential for these also. ConA-F direct excitation 
below 400 nm has a low chance of occurring allowing for optimal excitation of the donor to be 
achieved with the peak at 340 nm. However, the AcCDala 10 emission spectra shoulder above 500 nm 
(as is also the case with CDala-carbohydrate) means there will be some bleed-through into the signal 




Figure 3.24 Absorption and emission spectra for AcCDala 10 and ConA-F overlaid. AcCDala 10 𝜆ex 340 nm and 𝜆em 430 nm. 
ConA-F 𝜆ex 430 nm and 𝜆em 525 nm. Overlap between AcCDala 10 emission and ConA-F absorption profiles is indicative of 
potential energy transfer via FRET. 
Example FRET titration data is shown in figure 3.23 for AcCDala 10, CDala-mannose 15 and CDala-
galactose 14 with ConA-F. Starting spectra with donor only is shown in blue in each titration. Upon 
ConA-F additions the donor fluorescence at 430 nm decreases for CDala-mannose 15 and CDala-
galactose 14 and the acceptor signal at 525 nm increases with an isosbestic point clearly seen at 495 
nm. This is not the case for AcCDala 10 where the donor signal decreases to a lesser extent and the 
signal at 525 nm does not increase. This suggests that the CDala-carbohydrate donors are able to 
transfer energy to the acceptor fluorophore under the terms of distance dependent FRET meaning 
that ConA-F is closer to the CD than in the case of unfunctionalised CD. This indicates that the 
carbohydrate functionalisation does not impede FRET by increasing the distance between the CD and 
the acceptor. This also indicates no non-specific FRET with AcCDala 10. CDala-mannose 15 also shows 
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Figure 3.25 Raw FRET assay raw data of 10 aliquots of ConA-F titrated into AcCDala 10 (A), CDala-mannose 15 (B) and CDala-
galactose 14 (C). Starting spectra blue, last titration dark green in all cases. 
 
Figure 3.26 CD-carbohydrate + ConA-F FRET assay plotted using one site total binding – variable slope Hill plots of direct dye 
excited corrected ratiometric FRET 𝐼'($		/	𝐼*+*  



































































The data was processed according to ratiometric method outlined in section 3.1.1 and developed by 
Guo et al.42 Presented in figure 3.24 is 𝐼8>1	/	𝐼7-7 having subtracted the direct dye excitation 
background. Upon additional aliquots of acceptor (40 𝜇g) the ratio decreases, initially faster and 
begins to plateau. The AcCDala 10 control (light green line) has a more linear curve suggesting that 
the acceptor has a signal independent of binding. The gradient of each slope is used by GraphPad 
Prism software to determine the apparent dissociation constant kd which are shown in table 3.4. 
It is worth noting that whilst carrying out the experiment, upon the addition of ConA-F aliquots, a 
precipitate formed and dropped out of solution. This could be the result of the donor and acceptor 
interacting and forming aggregates this means that not all the binding can be observed on a time scale 
which is measurable by the instrument setup.  
 
The apparent kd values for short linker CDs are within the low 𝜇M range, which confers binding you 
may expect for ConA where multivalent interaction may be responsible.21 Nanomolar values are the 
golden standard for this work and are achieved by using glycodendrimers with 12, 24 or more 
molecules per molecule.35 However, these results are apparent kd values and can be compared using 
this assay only. And the AcCDala 10 control has a comparatively strong interaction with a kd of 4.363 
𝜇M – on the same order of magnitude as all CDala-mannosides tested. The apparent kd for the CDala-
mannosides although similar between the range 0.97-1.99 𝜇M. However, CDala-galactose 14 also falls 







CD-carbohydrate Apparent kd (𝜇M) 𝐵9!' NS R2 
AcCDala 10 4.36 ±	7.22 -1.7 ±	3.3 -0.3 ±	 0.2 1.00 
CDala-galactose 14 1.63 ± 0.36 -7.6 ± 1.2 0.04 ±	0.14  1.00 
CDala-mannose 15 1.36 ± 0.07 -6.9 ± 0.2 0.04 ± 0.03 1.00 
CDala-4-O-mannobiose 12 0.97 ± 0.03 -5.6 ± 0.06 -0.05 ±	 0.01 1.00 
CDala-1,4-mannotriose 11 1.99 ± 0.37 -5.3 ± 0.8 -0.14 ±	0.08  1.00 
CDala-1,3-1,6-mannotriose 13 1.23± 0.04 -6.7 ± 0.1 0.05 ±	0.02 1.00 
Table 3.4 Apparent dissociation constants kd (with SEM) for CDala-carbohydrate from FRET assay with ConA-F determined from 
graph in figure 3.24. Where 𝐵,-& is the maximum specific binding in terms of 𝐼'($/𝐼*+* and NS is the slope of the non-specific 




3.5.5 FRET between ConA and CD-carbohydrate (Longer linker) 
 
 
The long linker spectral profile was overlaid with that of ConA-F to assess the FRET potential, data is 
presented in figure 3.25. The excitation and emission spectra for AcCD 17 are shown in blue and red 
respectively. CD-carbohydrate spectra are similar enough that AcCD 16 is a good indication of the FRET 
potential for these also. Long linker CDs have similar photoluminescence profiles to short linker CDs 
hence the same excitation 340 nm can be used. Similar to the short linker CD, spectral bleed-through 
at 525 nm will occur.  
 
Figure 3.27 Absorption and emission spectra for AcCD 17 and ConA-F overlaid. AcCD 17 𝜆ex 340 nm and 𝜆em 430 nm. ConA-F 
𝜆ex 430 nm and 𝜆em 525 nm. Overlap between AcCD 17 emission and ConA-F absorption profiles is indicative of potential 
energy transfer via FRET. 
Considering the longer linker on these CDs compared to the short linker CDs, the distance between 
the donor and acceptor will be further away hence a reduced FRET signal would be expected. This is 
assuming that the carbohydrate is covalently conjugated to the linker, interacting with the ConA-F and 
fully extended from the CD surface. The FRET titration data however, indicates FRET has occurred due 
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Figure 3.28 Raw FRET assay raw data of 10 aliquots of ConA-F titrated into AcCD 17 (A), CD-mannose 22 (B), CD-galactose 
21 (C), CD-4-O-mannobiose 19 (D), CD-1,4-mannotriose 18 (E) and CD-1,3-1,6-mannotriose 20 (F). Starting spectra blue, last 







Figure 3.29 CDala-carbohydrate + ConA-F FRET assay plotted using one site total binding – variable slope Hill plots of direct 
dye excited corrected ratiometric FRET 𝐼'($		/	𝐼*+*  
 
As before, the same ratiometric method 𝐼8>1	/	𝐼7-7 and was plotted as a function of acceptor 
concentration as shown in figure 3.27. The slope of the control, AcCD 17 (black line) looks more linear 
than the carbohydrate containing samples indicating a lack of FRET similar to the data seen with short 
linker data. The kd was extracted from the slope of the curve in GraphPad Prism and collated into table 
3. Interestingly, there are greater differences between CD-carbohydrate samples with a long linker 
than with the short linker. From table 3.5 the AcCD 17 shows a 10-fold higher kd of 36.67 𝜇M than 
observed in short linker results. This suggests a weaker interaction between the AcCD 17 surface and 
ConA-F than with AcCDala 10. CD-galactose 21 kd of 7.84 𝜇M can be compared with the CD-mannoside 
samples. CD-4-O-mannobiose 19 had a kd of 9.29 𝜇M which is greater than the CD-galactose 21 
control. Assuming 𝛼-mannose binding occurs, this result indicates a lack of specific binding by ConA 
to this disaccharide. The other CD-mannosides have comparable values as seen with short linker 
CDala-mannosides which indicates that the FRET distance is not much different between CD linker 
length. This suggests that the linker does not play a role in mediating a distant dependent result. 






























Considering FRET data for both the short and long linker CDs in combination with structural 
information gleaned from chapter 1 which showed that carbohydrate exists in the sample which is not 
covalently bound to the CD. ConA may have greater affinity for this free carbohydrate and if it is in 
greater concentration than the ConA binding sites available, a lack of FRET may result. If ConA-F binds 
unconjugated but CD associated carbohydrate, this could bring fluorescein in closer proximity to the 
CD donor, hence, FRET does not infer conjugated carbohydrate binding. Furthermore, CDala-galactose 
14 and CD-galactose 21 both have a better FRET signal compared to unfunctionalised CDs. This 
suggests that non-specific carbohydrate interaction is involved in FRET observed independent of linker 
length.  
 
3.5.6 Caveats of our system 
 
We use glycan functionalised carbon dots as our donor system and the fluorophore fluorescein 
conjugated to the lectin Concanavalin A (ConA-F) as our acceptor. In our system we do observe 
crosstalk as shown by control data with ConA-F only. This is relatively high considering the minimal 
excitation seen for Con-F in its spectra. However, this is subtracted from the raw data before FRET 
efficiency equations are applied.  
 
There is a baseline level of bleed-through of CD donor fluorescence at 525 nm in the acceptor channel 
which is difficult to remove. Although the donor concentration does not change over the course of 
the experiment (the acceptor aliquot added contains donor so that the overall donor concentration 
remains consistent), the CD fluorescence reduces as FRET occurs to the acceptor. Hence, three-cube 
methods could overcome this. In our system we observe non-specific aggregation in DLS with CD-
galactose 21 + ConA. Hence, a lack of distinguishable FRET efficiency observed with CD-mannose 22 
could be a result of non-specific FRET occurring. 
𝑰𝟒𝟑𝟎		/	𝑰𝟓𝟐𝟓 
CD-carbohydrate Apparent kd (𝜇M) 𝐵9!'  NS  R2 
AcCD 17 36.67 ± 46.44 -73.2 ± 167 1.2 ± 167 0.9998 
CD-galactose 21 7.84 ± 2.78 -13.0 ± 6.4 0.2 ± 6.4 0.9997 
CD-mannose 22 2.44 ± 0.04 -6.6 ± 0.1 0.06 ± 0.1 1 
CD-4-O-mannobiose 19 9.29 ± 2.78 -18.8  ± 7.7 0.6 ±	7.7 0.9993 
CD-1,4-mannotriose 18 1.85 ± 0.39 -4.9  ± 0.8 -0.2 ± 0.8 0.9994 
CD-1,3-1,6-mannotriose 20 0.89 ± 0.16 -5.1  ± 0.5 -0.2 ± 0.5 9.9987 
Table 3.5 Apparent dissociation constants kd (with SEM) for CD-carbohydrate from FRET assay with ConA-F determined from 
graph in figure 3.27. Where 𝐵,-& is the maximum specific binding in terms of 𝐼'($/𝐼*+* and NS is the slope of the non-




In our case we have a multivalent donor which presents binding sites in 3-dimensions. The acceptor 
fluorescein is conjugated to ConA to make ConA-F which can bind in 3-dimensions also, having four 
identical independent binding sites. This means that there is potential for an aggregate to form as a 
result of these specific interactions which means multiple donor to acceptor potential FRET 
opportunities and a mixed fluorophore population. Furthermore, commercially acquired acceptor 
ConA-F has on average 4.5 fluorophores conjugated per ConA tetramer. Which means FRET 
interactions from one donor to one acceptor binding event will still have multiple fluorophore 
populations.  
 
With our carbon dots the surface functionalisation is known to impact the fluorescence peak shoulder 
~ 520 nm hence binding with an acceptor fluorophore such as fluorescein (𝜆&' 530 nm) could impact 
this. This would affect the acceptor channel potentially to a greater extent than the donor channel as 
a result. Control experiments with a non-fluorescent ConA or further investigations with methyl 𝛼-D-
mannose could investigate the effect of protein binding in this case. Furthermore, raw FRET titration 
data shows a donor peak blue-shift upon each addition of ConA-F. This could be a property on the 
aggregate which could cause detection in the donor channel to be misleading. 
 
2.5.7 Methyl-𝜶-D-mannose competitive studies  
 
Post FRET titration methyl-𝛼-D-mannose was added to the sample in a competition assay. Methyl-𝛼-
D-mannose is bound irreversibly by ConA.145 When added into solution with CD-mannose 22, and AcCD 
17 it competes with specific mannose binding in CD-mannose 22 or can simply remove non-specific 
interactions between AcCD 17 and ConA-F. Figure 3.28 shows that for AcCD 17, addition of methyl-𝛼-
D-mannose, up to 1000 ug, causes a removal of FRET signal upon 340 nm irradiation. The donor 
fluorescence peak at 430 nm increases, meaning the CD can undergo radiative emission and the 
isosbestic point at 515 nm is no longer observed. However, the peak at 525 nm corresponding to the 
acceptor peak fluorescence increases with each addition of methyl-𝛼-D-mannose too. This suggests 
that as the donor becomes unbound, ConA-F becomes more fluorescent. This seems counter intuitive 
as the donor is further away hence cannot FRET, meaning lower fluorescence signal at 525 nm would 
be expected. However, direct dye excitation of fluorescein could be occurring.  Figure S.3.3 shows that 
ConA-F fluorescence at 525 nm reaches 200 a.u. upon the highest ConA-F concentration. This is much 
greater than the fluorescence seen in in figure 3.28 of AcCD 17 + ConA-F at the final titration (>100 
a.u.).  Hence, restoration of this direct dye excitation may be occurring when ConA-F binds methyl-𝛼-
D-mannose. Furthermore, this could indicate ConA-F fluorescence is quenched when it is bound to 
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the CD, perhaps by the CD or self-quenching due to a high level of fluorescein aggreged at the CD 
surface.  
 
Figure 3.30 Addition of methyl-𝛼-D-mannose which irreversibly binds ConA was added to FRET titrations post ConA FRET 
experiments. 
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3.5.8 CD-sialyl-D-lactose FRET  
 
CD-3’-sialyl-D-lactose 26 and CD-6’-sialyl-D-lactose 27 were tested in the same ratiometric FRET assay 
with the Elderberry Bark lectin - Sambucus Nigra lectin (SNA) conjugated with fluorescein (SNA-F). SNA 
is a tetrameric lectin of size 140 kDa which is known to specifically bind 𝛼-2,6-sialyllactose over 𝛼-2,3-
sialyllactose.146 This is due to interaction between the terminal sialic acid in 2,6-sialyl-D-lactose which 
is bound with greater affinity by SNA based on binding site interaction with the carboxylic acid and 
glyceryl (C7-C9) side chain.147  Sialic acid is one biomarker of cancer cell progression and metabolism 
in some breast cancer cases.148 Furthermore, sialic acid linkage is important in cancer. For example, 
non-small cell lung cancer tumours it was observed that 𝛼-2,6- galactose linked sialic acid was 
overexpressed in well differentiated cells and not in poorly differentiated cells within the same 
tumour.149 Hence this has the potential to be exploited for targeted cancer treatment.  
 
The FRET assay raw data can be seen in figure 3.31. The same FRET donor and acceptor are used in 
this assay as previous work. The donor peak has a double humped fluorescence peak which means 
that measuring the signal by integrating over a range would be more accurate than at one wavelength. 
However, the intensity at 430 nm and 525 nm were plotted using non-linear fitting according to Hill’s 
equation as seen in figure 3.32. The apparent kd from SNA with CD-3’-sialyl-D-lactose 26 was 1.185 ± 
0.008 𝜇M (R2 = 0.9999) 𝐵9!'	is -5.0 ±	0.1 and NS is -0.03 ± 0.01 and with CD-6’-sialyl-D-lactose 27 
was 0.6044 ± 0.007 𝜇M (R2 = 0.9996) 𝐵9!'	is -5.2 ± 0.1 and NS is -0.03 ± 0.02. This result fits with 
the knowledge that SNA has greater specificity for the 𝛼-2,6- version of sialyllactose having almost 
half the affinity in this assay. This indicates differential binding information can be observed and could 






Figure 3.31 FRET Raw FRET assay raw data of 10 aliquots of SNA-F titrated into 𝐶𝐷-3’-sialyl-D-lactose 26 and 𝐶𝐷-6’-sialyl-D-
lactose 27. Starting spectra blue, last titration dark green in all cases. Molar concentrations of SNA-F were the same as those 
used for ConA-F and the CD-carbohydrate concentration was also the same 1 mg ml-1. 
 
Figure 3.32 CD-3’-sialyl-D-lactose 26 + ConA-F and 4 CD-6’-sialyl-D-lactose 27 + ConA FRET assay plotted using one site total 
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3.6 Conclusions and Future Work  
 
Physical DLS, TEM and AFM characterisation revealed carbohydrate-based aggregation between CD-
mannose and CD-galactose with ConA. Although this has not been carried out for shorter linker CD’s 
we anticipate similar aggregation induced by ConA-F, based on known surface functionality. AFM 
studies revealed CD-carbohydrate-based aggregation between 200-500nm which was not seen in 
AcCD 17. These structures were also seen in TEM and DLS. This data alluded to different modes of 
binding between CD-mannose 22 and CD-galactose 21 reflecting ConA specificity for 𝛼-D-mannose, 
seen through two distinct types of aggregates. These were thought to reflect tight and loose 
aggregates in solution. The prevalence of these aggregate types differed between CD-mannose 22 and 
CD-galactose 21 needs further investigation. 
 
FRET results indicate differences between short and long linker CD-carbohydrate binding by ConA. The 
comparison between control AcCDala 10 and AcCD 17 in FRET assay with ConA-F with apparent 
dissociation constants of kd of 4.36 𝜇M and kd of 36.67 𝜇M reveals a 10-fold difference in affinity. 
Considering they have the same terminal carboxylic acid group the basis for this difference is unclear. 
The TTDDA and succinic anhydride linker on AcCD 17 may add increased distance between the CD 
fluorescence centre and fluorescein. 
 
For the shorter linker FRET result, AcCDala 10 and CDala-galactose 14 having comparable affinity to 
the CD-carbohydrates indicates a non-specific interaction. Longer linker CDs seem to not impose an 
improved affinity compared to CDala-carbohydrates, rather better controls where AcCD 17 has a 10-
fold greater dissociation constant (36.67 𝜇M) and CD-galactose 21 (7.84 𝜇M) is also larger than CD-
mannosides. This suggests CD-mannoside results result from specific binding of ConA. In order to 
investigate these results further, reliability should be improved by repeating these assays so that 
significant differences can be concluded. Whether these results can be reproduced using a different 
synthesis is also an important point. Carbohydrate functionalisation is an unknown variable with this 
material. Between syntheses this could vary and assessing this would be difficult. Chapter 2 outlined 
how the Molisch’s test can be used to determine the carbohydrate present on the surface of the CD. 
However, this does not differentiate if and how much is covalently or associated with the CD. 
Furthermore, a second interaction was assessed in this assay using the same FRET donor and acceptor. 
Results of this fit with known binding affinity of SNA for 𝛼-2,6-sialyl-D-lactose over 𝛼-2,3-sialyl-D-




R0 range between 2-2.9 nm and spectral overlap indicate that FRET could occur with the materials 
used, the minimum distance possible being 0.84 nm calculated from known physical characteristics of 
our system. Hence, it is feasible that FRET could be the basis for the results we observe.  So far 
ratiometric FRET seems to provide apparent FRET binding constants which show similarity between 
two types of CD, which suggests reliability.  
 
Interestingly, competition studies with the long linker CD show a distinct removal of FRET interaction 
with AcCD 17. This suggests a different binding mechanism between ConA-F to carboxylic acid 
functionalised CDs and a carbohydrate. However, differences in this study could not be distinguished 
at the concentration range of competitive inhibitor used. 
 
In order to investigate this further CD-galactose 21 should be tested in a competition assay with 
methyl-𝛼-D-mannose to observe whether an effect similar to AcCD 17 in which case the result with 
CD-mannose 22 would be specific to the ConA specificity for mannose. If CD-galactose 21 has a result 
similar to CD-mannose 22 then this suggests this effect is an indication of non-specific binding and 
suggest CD-mannose 22 is non-specifically bound by ConA-F.  
Furthermore, if these results can differentiate between lectin-carbohydrate binding and non-specific 
binding then inhibition experiments could be used to measure the binding affinity, where the donor 
fluorescence recovery could be the parameter indicative of binding. This could also be used to quantify 
the CD-carbohydrate interaction with ConA. The amount of methyl-𝛼-D-mannose required to restore 
donor fluorescence, through an inhibitory binding study, could reveal how much carbohydrate was 
bound on the CD surface by ConA.  
	
To overcome the 𝛼-D-galactose non-specific interaction and confirm that the FRET signal is specific 
between ConA and our CD-mannose it would make sense to instead carry out Ca2+ omitted 
experiments between ConA and CD-mannosides. This should show a removal of FRET. Also, ConA-
succinyl could be used as a means for assessing multivalent binding of CD-carbohydrates. Succinylating 
the lectin causes a dimer to exist in solution instead of a tetramer at pH 7.4. The lectin binding will be 
much lower if reflecting the reduced multivalency. This could also be assessed in terms of aggregate 
size formed. ConA-succinyl would cause a reduction in aggregate size if the aggregation is the basis of 






3.7 Experimental   
 
Lectins Concanavalin A fluorescein conjugated (ConA-F) and Sambucus Nigra Lectin fluorescein 
conjugated (SNA-F) were purchased from Vector Labs.  
 
3.7.1 DLS and zeta potential sample preparation 
 
CD-carbohydrate was diluted to 1 mgml-1 in 0.1 M HEPES buffer with 5 mM MnCl2 and 5 mM CaCl2 and 
ConA was diluted in the same buffer and added in mass ratios 1:1 to 1:0.00625 to the CD-carbohydrate 
sample. 
1 ml of sample was made total. A plastic 70 𝜇L cuvette was used to measure hydrodynamic size in DLS 
and a plastic zeta potential cell was used to measure the zeta potential, 700 𝜇L required. Before DLS 
and zeta potential measurements samples were vortexed for 10 seconds in a 1.5 mL Eppendorf tube. 
3.7.2 AFM sample preparation   
 
AFM sample preparation was carefully and iteratively optimised to the following. Fresh buffer (0.1 M 
HEPES buffer with 5 mM MnCl2 and 5 mM CaCl2 ) was prepared from 0.2 𝜇m cellulose membrane 
filtered ultrapure water and samples with CD-mannose 22, CD-galactose 21 and AcCD 17 were 
prepared with ConA at the ratio 1:0.025 (0.24 𝜇M). Samples were vortexed for 10 seconds in 1.5 mL 
Eppendorf tubes for before deposition. Fresh mica surface was prepared by cutting up 1 cm2 squares 
and cleaved with Scotch tape to reveal a fresh atomically flat surface. Samples were diluted 1000-fold. 
20 𝜇L of sample was drop deposited on the surface and left for 2 minutes. White roll was used to 
carefully remove excess sample from the side of the mica. N2 was gently blown on the surface for 
drying. Samples were left overnight before imaging to dry completely. Variables optimised in AFM 
sample preparation include drying time, concentration of sample, buffer cleanliness and drying 
method i.e. spin drying.  
 
3.7.3 TEM and STEM sample preparation  
 
CD-mannose 22, CD-galactose 21 and AcCD 17 were prepared in the same way in 0.1 M HEPES buffer 
with 5 mM MnCl2 and 5 mM CaCl2 and ConA added at the ratio 0.25 (0.24 𝜇M).  Sample was vortexed 
before deposition. 20 𝜇L of sample was drop deposited onto a 4 nm carbon coated copper grid and 




3.7.4 FRET assay experimental conditions 
 
CD-carbohydrate of interest was diluted to 5 mg ml-1 in 0.1 M HEPES buffer with 5 mM MnCl2 and 5 
mM CaCl2. Molar concentration was calculated using a ConA mass of 104 kDa and SNA mass of 140 
kDa into a quartz cuvette was added 120 𝜇L of sample and 480 𝜇L of buffer only (1 mg ml-1). 
Fluorescence was measured using a fluorometer set to 700 V laser power, slit width 10 nm. ConA-F 
was dissolved to 5 mg ml-1 in 0.1 M HEPES buffer with 5 mM MnCl2 and 5 mM CaCl2 which also 
contained CD-carbohydrate of interest at 1 mg ml-1. i.e. preparing the guest solution in the host 
solution as seen in supramolecular titrations.150 8 𝜇L of ConA-F solution was titrated into the CD-
carbohydrate solution and mixed by pipette mixing 3 times. Fluorescence was measured upon each 
titration up to 10 additions.  
 
Fluorescence at 430 nm and 525 nm were taken as the donor and acceptor signal respectively. These 
were plotted ratiometrically 𝐼8>1/𝐼7-7 having subtracted the direct dye excitation background. This 
data was plotted in GraphPad Prism software using non-linear fitting, one-site total binding fitting 
(Model: 𝑌 = 𝐵𝑚𝑎𝑥	𝑋/(𝑘" + 𝑋)	+ 𝑁𝑆	𝑋 + 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)	and the kd values reported were those 
reported by the software. 
3.7.5 Supplementary graphs  
                
Supplementary Figure 3.1 DLS raw data of % intensity data for CD-mannose 22 + ConAat a range of concentrations  in a 
binding study. 
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Supplementary Figure 3.2 DLS raw data of % intensity data for CD-glactose 21 + ConA at a range of concentrations  in a 
binding study. 
 
Supplementary Figure 3.3 Direct dye excitation (𝜆ex 340 nm) of ConA-F acceptor. 
 
 
Supplementary Figure 3.4 Control experiment. Additions of ConA without fluorescein to CD-mannose 22 to observe if CD-
mannose quenching occurs without an acceptor fluorophore.  
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4. Carbon Dots for Anti-Cancer Drug delivery 
4.1 Introduction  
4.1.1 Cancer  
 
Cancer is one of the most prevalent and deadly diseases in the world, with 1 in 2 people developing 
the disease over the course of their lifetime and is still one of the leading global cause of death. 
Therefore, research into treatments for cancer represents a big proportion of efforts in medical 
research151,152. The variety of cancers are vast, commonly of the liver, prostate, colorectal, stomach 
are believed to be caused by intricate multifactorial biological pathways151. Hence, cancer treatments 
are often not universal, and research is devoted to develop novel therapies that can intervene at 
different stages of cancer progression. In addition to existing treatments such as radiotherapy and 
chemotherapy clinically used, personalised medicines e.g. immunotherapy and targeted therapy are 
technologies at the forefront of clinical research153. They both offer tailored treatments which can be 
used more sensitively in terms of earlier treatment, reduced side effects and have high efficacy. 
However, the expense of developing these treatments in a highly tailored way may not be sustainable 
in a medical climate where resources are increasingly restricted, and cases are increasing (due to aging 
and growing population and unhealthy lifestyle)154. Furthermore, a good understanding of the 
underlying mechanisms of action of the cancer pathway is required for the development of suitable 
treatments, however this is not always be possible. In this context, patients with novel or complex 
cancer origins often have to rely on traditional therapies which effect have high levels of non-specific 
cellular damage and hence side effects associated. 
 
In the first instance novel treatments need not focus on exploiting an underlying mechanism, rather 
the novelty can come from exploiting known cancer associated biological markers in a new way. These 
can include increased vasculature around the tumour, faster cell growth and division and invasiveness 
and metastatic cellular behaviour155. Hence, novel treatments which are more broadly applicable are 
a good alternative to tailored treatments but also have improved treatment over traditional clinical 
methods. These novel treatments could also reduce the cost of current treatments such as 
radiotherapy and chemotherapy. This is not to say novel technologies cannot be used in combination 
with targeting treatments in a combined treatment which may then lead to very highly targeted 






4.1.2 Current treatments  
 
4.1.2.1 Radiotherapy  
 
Radiotherapy was first used as a therapeutic agent against stomach cancer in 1896 and the reduction 
of the associated tumour was noted157. Since then radiotherapy has been widely used as a means to 
kill target cancer cells within a tumour through damaging their DNA with radiation. The radiation 
source can be X-ray or gamma radiation. The electromagnetic waves cannot penetrate deep into the 
body hence the tumour site can be spatially targeted via external source manipulation. Downsides to 
radiotherapy include fatigue, skin blistering, hair loss and sickness158 as irradiation of DNA can cause 
DNA damage but not cell death. This can lead to the development of a secondary tumour so must be 




Immunotherapies are a more targeted type of cancer treatments which prompt the patient’s immune 
system to recognise and destroy cancer cells.153 It is a relatively non-invasive technique and evades 
resistance issues as with drug treatments. The main types of immunotherapy that are available include 
monoclonal antibodies for which a Nobel prize was won in 1984160, cancer vaccines161 and (chimeric 
antigen receptor t-cell) Car-T cell therapy.162 Monoclonal antibodies are proteins which bind cancer 
cells and elicit a natural immune response.163 They are generated in response to a specific cancer cell 
antigen within a patient in a mouse host. The cancer cells are injected into the mouse and an antibody 
response is generated. The mouse spleen cell is then fused with blood cells of the host which can then 
generate an endless supply of antibodies. These are then injected back into the human host 
periodically and cause cancer cell detection and destruction.164 However, fusion of mouse and host 
cells is difficult to achieve, and contamination can occur.  
 
Newer CAR-T cell therapy works differently to also induce an immune response. This can be more 
specific to the cancer markers of interest as it uses gene editing. T-cells (part of the immune response) 
are removed from the patient and engineered with the chimeric antigen receptor or receptors of 
interest. These are then grown in vitro before reintroduction into the patient where they can bind 










Chemotherapy refers to the use of drugs killing cancer cells as treatment. The treatment targets fast 
growing cells and is often specific to certain cancers. Chemotherapy drugs can be used in combination 
and usually elicit the greatest treatment response of therapies available. They work on the basis of 
interfering with DNA transcription and translation or arresting the cellular growth cycle which is more 
frequent in cancer cells compared with healthy cells. With chemotherapy, the therapeutic window 
must be considered, this refers to the concentration range where the drug is toxic enough to induce 
enough damage to cancer cells but preserve healthy cell modes of action. Damage includes covalently 
bonding with DNA or RNA and proteins by alkylating agents or alkaloids,166 cross-linking DNA strands 
with each other by platinum agents,166 antimetabolites competing with DNA or RNA nucleotides to 
disrupt synthesis or antibiotics which form free radicals and damage DNA.166 For example, the drug 
doxorubicin (dox), which is part of the anthracycline antibiotic class, intercalates within the minor DNA 
grooves preventing transcription machinery association.  
 
                         
Figure 4.1 Multidrug resistance (MDR) refers to the upregulation of the p-glycoprotein in cancer cells. Doxorubicin is readily 
removed from the cytosol. When a drug is nanoparticle bound it is able to evade removal.  
 
However, resistance to small molecule drugs can build-up over time and this will lead to reduced 
treatment options. This is commonly referred to as multidrug resistance (MDR) and is often due to 
the upregulation of the MDR-1 gene encoding the membrane p-glycoprotein which is presented at 
the surface of cancer cells166 (Figure 4.1). This effectively pumps out the small drug indiscriminately 
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not be recognised by this protein due to NP carrier methods, then evasion of removal can be achieved. 




Doxorubicin is a chemotherapy drug used since the 1970’s which was isolated originally from 
bacterium Streptomyces peucetius167 and is part of the anthracycline family (Figure 4.2). 
Doxorubicin.HCl is a commercial hydrophilic drug molecule which contains a carbohydrate moiety 
with an amine group and tetracyclic aglycon component. Its mode of action involves binding to the 
minor groove of Deoxyribonucleic acid (DNA) and preventing topoisomerase II association and 
therefore arresting DNA transcription168. Doxorubicin is a planar molecule that intercalates between 
two pairs of GC (guanine-cytosine) bases forming hydrogen bond interactions with guanine and can 
form covalent linkage through its amino sugar to a guanine base. Doxorubicins protonated amine has 
a pKa at 9.93 and a pKa at 8 (hydroquinone -OH), meaning at physiological pH 7.4 the molecule 
becomes protonated at the amine, making it positively charged169.  
 
Figure 4.2 Doxorubicin binds dsDNA by intercalating between 2 pairs of guanine and cytosine DNA base pairs. Red dotted 
lines indicate hydrogens bonding between doxorubicin and guanine base I. Blue covalent line indicates bond between 
doxorubicin amino sugar and guanine base II via a formaldehyde170 on the opposite DNA strand.  
 
Doxorubicin is widely used commonly to treat breast, bladder, lymphoma, Kaposi’s sarcoma and acute 
lymphoblastic leukaemia cancers. The drug has certain side effects associated with its use including 
hair loss, weakened immune system, darkened skin, diarrhoea and loss of appetite as well as the 

















































the dosage) and can occur long after remission 17 years post treatment in one study.171 Once 
cardiomyopathy develops prognosis is 50 % survival.172     
 
The cause of cardiotoxicity from doxorubicin is believed to be oxidative stress in the cardiomyocytic 
cells which particularly harms mitochondrial enzymes such as NADPH oxidase.173 It also induces 
apoptosis via p53 (a cancer upregulated protein) activation once superoxides have been generated 
meaning poorer heart function174. This is dose dependent so if doxorubicin’s therapeutic index can be 
improved and hence less drug needs to be administered, then the risk of cardiomyopathy will be 
reduced. Because doxorubicin is used so widely research into reducing the known associated side 
effects of doxorubicin is a large field. Some other areas of research include developing analogues of 
doxorubicin hence improving the therapeutic index, combining doxorubicin with cardio-protectant 
and also targeting circular cardiomyocyte Ribonucleic acid (RNA) associated with doxorubicin 
toxicity173.  
 
Doxorubicin effectiveness has been assessed in vitro extensively in two breast cell lines; MDA-MB-231 
and MCF-7.175 These cancer cell lines involve different pathways which make them cancerous and as 
a result differ in metastatic severity. MDA-MB-231 is more aggressive and metastatic, whilst MCF-7 is 
less so, growing slower and providing better prognosis on average. Doxorubicin is known to work more 
successfully on MCF-7, whilst MDA-MB-231 has a developed resistance at clinically relevant 
concentrations.175 Hence developing treatments which are able to improve the efficacy of doxorubicin 
in MDA-MB-231 are sought after whilst MCF-7 is used often as a comparative cell line.  
 
Anti-cancer treatments include looking for unique biomarkers associated with these cell types. 
Growth signals such as G protein coupled receptor (GPCR) and interleukin 6 (IL6) are examples of 
markers which can be targeted. However, these pathways can be circumvented by cancer cells and 
therefore targeting these pathways for downregulation do not necessarily offer long-term targets. 
Cancer cell drug resistance methods include DNA damage repair upregulation, histone reorganisation, 
epithelial-mesenchymal transition and drug efflux -also known as multi drug resistance as seen for 
doxorubicin removal.176  
 
Furthermore, when considering the structure of a tumour is important when approaching treatment 
design. Being able to understand the 3D arrangement of these cells shows that the most resistant cells 
are the outermost cells of the tumour where the extracellular doxorubicin concentration is highest.176 
One study used 3D cell cultures in an effort to identify markers responsible for the resistance of MDA-
MB-231 to doxorubicin. Key observations included that resistance in both MCF-7 AND MDA in the 3D 
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culture compared to 2D culture. They determined that underlying causes for poor doxorubicin efficacy 
were due to pathways for decreased cellular proliferation of cells at the core of the tumour and poor 
ECM adhesion. Hence treatments could include molecules which would intercept these pathways and 
make the tumour cells more amenable to doxorubicin treatment175. 
 
4.1.2.5 Methods for improving efficacy 
 
Improving the efficacy of a clinically used drug is one way to improve chemotherapy treatments. 
Addressing either the problems associated with a particular drug involved such as multi drug 
resistance in tumours, or by looking at the pathways involved exclusively in cancer progression can 
offer potential for improving efficacy. Furthermore, the drug efficacy must be considered in 
combination with the toxicity to healthy cells, which is known as the therapeutic window. In the case 
of doxorubicin, the dosage is directly linked to the rate of a cardiomyopathy side-effect. In one study 
the rate of heart failure was 26 % for a cumulative dose of 500 mg/m2, 48 % for 600 mg/m2 and 100 % 
when 800 mg/m2 was administered in a study of 530 patients. Clinically, the cumulative dose does not 
usually exceed 300 mg/m2 keeping the risk of cardiotoxicity low.177 
 
Assessing the toxicity of a drug in vitro can be conducted through calculating the IC50 values which is 
the half maximal inhibitory concentration of a drug of interest compared to control. The IC50 value 
obtained depends on the cell line and experimental conditions used, but through controlled repeats 
values become comparable. Doxorubicin is a well-studied drug in vitro and the IC50 values for a number 
of cell lines has been conducted. These control values can be used to measure the efficacy of a new 
drug or modified version of a drug to see how it would compare to the clinical version. The IC50 value 
is the concentration of drug required to cause 50% cell death. For doxorubicin, the IC50 values in HeLa, 
MDA and MCF-7 are 0.14 𝜇M, 1.26 𝜇M, and 0.01 𝜇M178 respectively according to the Genomics of 
Drug Sensitivity in Cancer Project database. The IC50 value does not tell much about the therapeutic 
window. The steepness of the dose-response curve measured through the Hill slope or slope factor 
(𝑚) does however. The larger this value the more steep the curve is and the greater the effect of a 
drug at concentrations either side of the IC50. For example, to maintain the drug activity between ± 
10 % of the IC50 when 𝑚 = 3 requires the drug concentration to not vary more than 15 % , however, if 
𝑚 = 1, then the drug concentration can vary up to 40 % for the same activity179. Hence, when 𝑚 = 1 
i.e. is smaller (and less steep), there is a greater therapeutic window. Clinically speaking this means 
there is a greater difference between the concentration required to elicit a therapeutic response and 
the concentration which would be overly toxic. Hence, the greater the therapeutic window, the safer 




Since 1995 two FDA-approved liposome-based products have been marketed, which deliver 
doxorubicin with a wider and therefore improved therapeutic window, these are called Doxil® and 
Myocet®. The drug formulations work on two factors; doxorubicin is sequestered from multi drug 
resistance pathways and the nanoparticle facilitates improved drug uptake. Hence, less doxorubicin is 
required to elicit the same toxic response. These were the first generation of nanoparticle-based drug 
delivery vehicles used and since the liposome and micellar drug delivery is commercially common. 
These two examples are described in more detail in sections 4.1.3.  
 
Having a nanoparticle can improve efficacy via passive and active targeting methods. Passive methods 
involve using known different biological differences between cancerous and healthy cells such as pH, 
ionic strength and temperature as a mechanism for drug release. Active methods involve adding, 
usually covalently, a specific molecule to the nanoparticle surface which has a known targeting effect 
such as promoting uptake or evading removal. Targeting agents include folic acid (FA), transferrin and 
hyaluronan have been used as targeting agents, conjugated to carbon dots by simple a EDC/NHS 
coupling mechanism180 (see section 4.3.1.3).  
4.1.3 Nanoparticles for drug delivery  
 
4.1.3.1 The ERP effect for nanoparticles 
 
The enhanced retention and permeability (ERP) effect is widely known to be the basis for favourable 
nanoparticle uptake in cancer cells (Figure 4.3). It was first observed by Matsumara and Maeda in 
1986 when a chemotherapy protein conjugated to a polymer was observed to accumulate mainly at 
the tumour site in mice.181 The team proposed that the macromolecule they generated worked better 
based on a size selecting basis within which nanoparticle delivery systems reside and allows non-
specific uptake of the nanoparticle and also associated cargo. Firstly, the nanoparticle, > 5 nm, is too 
large to undergo renal excretion. Secondly, tumours have increased vasculature as they require 
increased nutrition and oxygenation as the cells grow and divide faster than healthy cells. Associated 
with the additional blood vessels is abnormal transport pathways favouring larger particles being 
transported to the tumour. Once there, the nanoparticles are easily able to escape the blood vessels 
and cross into the cancer cells due to abnormal, leaky vessels. This results from incomplete epithelial 
lining with pores 0.1 – 3 𝜇m wide. In healthy cells the epithelial layer is not compromised so larger 
nanoparticles less easily enter healthy cells. Overall delivery of nanoparticles to cancer cells is twice 





Figure 4.3 Enhanced permeability and retention effect (ERP) illustration. Free doxorubicin can traverse the blood vessel 
endothelial cells due to “leaky” vessels and increased vasculature seen at the tumour site. Once there, doxorubicin 
accumulates as it cannot leave via the lymphatic capillaries causing a high local concentration. This is the basis for passive 
nanoparticle drug delivery to cancer cells.  
 
Within the tumour, ECM larger particles are retained for longer than smaller particles as their usual 
removal through the lymphatic drainage system is not possible as it is not developed in tumours. This 
retention of larger sized particles means that their residence time in the tumour extracellular 
environment is extended and their effective uptake and toxicity is enhanced.183 Many drug delivery 
systems rely on this as no targeting moiety is required. Liposomal delivery systems work through this 
method and have been used to deliver doxorubicin to tumour sites more effectively than to healthy 
cells.184 
 
The ERP effect means that nanoparticle uptake can be promoted by upregulating the pathways 
underlying it. Nanoparticles already accumulate within tumours, molecules and proteins which 
promote certain features of the ERP can be delivered.183 This includes attaching vasodilators such as 
nitric acid or botulinum neurotoxin which increase blood flow through the tumour.182 By delivering 
growth factors, tumour necrosis factors or inducing hyperthermia, blood vessel walls can be made 
more permeable for nanoparticle uptake. These agents can be co-delivered to improve the uptake of 
a nanoparticle in a drug delivery capacity. Interestingly vasculature can be damaged with external 
thermal prompting termed superenhanced permeability and retention (SUPR). Photo dynamic, photo 










ERP effect – Enhanced Permeability and Retention Effect 
0.1 - 3 µm 
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promote up to three times as much nanoparticle delivery. One example used NIR and an 
immunotherapeutic agent to achieve SUPR. The agent is a monoclonal antibody which has a NIR 
absorbing molecule attached which binds perinuclear cells. Upon NIR irradiation the cells die and 
cause the vessels to become more permeable. A nanoparticle can then be administered and have 
greater invasion. This SUPR technology is FDA approved182.  
 
4.1.3.2 Drug loading on Nanoparticles 
 
Generally speaking, the greater the drug loading capacity of a nanoparticle the more efficient its 
capacity for drug delivery and the overall toxicity due to the higher local drug concentration. 
Furthermore, in the case of doxorubicin, if the tumour is treated with high local dosage then resistance 
is less likely to develop before the tumour is destroyed.  
 
Drug loading is usually measured through equation 4.1a to obtain the % weight of the drug on the 
nanoparticle carrier.185 Experimentally, the loading capacity of a drug can be inferred through how 
much drug is left after loading has occurred. However, this value is dependent on the amount of drug 
used in the conjugation and is not therefore comparable between studies. There are a number of ways 
drugs can be loaded either onto or into a nanoparticle, or in fact if the drug is crystallised then there 
is no physical carrier at all so that the drug composes the nanoparticle. Types of nanoparticle scaffolds 
include metal organic frameworks (MOFs), porous particles made from a variety of materials such as 
silica or protein, liposome and micelles, polymer meshes and or block co-polymer type self-assembling 
nanoparticles, drug crystals or metal-bio frameworks or ionically associated nanoparticles186. Once the 












Equation 4.1 Two methods used for measuring the loading of drug onto a nanoparticle drug delivery system. A) Drug loading 
weight % of drug onto a nanoparticle equation. B) Drug loading efficiency DLE, the loading of a drug can be inferred by how 
the percentage of drug left after loading.  
The different methods of drug loading dictates the off-loading properties of the drug from the 
nanoparticle. Hence, the drug delivery system must be designed with the cargo and the target site in 
mind. In non-covalently loaded systems such as encapsulation, electrostatic, hydrogen bonding, 
hydrophobic interactions and metal coordination, natural changes in the environment can be utilised 
for specific drug release at the tumour site through pH, temperature or ionic induction.187 Covalently 
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loaded drugs can also use biological environmental changes to achieve off-loading at the target site. 
With the strength of the covalent bond sequestering the drug when the nanoparticle is not at the 
target site, this is an efficient means for achieving low non-specific delivery. Release has been shown 
to be achievable via nanoparticle degradation and the use of cleavable linkers such as low pH cleavable 
amide bonds, imines, hydrazones, and others187. 
 
External sources are another method to achieve triggered release and can be a good way of 
administering a drug as it can give both spatial and temporal control. There are a number of light, 
magnetic, electric field and ultrasound responsive nanoparticles which have shown potential for this 
type of treatment.188 Usually this involves a complete disassembly of the nanoparticle to induce drug 
release188 hence is good for covalently linked drug release.  
 
Other methods have been developed that are based on pH-dependent release mechanisms have been 
well studied for tumour site release as cancer cells induce low pH in their extracellular environment 
with respect to healthy cells. Hence, the drug can be delivered to the cancer cell and normal uptake 
proceeds. This pH-controlled release mechanism is relatively sensitive to the local pH, and hence a 
relative drug concentration can be delivered with high precision.168,189  
 
pH release can easily be achieved by using an acidic group on the nanoparticle, which becomes 
protonated in acidic conditions so that an electrostatic interaction is removed which releases a drug 
molecule. In the gastrointestinal tract the pH varies considerably with the stomach being acidic and 
the small intestine slightly basic. This can be used as the basis for delivery. In one study, pH was used 
to trigger the disassembly of a polymer-based polyelectrolyte nanoparticle complex for insulin 
delivery to the extracellular environment of epithelial cells at pH 7.4. The polymers 𝛾-polyglutamic 
acid (PGA) which contains carboxylic acids and the polymer chitosan which contains amines made up 
the nanoparticle complex. At pH 7.4, the amine groups become neutral upon reaching the target area 
and the polyelectrolyte complex disassembles as the inter polymer chain electrostatic interactions are 
removed, releasing the insulin.190 Similarly causing disassembly, at low pH (< 2) the carboxylate anions 
form carboxylic acid groups on 𝛾-PGA as they become protonated. Peptides are often used in a similar 
pH responsive capacity as they possess pKas within a biologically relevant range allowing for pH based 
nanoparticle drug release to be tuned.189  
 
Alternatively, the carboxyl group can be used as a means to swell or shrink polymersomes, micelles 
and hydrogel nanoparticles in response to pH to cause drug release. In one system, a polymersome191 
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was made from a polymer containing carboxylic acids. At biologically high pH (>7), the carboxylic acid 
is deprotonated and this causes the hydrogel to swell. This increases the intraporosity and the drug 
sequestered is able to diffuse out. The remaining hydrophobic interactions prevented complete 
disassembly of the polymers192. Ionic strength is another cellular environmental change which can 
induce nanoparticle swelling. In cancer cell membrane depolarisation can occur which, depending on 
the type of cancer, can cause various ion (K+, Cl-, Ca2+ and Na+) efflux and influx changes. A nanoparticle 
was made from L-glutamic acid (COO-) and L -lysine (NH3+). Release in one system was investigated as 
a function of NaCl concentration, which was varied between 0.1 and 1 M whilst pH was maintained at 
7.4. A positive swelling effect was observed with ionic strength. When the ionic strength was low, the 
NH3+ and COO- groups were able to interact more without interference from Na+ and Cl- ions from the 
solution.193  
 
A  common doxorubicin loading strategy used to investigate novel nanoplatforms and novel 
theranostic platforms is the formation of a Schiff base imine between the doxorubicin amine and an 
aldehyde or ketone of a polymer which can self-assemble into a micelle or polymersome 
nanoparticle180,194. Aromatic imines have been shown to have good stability in water at neutral pH, 
due to extended 𝜋 − 𝜋.195 
 
Loading of doxorubicin can be achieved through hydrophobic interactions and 𝜋 − 𝜋 stacking 
between the drug and mesoporous polydopamine196 or graphene oxide nanoparticles197. The 
underlying release of doxorubicin in these systems also relies on low pH. Under acidic conditions the 
doxorubicin amine is protonated and doxorubicin dissociates from the nanoparticle. In one study Xing 
et al. were also able to attach a p-glycoprotein inhibitory molecule D-α-tocopheryl polyethylene glycol 
1000 succinate (TPGS) for improved in vitro doxorubicin delivery to the nucleus and then induce 
doxorubicin unloading via two techniques. Near-infra red irradiation (808 nm laser at 2 W cm−2) 
induced localised heating and the addition of glutathione disrupted stacking interactions promoting 
dissociation. Endosomal escape of the nanoparticle was inferred through visualisation of doxorubicin 
in the cytosol.196 
 
Iron oxide nanoparticles have superparamagnetic properties allowing an external magnet to be used 
to induce drug release. Superparamagnetism also facilitates specific and controlled delivery of the NP-
drug system and is also a contrast agent for magnetic resonance imaging (MRI). More recently it has 
been used as a means for localised heating induced apoptosis and tumour treatment. Using an 
external alternating magnetic field (AMF), the nanoparticle magnetic moment can be made to flip fast 
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enough to generate significant Brownian motion of the particle which causes local temperature 
increase.198 This system can be used in combination with covalently linked drugs as the nanoparticle 
heating can lead to covalent bonds breaking.  
 
Schiff base bond between doxorubicin-like molecule and fluorescein amine or carbonyl on a diblock 
copolymer was used as a pH sensitive drug delivery mechanism. The nanoparticle combined diblock 
copolymer and iron oxide and was used to achieve tumour targeted release where the pH reached 
5.5. The imine between the amine of the dye and the carbonyl of the polymer was seen not to 
hydrolyse at pH 7.4. Upon AMF treatment at pH 5.5 the release was described as having a burst effect 
greater than pH 5.5 alone, induced by the heat generated from the nanoparticle.199  
 
Click chemistry has been used as a facile way to attach drugs or dyes to nanoparticles as a means for 
covalent conjugation free from complex reaction conditions such as heat, organic solvent and or 
catalysts.200 This makes click chemistry more amenable for reactions involving biologically relevant 
materials such as proteins. The main copper-free click reaction is based on the strain-promoted alkyne 
cycloaddition with a given azide. Commonly, commercial biological molecules can be purchased with 
azide groups installed for easy conjugation. In vitro click chemistry can also be used as an investigative 
tool using bioengineering of molecules of interest to have an alkyne group.201 Nanoparticles containing 
an azide can be clicked and used for covalent labelling200.  
 
Gold nanoparticles lend themselves to thiol based covalent binding as AuNPs become stabilised upon 
thiol coating as the sulphur-gold bond is stronger than gold-gold.  The thiol group becomes a good 
functional handle making AuNPs easy to work with. The thiol handle offers the potential for exchange 
with thiol containing molecules so that the molecule is presented on the surface of the AuNP. 
Interestingly, there is precedent showing that rare earth elemental ions are able to break the gold-
sulphur bond and displace it, hence leading to drug release application and possible dual therapy 
applications with their photon up-converting properties.202 
 
Ultrasound can be used as a means for theranostic nanoparticle drug delivery and imaging method. In 
one study doxorubicin was loaded onto the surface of an alginate nanodroplet containing non-polar 
perfluorohexane (PFH). Upon ultrasound irradiation which are high-frequency sound waves, the 
droplet vaporises in vivo to a gas forming microbubbles and facilitating doxorubicin release. This 





Light can be used as an external trigger for nanoparticle drug release. Depending on the wavelength 
used different penetration depths are possible with the best being near-infra red penetration 
centimetres deep (Chapter 5). The nanoparticle itself can be photo responsive, for example gold and 
rare earth metal containing nanoparticles produce heat which can induce release of their cargo, or a 
photosensitiser molecule or linker such as 2-nitrobenzyl ester195 can be incorporated on the 
nanoparticle to initiate nanoparticle instability and drug release.204  
 
The toxicity of the nanoparticle post-delivery must be considered for the system to be feasible. Often 
the drug is occluding the nanoparticle from the biological environment and from inducing toxic effects. 
If the particle is highly toxic such as with quantum dots, then its toxicity must be evaluated against the 
treatment payoff. The half-life is one measure of the circulation time of a nanoparticle in the body to 
assess the toxicity of a nanoparticle187.  
 
Overall, drug loading can be achieved through a number of non-covalent and covalent means. Non-
covalent methods allow for easy synthesis, commonly passive delivery and drug release via pH, ionic 
or redox features of cancer cells. Covalent methods can confer greater targeting, evade multi drug 
resistance and less non-specific delivery induced by light, ultrasound, magnetic fields, electrical fields, 
but require an external source to induce drug off-loading. Having a covalent targeting molecule and 
electrostatically bound drug is one way to achieve a high level of targeting and high off-loading.  
 
4.1.3.3 Liposomal NPs for Doxorubicin delivery  
 
Doxil® (1995) and Myocet® (2000) are the two main FDA approved doxorubicin drug delivery 
treatments used clinically today. They have better cardiotoxic outcomes due to their improved 
therapeutic index and have an improved or the same efficacy as doxorubicin alone. Doxil is a 
PEGylated liposome which delivers doxorubicin to the tumour site based on the ERP effect. The PEG 
coating contributes improved circulation time, prevents aggregation and reduced immune 
response.205 Doxil has a high residency time in the body, still observed up to 3 days post treatment.206 
The liposome component can biologically assimilate and offers a simple and adaptable scaffold upon 
which desired properties can be added. Liposomes are also able to carry a large drug payload as they 
can simply sequester the same volume of drug that they have volume inside them.  
 
One drawback of this system is that the PEG coating causes the nanoparticle to accumulate in the skin, 
mainly the hands and feet and hand-foot syndrome can result. This results in release of high 
concentrations of  doxorubicin at these sites causing sore skin and breakage.207 Furthermore, the long 
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residency time in the body means that doxorubicin is being continuously released from the 
nanoparticle for longer times than when doxorubicin is used alone, thus killing healthy cells 
dramatically as a result. Hence, combining slow release with improved targeting would avoid the side 
effects. 
  
Myocet® is a liposomal doxorubicin delivery nanoparticle which does not have PEGylation hence hand 
and foot syndrome is not seen in this treatment. This system has a residency time of around 1 hr, a 
lot less than with Doxil®.206 This however also means that this treatment needs to be administered 
more often than Doxil® in order for the same cytotoxic levels to be reached.208 The liposomal seclusion 
of doxorubicin in the blood system again means that multidrug resistance is not seen as much over 
the course of doxorubicin delivery and improved efficacy is observed compared to doxorubicin alone. 
 
                              
Figure 4.4 Two commercially available nanoparticle liposome doxorubicin delivery systems. Orange chains are PEG linkers 
which imposes improved circulation time. 205 
 
4.1.3.4 Carbon dots for doxorubicin delivery  
 
Carbon dots have been trialled in a number of studies for doxorubicin delivery168,180,185,209,210. Both 
covalently linked and electrostatically adsorbed doxorubicin have been shown to have improved 
bioavailability and toxicity over doxorubicin alone owing to improved cancer cell uptake and good off-
loading once at the tumour. Doxorubicin being red fluorescent (𝜆&'	480, 𝜆&9	590 nm)211 offers a good 
model drug to observe in vitro cellular uptake allowing for ease of identification and quantification 
through flow cytometry.  
 
Electrostatic adsorption of doxorubicin onto carbon dots is an efficient means for delivery in 
vitro,185,212,213 owing to the easy of loading doxorubicin simply by mixing with CDs at the desired 
Myocet (Teva, UK) 2000 Doxil (Janssen) 1995 
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concentration. Direct characterisation of electrostatic loading is not observed; however, zeta potential 
and in vitro effects can be used to infer information.  
 
Carbon dots synthesised by Kong et al.185 via hydrothermal methods from citric acid and ethylene 
diamine were shown to have good electrostatic doxorubicin loading and improved toxicity in MCF-7 
cancer cell line than free drug. DL was 2.88 % and DLE was 57.7 %. Zeta potential data showed the CD 
was -5.12 mV, doxorubicin alone was 5 mV and the CD-dox was 1.07 mV. This suggests loading onto 
the carbon dot occluding the negative surface charge of the particle from the solvent. They 
demonstrated their lowest tested pH 5.0 achieved the best unloading of doxorubicin of 82.0 % after 
72 hrs. Confocal microscopy showed colocalization between the carbon dots (𝜆&'360 nm, 𝜆&9	450 
nm) and doxorubicin in MCF-7 cells, providing evidence for carbon dot mediated intracellular delivery. 
This was carried out after 4 hrs supporting the theory that doxorubicin is sequestered on the carbon 
dot surface post internalisation and can evade MDR removal.  
 
Another study using electrostatically loaded doxorubicin on carbon dots was carried out by Yuan et 
al.213 Carbon dots were synthesised from supermarket bought milk in a hydrothermal synthesis to 
generate 450 nm (𝜆&' 360 nm) fluorescent carbon dots which were determined through FTIR to have 
carboxyl groups (1100 cm-1) on the surface. The carboxyl groups were thought to be the basis of 
electrostatic interactions with doxorubicin for loading achieving DL of 4.35 % and DLE of 87 %. They 
also propose the hydrophilicity of their carbon dots allows for additional hydrogen bonding with 
doxorubicin. Similarly to Kong et al.185, they observed pH dependent release of doxorubicin from the 
CD at pH 5.0 in a dialysis experiment. Cytotoxicity experiments in ACC-2 (cancerous) at 24, 48 and 72 
h, all showed greater toxicity with the CD-dox system than free dox. In L929 (healthy) cell line lower 
toxicity was seen with the CD-dox than free doxorubicin at the same concentration (1.5 𝜇M). 
Interestingly, at 72 h in L929, free dox had significantly greater toxicity compared to CD-dox than at 
either 48 or 24 h. This suggests that the sequestering of doxorubicin on the CD persists up to 72 h.  
 
The ketone appended onto the tetracyclic aglycone component of doxorubicin has the potential to be 
involved in imine bond formation with an amine on the surface of carbon dots.214 Zhang et al. 
synthesised hollow carbon dots from L-ascorbic acid and urea (1:7 molar ratio) in a hydrothermal 
synthesis and were able to load doxorubicin through imine formation and observed pH sensitive 
intracellular release168. They show evidence of this covalent linkage via FTIR peak presence at ~ 1651 
cm-1 characteristic of imine bond presence. They also suggest that covalent bonding could also occur 
between the doxorubicin amine and carboxylic acid groups on the CD surface, coupling agents 
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potentially used include EDC and CDI among others. Furthermore, electrostatic interaction between 
the amine and carboxylic acid at physiological pH 7.4 could in part be responsible for doxorubicin 
loading. In addition to these interactions on the CD surface, they propose doxorubicin encapsulation 
by the hollow CDs. Overall the DL achieved was 42.9 %. They observed improved drug delivery 
potential compared to free doxorubicin through pH dependent drug off-loading in dialysis with best 
dox release 74.7 % achieved at pH 5.0. Reduced cytotoxicity at 48 h was seen at concentrations of 5, 
10, 20 and 40 𝜇gml-1, where CD-dox had ~ -
>
 toxicity as that of free dox. CD-dox having lower toxicity 
then free dox and vice versa have both been used as an indication of efficient drug delivery. They 
suggest the cause of a reduction in toxicity is greater sustained release properties of CD-dox making 
it less toxic initially.  
 
Hydrophobic interactions including 𝜋 − 𝜋 stacking between doxorubicin and carbon dots was 
attributed as the main adsorption method in a study by Sun et al.212 They highlight evidence of 
doxorubicin 𝜋 − 𝜋 stacking was shown with carbon nanotubes215 early as 2009 which was evidenced 
by in vitro improved efficacy. They also reference Strauss et al216. who show favourable  𝜋 − 𝜋 stacking 
and also ionic interaction between carbon dots and perylenediimides (PDI) through computational 
modelling. Carbon dots were synthesised hydrothermally from D-glucose and L-glutamic acid in a 1:1 
molar ratio and DLE was determined to be 260 %. Prolonged dox release was observed compared to 
free dox through dialysis which they attribute to a low pH of 5.0, protonating the doxorubicin amine 
and improving drug hydrophilicity and release. Interestingly, similar to Zhang et al.168 cytotoxicity data 
shows a reduced toxicity effect compared to free dox at 48 h between 0.005 - 0.5 𝜇gml-1. At greater 
concentration of 5 𝜇gml-1 they then observe that CD-dox and free dox have similar cytotoxicity, which 
suggests that at a high enough dose there is enough free dox released from CD-dox to make the 
delivery system non-effective. Furthermore, they then showed they were able to further modulate 
and reduce dox release and cytotoxicity from CD-dox by adding a polydopamine (PDA) coating simply 
by mixing CD-dox with PDA for 3 h in TRIS buffer (10 mM pH 8.5).  
 
Covalently conjugated doxorubicin to carbon dots is seen in the study by Li et al.217 EDC/NHS 
conjugation between the doxorubicin amine and the carboxylic acid on the carbon dot surface or the 
already conjugated transferrin protein carboxylic acid groups. The toxic effect of this system was 
assessed in paediatric brain tumour cells. After conjugation size exclusion was used to purify the 
conjugate so that no free doxorubicin or transferrin was present. They observed a 14-45 % reduced 
cell viability compared to doxorubicin alone at a concentration of 10 nM. Interestingly, they have no 
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evidence for the doxorubicin dissociation from the nanoparticle and therefore the effect observed is 
that of the CD-doxorubicin and transferrin conjugate as a whole. 
 
 
Figure 4.5 Possible doxorubicin - carbon dot interactions. Carbon dot shown is a general structure with functional groups for 
illustration purpose. Electrostatic interaction between doxorubicin amine and carboxylic acid at physiological pH. Imine 
formation between an amine and a ketone of the doxorubicin. Hydrogen bonding between hydrogens and oxygens from 
either of the doxorubicin or the CD surface. CH-𝜋 bonding between cyclic carbohydrate and doxorubicin. And 𝜋 − 𝜋	between 
aromatic groups on the CD and doxorubicin.  
When looking to improve targeting of CD-doxorubicin delivery systems, biofunctionalisation is a good 
starting point218. In each example outlined below, folic acid (FA), transferrin or hyaluronan (HA) has 
been conjugated alongside doxorubicin onto carbon dots as a means for improved doxorubicin 
delivery in vitro.180 FA targets FA receptors which are over expressed in some cancers namely; 
colorectal, breast, cervical, ovarian, epithelial, lung, kidney and brain. FA is a heme containing protein 
hence can bind iron and oxygen which is required in cancer cells for oxygenation where metabolism 
is high. Furthermore, due to its iron binding properties FA has MRI agent applications.180,219 Iron shows 
good contrast in MRI due to its ferromagnetic property. In one literature procedure, green fluorescent 
carbon dots were synthesised from sorbitol and sodium hydroxide in a microwave reaction. Bovine 
serum albumin (BSA) was coated onto the surface of the carbon dot before folic acid was conjugated 
using DCC/NHS to BSA and the doxorubicin to BSA also using TEA. 85.6 % dox loading was achieved 
and improved toxicity in HeLa cells and reduced non-specific toxicity were observed. Hence this 




Transferrin is able to cross the blood brain barrier (BBB) and be bound by transferrin receptors which 
are overexpressed on brain tumour cells, hence is useful to promote nanoparticle crossing and 
treating hard to reach brain cancers and is known to have MDR evasion properties217. Carbon dots 
were synthesised from carbon powder with nitric acid and sulfuric acid (top-down method) to afford 
green fluorescent particles (𝜆&' 540 nm, 𝜆&9	580 nm). Transferrin and then doxorubicin were 
covalently conjugated onto carboxylic acid coated carbon dots using EDC/NHS. Uptake and 
cytotoxicity of a paediatric brain tumour cell line was greater for CD-transferrin conjugated dox than 
free dox.  After 18 hrs, the uptake was 5-fold greater for the delivery system and the cytotoxicity 14-
45 % at 10 nM. Interestingly, they considered an increase in cytotoxicity as evidence for improved 
delivery, likely owing to the greater doxorubicin uptake.  
 
HA is a glycosaminoglycan present in the ECM which binds CD44 protein presented on cancer cell 
membrane, hence can actively targeting carbon dots or graphene carbon dots to lung carcinoma A549 
cells220,221. In vitro studies of cancer cells with CD44 overexpressed on their surface have been used to 
test the applicability of CD bifunctionalised with doxorubicin and HA for targeted delivery. The HA was 
covalently conjugated onto the CD before doxorubicin was linked via the pH cleavable linker 4-
carboxybenzaladehyde (p-CBA). It was observed in vitro in 4T1 cells that free dox uptake peaks at 1 h 
and the CD-HA-dox uptake increased over 4 hr which was mainly localised in the lysosome. This 
suggests that the HA-CD44 mediated uptake caused lysosomal accumulation. Here the low pH induced 
dox release via the pH cleavable linker and accumulation in the nucleus occurred. The slow uptake 
and slow release from the lysosome to the nucleus correlated with a reduced cytotoxicity for CD-HA-
dox then free dox at 24 h. Furthermore, in vivo studies supported in vitro results described and also 
showed that for CD-HA-dox, strong accumulation was seen in the tumour site and liver (where there 
are HA receptors on endothelial cells) compared to non-specific targets e.g. lung and kidney. This 
supports HA based uptake and tumour specific delivery221.  
 
Nuclear targeting can be achieved with nuclear localised signal peptide (NLP) which was applied to a 
carbon dot-based doxorubicin delivery by Yang et al.210 Similarly to hyaluronan conjugated CDs the 
doxorubicin was attached via a pH hydrolysable bond. In vitro and in vivo studies observed improved 
targeting and efficacy for the CD drug delivery system over free dox. Interestingly they saw that the 
NLP facilitated the whole CD-NLP-dox system was taken up by the nucleus which is not seen with other 
delivery systems which target the cell membrane. Hence, the NLP is able to facilitate direct delivery 
of dox to the nucleus. This improves the efficacy and therapeutic window as the p-glycoprotein is less 




Overall, a number of carbon dot-based doxorubicin delivery systems have emerged in the last five 
years offering improved doxorubicin delivery, measured through good loading efficiency, better in 
vitro uptake than free doxorubicin and pH dependent release all on non-toxic platforms. Interestingly, 
cytotoxicity is not a conclusive measure of delivery by itself. Studies conclude both an increase and 
decrease in cytotoxicity compare to free dox as an improvement in drug delivery. Hence, cytotoxicity 
must be considered in the context of uptake and the time point after doping. Areas which need more 
definition include understanding of the basis of CD-doxorubicin binding, doxorubicin release 
mechanism in vitro and measuring this over time. Furthermore, comparing cancer cell lines could 
allow specific targeting and hard to treat cancers to be investigated. 
4.2 Aims  
 
In this work we aim to develop a non-toxic platform for the selective delivery of anti-cancer drugs to 
cancerous cells. Doxorubicin is a well-known anti-cancer drug used in a myriad of cancer treatments; 
hence we use this model drug as part of an initial foray into testing our carbon dots for drug delivery. 
We aim to develop a platform which can be bi-functionalised, combining glycan functionalisation and 
drug loading for the aim of targeted drug delivery to avoid non-specific drug delivery to healthy cells 
and minimise side-effects. The glycan and drug bi-functionalisation would represent a proof of 
concept and hope to showcase that a carbohydrate with known targeting ability could be used for 
targeted anti-cancer delivery. We focus on using lactose to target our system to HeLa, MCF-7 and MDA 
cancer cells. Lactose has been shown in previous work in the Galan group to allow for selective cell 
uptake of QD.44 Cytotoxicity assays and confocal microscopy will be used as a means to measure the 
delivery system efficacy compared to control.  
 
4.3 Results and discussion 
 
This chapter outlines the development of an anti-cancer drug delivery system using carbon dots as the 
nanoparticle carrier and doxorubicin as the drug. Carbon dots used are the particles described in 
chapter 1 as the long linker blue fluorescent carbon dots (AmCD 16). The work in this chapter was 
conducted in collaboration with another Galan group member, Sylvain Penasse. Data for sections 
4.3.2.5 – dialysis to determine release rate and 4.3.2.6 – FTIR to show imine formation, was generated 
by Sylvain Penasse. This is indicated again at the beginning of both sections. 
 
Four carbon dots with the surface functionality of amine (AmCD 16), carboxylic acid (AcCD 17), lactose 
(CD-lactose 25) and a fourth CD with both lactose and TTDDA (defined as CD-lac-TTDDA 28) were 
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tested for their dox loading capacity. Nuclear delivery potential of these systems can be assessed 
through confocal microscopy since doxorubicin is red fluorescent. The drug nanoparticle complexes 
were characterised via NMR, DOSY, DLS and zeta. Three cancerous cell lines MDA-MB-231, MCF-7 and 




Four differently functionalised nanoparticles were loaded with doxorubicin; AmCD 16 (Chapter 
2.2.1.1), AcCD 17, CD-Lactose (25) and CD-lac-TTDDA 28, first introduced in this chapter, termed 28. 
CD-lactose was synthesised via EDC coupling of AcCD 17 and 1-amino lactose 2. The aim of this was to 
achieve a carbon dot with both carbohydrate targeting moiety and amine group presented on the 
surface. Similarly, CD-lac-TTDDA 28 was synthesised from CD-lactose 25 via EDC coupling with TTDDA 
(equimolar ratio to the lactose used in the previous step).  
 
Doxorubicin loaded nanoparticles AmCD-dox (N1-8), AcCD-dox (C1-8), CD-lactose-dox (L1-8) and CD-
lac-TTDDA-dox (LT1-8) were prepared by combining the carbon dot and a 0.1 mg ml-1 solution of 
doxorubicin in H2O and freeze drying overnight (hence consistent dox amount was achieved). The ratio 
of CD:Dox and the nomenclature used are summarised in Table 4.1. Loading of doxorubicin was carried 
out on a 1 mg scale. Post lyophilisation the material afforded was a red powder which was stored at 
4 oC and redissolved in H2O to 0.1 mg ml-1 immediately before use.  
  










0 16 17 25 28 
1:1 N1 C1 L1 LT1 
1.25:1 N2 C2 L2 LT2 
2:1 N3 C3 L3 LT3 
3.33:1 N4 C4 L4 LT4 
10:1 N5 C5 L5 LT5 
20:1 N6 C6 L6 LT6 
100:1 N7 C7 L7 LT7 
1000:1 N8 C8 L8 LT8 
Table 4.1 Nomenclature used when describing the ratio of AmCD (N), AcCD (C), CD-lactose (L) and CD-lac-TTDDA (LT) to 














Corrected diffusion coefficient 




N5 Dox:  0.94      CD:  1.88 
C5 Dox:  2.49 CD:  4.18 
Table 4.2 Diffusion coefficients of doxorubicin, carbon dot, N5 and C5 determined through DOSY which have been corrected 
to allow comparison against the water diffusion coefficient. Repeat measurements were not conducted hence error was not 
calculated for this data. 
N5 and C5 CDs were assessed for doxorubicin loading using diffusion ordered spectroscopy (DOSY) 
(Table 4.2). Using this technique, the diffusion coefficient of a molecule or particle can be measured 
in solution. If a sample contains two non-interacting particles or molecules, then their diffusion 
coefficient will be at least an order of magnitude different. Water can be used as a reference by which 
diffusion coefficients can be adjusted in order to make two spectra comparable (if the water diffusion 
coefficients are different between spectra). In this work the doxorubicin diffusion coefficient was 
measured to be 1.66 x10-6 cm2 s-1. The diffusion coefficient of doxorubicin in the form N5 and C5 was 
determined as 0.94 x10-6 cm2 s-1 and 2.49 x10-6 cm2 s-1. These are both not an order of magnitude 
slower as you may expect if associated with a larger particle such as a carbon dot. However, the 
diffusion coefficient of AmCD 16 and AcCD 17 are 3.83 x10-6 cm2 s-1 and 2.86 x10-6 cm2 s-1 respectively. 
These are within the same order of magnitude as free doxorubicin hence, results cannot be conclusive. 
However, for both the doxorubicin and carbon dots the diffusion coefficient changes when combined 
therefore some interaction is suggested.   
 
4.3.2 Drug loading studies 
 
Using UV-Vis or fluorescence to determine doxorubicin loading was not possible with our system as 
the spectral overlap between the carbon dots and doxorubicin was too great. Although the peak 
absorption and fluorescence for each are separated by 160 nm, the baseline absorption and 
fluorescence of carbon dots is relatively high due to self-absorption properties. Increasing the CD-dox 
concentration does not improve this due to self-quenching effects causing absorption and 
fluorescence values which are non-linear as a function of concentration. As a result, other techniques 
were used to assess the loading of doxorubicin onto the carbon dot.  
 
FTIR provided definitive evidence of interaction between doxorubicin and AmCD 16 in the form of 
imine formation, suggesting that a covalent imine conjugation underlies doxorubicin loading. 
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Doxorubicin ketone signal at 1717 cm-1 disappearance and imine peak formation at 1690-1640 cm-1 
(which are not seen in free dox or the CD spectra) provides evidence for this. This is not to say other 
hydrophobic; electrostatic and hydrogen bonding does not take place between these two 
substituents. It has been shown previously that doxorubicin can interact in these ways with carboxylic 
acids185 (hydrogen and electrostatic) and cyclic212 CH-𝜋 groups and sp2 conjugated systems 
(hydrophobic) which we have shown in chapter 2 are present on the AmCD 16 and AcCD 17 surface.  
Confocal results showed a positive concentration cytosol localisation for carbon dots AmCD 16, AcCD 
17 and CD-lac-TTDDA 28 without dox, implying an interaction between the CD and doxorubicin. DOSY 
was used to determine the diffusion coefficient of doxorubicin when carbon dots were similar, hence 
suggesting interaction. Dialysis studies were carried out to observe the diffusion of doxorubicin over 
time from the surface of carbon dots which was slower than that seen for doxorubicin alone at 
physiological pH (7.4) and at low pH (5.0). All of this data was used to infer interaction between the 
doxorubicin and the CD. The release was investigated through dialysis and confocal microscopy and 
cytosolic versus nuclear doxorubicin localisation was observed over 2 hrs.  
 
4.3.2.1 Confocal to determine optimal loading  
 
Initial confocal microscopy experiments were trialled to evaluate if the combination of carbon dots 
with doxorubicin had an effect on the intracellular uptake. N1-8, C1-8, L1-8 and LT1-8 (10 𝜇g ml-1) 
were incubated with 1x105 HeLa cells (100 𝜇L) for 1 h to allow for uptake. Live confocal images were 
taken after 1 h to observe whether uptake of doxorubicin had been achieved. In all cases, negative 
control images with no dox or CD present, saw no red fluorescence (emission window measured 570 
– 600 nm) upon excitation at 450-480 nm. Positive control with doxorubicin showed red fluorescence 
localised in the nucleus only. This agrees with literature evidence that doxorubicin readily internalises 
HeLa cells and localises at the nucleus.222 Bright field images where the nucleus and cell membrane 








Figure 4.6 Confocal image and brightfield images of HeLa cells overlaid. Fluorescence measured between 570-600 nm A) 




With CD-dox systems not only was uptake of doxorubicin facilitated by the CD seen, but also 
doxorubicin localisation in the cytosol (figure 4.7). This cytosol localisation is not seen for free 
doxorubicin. This is important for slow release of doxorubicin to the nucleus allowing for evasion 
removal by the p-glycoprotein. When cytosolic fluorescence is seen, it was thus established that an 
interaction between the CD and doxorubicin can be inferred, i.e. if the drug were free then nuclear 
delivery would be seen. Furthermore, this shows that the carbon dots are unable to cross the nuclear 
membrane. Doxorubicin loading onto the CDs at ratios between 1:1 and 1000:1 showed different 
localisations at 1 h upon incubation with HeLa cells (figure 4.7). This was used to infer the 
concentration for optimal drug loading on the carbon dots, but with no excess free drug. This is 
important for optimising the drug delivery system for good efficacy. Section 4.3.2.1.1. explains these 
experiments further.  
 
4.3.2.1.1 Acid & Amine CD-Dox  
 
 
The CD-dox materials N1-8 and C1-8 were tested in HeLa cells for uptake and their intracellular 
localisation observed. In figure 4.7, the intracellular localisation of doxorubicin can be observed as the 
red fluorescent areas in the images. Nuclear fluorescence shows free doxorubicin whilst cytosol 
fluorescence shows carbon dot bound doxorubicin. For both N1-8 and C1-8, there is a gradual shift in 
florescence from nuclear to cytosol localisation (from 1 to 8) correlating with the amount of carbon 
dot present. When there is more carbon dot present more doxorubicin is sequestered on the carbon 
dot surface. At N5 and C5 doxorubicin is seen predominantly in the cytosol. At N6-8 and C6-8, there is 
excess carbon dot and hence loading is less efficient. From this experiment it was determined that for 
both AmCD 16 and AcCD 17, the optimal loading of dox was seen in N5 and C5 respectively which have 
a 10:1 (CD:dox) ratio. Interestingly, the same loading was seen for both AmCD 16 and AcCD 17 despite 
differences in surface functional groups. The loading could involve electrostatic and hydrogen bonding 
as both carboxylic acid and amine functional groups have the potential to be charged and 
electrostatically interact168 with doxorubicin and also hydrogen bond213 via oxygen and hydrogen 






Figure 4.7 Confocal images of live HeLa cells incubated with N1-8 and C1-8 (10 𝜇gml-1) for 1 hr before imaging. Red florescence 
is doxorubicin. From 1 to 8, a gradual shift in fluorescence localisation from nucleus to cytosol can be seen. This correlates to 
the increase in carbon dot present from 1 to 8. Positive control shows free doxorubicin and negative control shows HeLa cells 






Quantification of the shift of localisation from the cytosol to the nucleus was quantified over time 
from a second experiment where the fluorescence per cell was measured at 15 minutes, 30 minutes, 
1 h and 2 h. The doxorubicin fluorescence seen in the confocal images (Figure 4.7) is a good reporter 
of the in vitro off loading and delivery of doxorubicin. The ratio of nuclear:cytosolic (N/C) fluorescence 
was calculated in Fiji software. The cytosol and nuclear regions were identified through bright field 
images and the fluorescence intensity per area quantified in terms of grey values. When the 
fluorescence intensity in the nucleus per area is equal to that in the cytosol the ratio is 1. This is 
denoted as the dotted line in figure 4.8. Free doxorubicin has a Nuc/Cyt value greater than 1 owing to 
the fact that it can freely localise in the nucleus even at 15 minutes. C5 (red bars) show that over time, 
doxorubicin moves from the cytosol to the nucleus. At 15 minutes there is equal distribution of 
doxorubicin through the cell. Over time, up to 2 hr this continues to increase up to Nuc/Cyt value of 
3. This same trend is seen for N5 (green bars); however, the initial starting point is a ratio of 0.2 
showing clear cytosolic localisation. The translocation to the nucleus is also much slower suggesting 
slower release from the carbon dot surface. This is a much greater difference between N5 and C5 than 
the confocal images in figure 4.7 would suggest. Hence, quantification and observation over time is a 
good way to understand intracellular delivery. 
  
Figure 4.8 Quantification of doxorubicin intracellular localisation. Cytosolic and nuclear fluorescence per unit area was 
quantified in each cell incubated with either free dox (blue bars) C5 (red bars) or N5 (green bars).The nuclear: cytosolic ratio 
(N/C)  was calculated for N=50 cells at time points 15 minutes, 30 minutes, 1 hr and 2 hr. Dotted line indicates where ratio 



























































































4.3.2.1.2 Doxorubicin loading on lactose-coated CDs 
  
Looking to exploit the role of sugars as targeting moieties, we loaded doxorubicin onto carbon dot CD-
lactose 25 using the same freeze-drying method as for N1-8 and C1-8 (section 4.3.10). Lactose 
functionalisation has been shown to induce cell selective uptake and intracellular localisation of 
quantum dots and facilitate uptake of bifunctionalised QDs which were not taken up without the 
lactose.44 Therefore, L1-8 were incubated with HeLa cells under the same conditions as with N1-8 and 
C1-8 for 1 hr. Live confocal microscopy imaging showed that doxorubicin was localised to the nucleus 
in all cases of L1-8 (Figure 4.9). This result shows a lack of interaction between the CD-lactose 25 and 
doxorubicin, hence the drug was free and able to enter the nucleus. This also suggests that 
hydrophobic CH-𝜋 interactions and hydrogen bonding between the doxorubicin and the lactose on 
the CD-lactose 25 surface does not allow for doxorubicin loading. This suggests that the doxorubicin 
loading observed in both AmCD 16 and AcCD 17 is electrostatic and any hydrophobic interaction 

















4.2.2.1.3 Doxorubicin loading on CD-lac-TTDDA 
 
Conjugating TTDDA onto the surface of CD-lactose 25 should allow for doxorubicin loading yet have 
lactose present as a targeting moiety. LT1-8 were incubated with HeLa cells under the same conditions 
at N1-8, C1-8 and L1-8 for 1 hr. For all of LT1-8 cytosolic doxorubicin localisation was observed as seen 
in figure 4.10. LT1-4 were not able to load doxorubicin as well as in N1-4, C1-4 and L1-4. This suggests 
that doxorubicin loading onto CD-lactose is less efficient than with AmCD 16 and AcCD 17. We propose 
 
Figure 4.9 Confocal images of HeLa cells incubated with L1-8 (10 𝜇gml-1) for 1 hr before imaging. Red florescence is 
doxorubicin. In all experiments in this figure, doxorubicin fluorescence is localised in the nucleus. This was confirmed through 
bright field images (not presented here). 
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that the conjugation of TTDDA provides a higher density of free amines on the surface than is seen in 
AmCD 16, hence this is the basis for introducing doxorubicin loading to CD-lactose 25. NMR provides 
evidence of the presence of TTDDA on the surface of CD-lac-TTDDA 28 (Figure A.28). Furthermore, 
figure 4.10 shows that at LT7 and LT8, there is no doxorubicin fluorescence. This implies that uptake 
is not possible when carbon dots are in a high excess and doxorubicin is not highly concentrated on 
the nanoparticle surface. To allow for comparison between the CD-doxorubicin drug delivery systems, 
LT5 was used henceforth in dialysis and cytotoxicity experiments.  
 
 
Figure 4.10 Confocal images of live HeLa cells incubated with LT1-8 (10 𝜇gml-1) for 1 hr before imaging. Red fluorescence is 
doxorubicin. In all these experiments doxorubicin is localised to the cytosol and in LT7 and LT8 no fluorescence con be seen 
indicating poor or no uptake. Note, these images were taken with a higher gain than images in figure 4 and 5, hence are not 
comparable in that respect.  
 
4.3.2.2 Dialysis to determine release rate  
 
The data in figure 4.11 was collected and collated by Sylvain Penasse. Dialysis (3,500 MWCO cellulose 
membrane) in PBS at pH 5.0, 6.8 and 7.4 was carried out to investigate the pH dependence of the 
doxorubicin release from N5 up to 157.5 hrs. Release was measured from doxorubicin concentration 
in dialysis solution outside the membrane, i.e. free doxorubicin, via doxorubicin fluorescence. 
Greatest doxorubicin release was observed at pH 5.0 from time point 47.7 h; 20 % to 45 %; 157.7 h. 
This fits with the formation of an imine bond between the carbon dot and doxorubicin. Between pH 
6.8 and 7.4 there is not much difference in release, never reaching 20 %. The imine bond is acid-labile 
and should be stable at physiological pH195, hence low pH induced doxorubicin release. Dialysis to 





Figure 4.11 Dialysis based doxorubicin release data at pH 5.0, 6.8 and 7.4 for N5 in PBS. Graph and data shown generated 
by Sylvain Penasse. 
 
4.3.2.3 FTIR to show imine formation  
 
The data for this section was generated by Sylvain Penasse. FTIR was used to probe the disappearance 
of the doxorubicin ketone peak at 1717 cm-1 (Figure 4.12) upon the addition of AmCD 16 at ratios 1:1 
(N1) and 5:1 (N5). In figure 4.13, the ketone peak of doxorubicin decreases as shown by the arrow 
towards the baseline. Upon addition of AmCD 16, reduction of ketone peak was observed correlating 
to the amount of AmCD 16 in N1 (green line) and N5 (purple line) this was taken to indicate imine 
formation with the doxorubicin. Furthermore, a peak at 1690-1640 cm-17 corresponding to imine3 
bond appears in N1 (green line) and N5 (purple line) when comparing to AmCD 16 (blue) or free dox 
(red) spectra. This is difficult to conclude as there is an overlapping peak at 1620 cm-1 from the free 
dox. AmCD 16 (blue line) does not have a peak at 1717 cm-1 so does not contribute to this signal. The 
concentration of doxorubicin was kept constant 0.1 mg ml-1. Overall, this supports imine linkage as 
being responsible for doxorubicin loading onto the AmCD 16. In the case of AcCD 17, the peaks at 1638 
cm-1 (HNCO) amide and at 1561 cm-1 (N-H) as seen in FTIR spectra of AcCD 17 in section 2.2.2.4 meant 
that the ketone peak at 1717 cm-1 could not be monitored accurately in the same way as they come 
at the same position as an imine 1690-1640 cm-1.223 Hence, imine formation could not be probed. FTIR 
to probe CD-lac-TTDAA to dox interaction has yet to be carried out, we anticipate a similar result to 
AmCD 16 as there both have a free amine on their surface, and we can infer interaction between CD-
lac-TTDDA 28 and dox through confocal similarly to AmCD 16.  


























              
Figure 4.12 FITR spectra of free doxorubicin. Peak at 1717 cm-1 (C=O) ketone is identified here and can be used to probe the 
formation of an imine via this ketone. Data for this graph generated by Sylvain Penasse. 
 
 
Figure 4.13 FTIR spectra of free doxorubicin (red), AmCD 16 (blue), N1 (green) and N5 (purple). The ketone signal from 
doxorubicin, as shown in figure 10, decreases stepwise upon the addition of AmCD 16 as shown by the black arrow first in N1 
then N5. Imine formation is supported by this data. Data for this graph generated by Sylvain Penasse. 
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4.3.3 Cellular studies  
 
4.3.3.1 Cytotoxicity of AmCD 16, AcCD 17 and CD-lac-TTDDA 28  
 
Cytotoxicity of carbon dots without doxorubicin loaded was conducted to observe if there was any 
toxic effect on HeLa cells which may interfere with measuring the toxicity of N5, C5 and LT5. Relative 
to control (untreated cells) there was no significant toxic effect observed in either the AB or Calcein 
assay for AmCD 16, AcCD 17 and CD-lac-TTDDA 28 (Figure 4.14).  
 
Figure 4.14 Cytotoxicity of AmCD 16, AcCD 17 and CD-lac-TTDDA 28 as measured via Calcein AM and Alamar blue tests at 
time points: 4hr (blue), 8 h (red), 12 h (green), 24 h (purple) and 48 h (orange). Experiments were conducted in triplicate.  
 
4.3.3.2 Cytotoxicity of N5, C5, LT5  
 
Cytotoxicity studies were conducted in three cell lines MDA-MB-231, MCF-7 and HeLa, at four time 
points 24 h, 48 h, 4 days and 7 days, for samples N5, C5 and LT5 which had suggested promise for 
slowed drug delivery (Section 4.3.2.1.1). Two cytotoxicity tests were conducted in parallel; Alamar 
blue (AB) and Calcein AM (Calcein) and a dose-response curve generated in each case (figures S4.1, 
4.2 & 4.3). Data was conducted in triplicate and averaged. From the dose-response curve inhibitory 
concentration (IC50) values were extracted.  
 
The data in this section offers information on the efficacy of N5, C5 and LT5 as a means for improved 
doxorubicin delivery. Firstly, in all cases as time increases, toxicity increases. This is observed in both 
AB and Calcein AM assays. Doxorubicin by itself is highly toxic and IC50 values are within the same 
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LT5 compared to all other delivery systems has the least toxic effect at all time points in some cases 
never reaching the same toxicity as free doxorubicin at the first time point of 24 hrs. Hence, the 
delivery is on a slower time scale than 7 days, potentially never fully releasing all the bound 
doxorubicin. This also agrees with confocal images which show that cytosolic retention of doxorubicin 
is greater than that seen for N1-8 or C1-8.  
 
As expected, free doxorubicin had a greater toxicity than all of N5, C5 and L5 at time points 24 h and 
48 hr. This suggests that the carbon dots sequester doxorubicin on their surface fitting with the 
proposed slowed release theory. However, and most interestingly, N5 has a greater toxic effect at day 
4 (AB only) seen in table 4.9 and in both cytotoxicity tests at day 7 in MDA – AB 0.00109 𝜇M and 
Calcein 0.00298 𝜇M compared to free doxorubicin with 0.00561 𝜇M and 0.0132 𝜇M respectively 
(Table 4.9).  
 





This “swap” in toxicity shows that N5 reaches greater toxicity at longer time points than free 
doxorubicin. In HeLa this effect is also seen with N5 at day 4 as well as day 7 (AB and Calcein).  
Furthermore, in MCF-7 at day 4 N5 has greater toxicity, however, at day 7 free doxorubicin is once 
again more toxic. C5 does not show increased toxicity to the same extent as compared to doxorubicin. 
In some cases, the toxicity is comparable, but not an order of magnitude greater as seen with N5 (table 
4.3).  
Free doxorubicin is known to be effluxed from the cancer cell via the p-glycoprotein. However, if 
doxorubicin is sequestered on AmCD, then this is reduced and as the drug is slowly released there is 
a greater likelihood that it can enter the nucleus where it is effective. Literature evidence has shown 
both a decrease or an increase in toxicity with a drug delivery nanoparticle as evidence for improved 
efficacy as discussed earlier in this chapter 4.1.3.4. Up to 72 hr a reduction in toxicity is used as 
evidence of sequestering of the drug168. But also, greater toxicity is seen by Li et al.217 who attribute 
this to greater uptake of the nanoparticle form.  
 
In vitro, the context is not similar to nature in that the extracellular environment is fairly consistent 
compared to in vivo. Hence, in vitro any free doxorubicin exocytosed by the p-glycoprotein could re-
enter the cell. This means that the benefits of our system could be underestimated in this experiment. 
Overall, by running our experiments at 4 day and 7 days our work is able to offer an explanation and 
MDA IC50 (AB assay) IC50 (Calcein) 
N5  0.00109 0.00298 
Dox 0.00561 0.0132 
Table 4.3 IC50 values (𝜇M) at day 7 for N5 and free doxorubicin in MDA-MB-231 cells.   
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evidence for the seemingly conflicting increased and decreased cytotoxicity seen for doxorubicin-
carbon dot delivery systems in the literature. Finally, MDA-MB-231 is known to be resistant to 
doxorubicin through MDR yet N5 worked best on this cell line, showing that the CD sequesters 
irrespective of the level of p-glycoprotein present. This suggests that N5 CD conjugate offers potential 

































AB IC50 MCF7 (𝜇gml-1)  24 hr 48 hr 4 day 7 day 
N5 0.236 0.141 0.00309 0.00176 
C5 0.0692 0.0118 0.00924 0.00437 
LT5 > 10 > 10 > 10  0.125 








AB IC50 MDA (𝜇gml-1) 24 hr 48 hr 4 day 7 day 
N5 > 10 0.0244 0.00255 0.00109 
C5 0.0887 0.0133 0.00278 0.00230 
LT5 > 10  4.980 0.212 0.0710 
Dox > 10* 0.00441 0.00427 0.00561 
 
Calcein IC50 MDA (𝜇gml-1) 24 hr 48 hr 4 day 7 day 
N5 > 10 > 10 0.0205 0.00298 
C5 16.8 > 10 0.00534 0.00365 
LT5 > 10  > 10 > 10 0.1780 
Dox 0.0251 > 10* 0.00124 0.0132 
 
AB IC50 HeLa (𝜇gml-1 ) 24 hr 48 hr 4 day 7 day 
N5 0.124 0.0284 0.00268 0.000231 
C5 0.186 0.0211 0.00410 0.00114 
LT5 > 10 1.27 0.239 0.0216 
Dox 0.0450 0.0177 0.00486 0.000695 
 
Calcein IC50 HeLa (𝜇gml-1) 24 hr 48 hr 4 day 7 day 
N5 0.136 0.0543 0.00146 0.000386 
C5 0.121 0.0543 0.00535 0.00136 
LT5 > 10 6.42 0.517 0.0244 
Dox 0.0430 0.0376 0.00381 0.000482 
Table 4.4 Cytotoxicity data for N5, C5 L5 and free doxorubicin in HeLa, MDA and MCF-7 cancerous cell lines. Values stated 
are Inhibitory concentrations - IC50 (𝜇M). Two cytotoxicity assays were conducted in tandem Alamar blue (AB) and Calcein 





Calcein IC50 MCF-7 (𝜇gml-1)  24 hr 48 hr 4 day 7 day 
N5 > 10  1.653 0.001365 0.00830 
C5 > 10 0.0490 0.00662 0.0129 
LT5 > 10 > 10 0.4080 14.80 
Dox 6.48 0.0130 0.00749 0.00472 
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4.4 Conclusions and future work 
 
In this work, four different carbon dot delivery-based doxorubicin delivery systems have been 
synthesised and tested with cancer cells with different doxorubicin loading. The structure and 
mechanism of loading was explored by varying the surface functionality of the carbon dot to match 
common trends in the literature. Our group expertise in carbohydrate functionalising carbon dots was 
used in this context to develop a lactose-based target system. Lactose functionalisation improved the 
specificity of delivery in previous work44 and has the potential for developing multivalent 
carbohydrate-based delivery systems.  
 
CD-lactose 25 was shown not to bind doxorubicin well i.e. hydrophobic (CH-𝜋) interactions are not 
sufficient for loading. In other words, removing the electrostatic interactions that occur between dox 
and N5 and C5 removes the loading potential. The fact N5 has slower drug release (dialysis and 
confocal N/C) and greater cytotoxicity at 7 days than C5 shows that additional interactions than just 
electrostatic must occur between the CD amines and Dox. We propose this is due to the imine 
formation between the doxorubicin ketone and the surface amines of N5. We suggest that this 
interaction is more favourable than forming corresponding carboximidate which would form between 
the doxorubicin amine and the carboxylic acid of C5. The carbonyl of carboxylic acids is much less 
electrophilic towards nucleophilic attack by an amine than the carbonyl of ketones, therefore forming 
a covalent linkage between dox and C5 in this manner is less favourable. Another factor could be the 
sterics of doxorubicin loading onto a nanoparticle in that AmCD 16 may offer more electrostatic 
interactions with doxorubicin than the AcCD 17 can provide.  
 
By synthesising CD-lac-TTDDA 28 by conjugating TTDDA onto CD-lactose 25, dox loading was restored 
to the carbon dot as seen in confocal microscopy. Cytotoxicity revealed that this system had the lowest 
toxicity for the same concentration of doxorubicin at 24 h, 48 h 4 day and 7 day time points. This 
indicates strong interaction, greater than amines only in the form of N5.  
 
N5 showed interesting cytotoxicity results compared to free doxorubicin explaining seemingly 
contradictory literature results. Both greater and lower cytotoxicity has been shown as evidence of 
improved efficacy for carbon dot doxorubicin delivery systems as discussed in section 4.1.3.4. 
However, this is because carbon dots improve doxorubicin uptake and also sequester it from p-
glycoprotein removal. Hence depending on the time point and concentrations the dominant effect 
changes. Initially N5 shows reduced toxicity compared to free doxorubicin which we suggest is due to 
sequestering effects. By carrying out these assays up to 7 days we observe that at longer time points 
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the toxicity of N5 becomes greater than free doxorubicin owing to the slow by continued release of 
doxorubicin to the nucleus. This is supported by confocal evidence where over 4 hrs doxorubicin 
translocated into the nucleus at different rates depending on the CD surface functionality.  
 
FTIR was shown for the first time to the best of our knowledge as indicating imine formation between 
doxorubicin and a carbon dot. This was inferred from disappearance of the signal resulting from the 
doxorubicin ketone removal upon sequential carbon dot addition. Previous studies comment that 
covalent bonding could occur between the Dox ketone and the CD amine, or the carboxylic acid on 
the CD and the Doxorubicin amine.168 Dialysis studies in vitro of N5 also showed low pH release which 
agrees with imines being acid-labile and is a good cancer targeting property to have as cancer cells are 
more acidic than healthy cells. Understanding the basis of doxorubicin loading is important for 
developing a system which has both specific and passive uptake properties.  
Zeta potential may be an interesting experiment to run. Literature evidence185 shows that doxorubicin 
increases the zeta potential upon conjugation to carbon dots which have a zeta potential close to 0 
eV. One experiment could be carried out to compare the zeta potential (at pH 7.4) of N5 with N5-dox 
and C5 with C5-dox. This would reveal the surface charge when doxorubicin has been loaded. The 
AmCD 16 surface would be occluded from the solvent upon loading and the doxorubicin amine would 
be bound to the carbon dot surface as an imine. In this case, a more negative zeta potential for N5 
would be expected compared to AmCD 16. For AcCD 17 upon loading, the doxorubicin amine would 
be solvent exposed and the carboxylic acid surface groups occluded from the surface. In this 
experiment the zeta potential of C5 would be expected to increase with respect to the AcCD 17. It is 
worth bearing in mind that the implications of cell media would need to be considered for these 
experiments and further along, the in vivo context. 
 
A further zeta potential experiment could be conducted at high pH (> 9.93) with C5 and N5. At pH 
above the Doxorubicin amine pKa of 9.93, the amine deprotonates. This negative change in charge 
would be expected to be greater for C5 then N5 reflected in zeta potential compared to when at pH 
7.4.  
 
Future work would include further quantification of nuclear/cytosol doxorubicin localisation in vitro 
over time of N5, C5 and LT5. Also, flowcytometry would allow high throughout data to be collected of 
uptake rates of CD-dox systems and hence delivery potential over time. Investigating lysosomal escape 
of CD-dox could be explored for improving delivery as it is a means by which delivery systems are 
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exocytosed as seem for many literature examples. Carbohydrate based targeting of cancer cells affects 


































4.5 Chapter 4 Experimental  
 
Doxorubicin.HCl was purchased from Sigma Aldrich. 
4.5.1 Synthesis  
 
4.5.1.1 Doxorubicin loading onto AmCD 16, AcCD 17, CD-lactose 25 & CD-lac-TTDDA 28 
 
A mixture of carbon dot (AmCD 16 or AmCD 17, CD-lactose 25 & CD-lac-TTDDA 28) and 
doxorubicin.HCl (0.1 mgml-1) were dissolved in H2O and then freeze dried overnight to afford a red 
powder N1-8 (from AmCD 16) or C1-8 (from AcCD 17) or L1-8 (from CD-lactose 25) or LT1-8 (CD-lac-
TTDDA 28). The material was redissolved to 0.1 mgml-1 doxorubicin concentration directly before use.  
 
4.5.1.1.1 NMR characterisation of doxorubicin, N5, C5 and L5. 
 
NMR of commercial Doxorubicin.HCl:  1H NMR (500 MHz): 𝛿 = 7.67 (d, 1H, J = 6.3 Hz, B), 7.45 (s, 1H, C), 
7.41 (d, 1H, J = 8.7 Hz, A), 4.27 (d, 1H, J = 7.0 Hz, D), 3.73 (s, 2H, F), 1.33 (d, 2H, J = 6.3 Hz, E) ppm. NMR 
matches previously reported data in the literature see ref .224 For DOSY the peak used to determine 
the diffusion coefficient of doxorubicin was at 7.67 ppm in 1H NMR. Appendix shows 1H NMR and 
DOSY spectra of Doxorubicin.HCl. 
 
NMR of N5, C5 and L5 show the same assignments as seen for doxorubicin.HCl and AmCD 16, AcCD 
17 and CD-lactose 25 respectively (see section 2.4.3 for assignments and appendix for spectra).  
For N5 DOSY the peak used to determine the diffusion coefficient of carbon dot was 3.5-3.6 ppm.  









4.5.1.2 CD-lac-TTDDA 28 synthesis and doxorubicin loading – LT1-8 
 
To CD-lactose 25, TTDDA (1:1 molar equivalent to lactose used in glycan functionalisation) was 
conjugated onto the surface to any remaining carboxylic acids via EDC coupling (4 equivalents) for 2 
hr in H2O (10 ml) on a 60 mg CD-lactose scale. CD-lac-TTDDA 28 was purified using dialysis using 500-
1000 MWCO cellulose membrane overnight. A mixture of CD-lactose 25 and doxorubicin.HCl (0.1 
mgml-1) were dissolved in H2O and then freeze dried overnight to afford a red powder N1-8 (from 
AmCD 16) or C1-8 (from AcCD 17) or L1-8 (from CD-lactose 25) or LT1-8 (CD-lac-TTDDA 28). The 
material was redissolved to 0.1 mgml-1 doxorubicin concentration directly before use.  
 
NMR of CD-lac-TTDDA 28: 1H NMR (500 MHz): 𝛿 = 5.24 (d, 1H, J = 3.8 Hz) 4.68 (d, 1H, J = 7.9 Hz), 4.57 
(d, 1H, J = 7.8 Hz), δ = 4.46 (d, 1H, J = 7.8 Hz)  3.50-3.70 (m), 3.00 (t, J = 7.2 Hz), 2.40 (s, 1H, Hz), 1.96 
(q, 1H, J = 6.7 Hz) ppm. Spectra  
4.5.2 DOSY 
 
Sample Diffusion coefficients / x 10-6 cm2 s-1 Water diffusion coefficient/ x 10-6cm2 s-1 
Doxorubicin 1.86 16.5  
AmCD 3.83 16.3 
AcCD 2.86 16.3 
N5 Dox:  2.14 CD:  3.08 17.5 
C5 Dox:  1.39 CD:  1.11-3.08 15.3 
Supplementary table 4.1 DOSY derived diffusion coefficients – raw values. These are corrected against the water peak and 
presented in the main text table 3. Data measurements were not conducted in triplicate hence errors were not calculated. 
4.5.3 Cell studies 
 
CD loaded doxorubicin toxicity in HeLa, MDA and MCF7 cancer cells was determined by way of IC50 
measurement using a Calcein assay and an Alamar Blue assay which were performed in tandem. HeLa 
cells were plated at 1x105 cells per well in a 96-well plate and incubated overnight. The next day cells 
were incubated with nanomaterial in dilution to produce inhibition curves. Samples used for these 
experiments were those named C5, N5 and LT5 (see table 4.1 for reference), which were at 10:1 
Dox:CD mass ratio. Concentrations used in these experiments were between 100-0.1 𝜇gml-1 with 
respect to doxorubicin. After incubation with nanomaterial for either 24 hr, 4 day or 7 day cells were 












Supplementary Figure 4.1 MCF-7 Toxicity dose-response (inhibition) curves plotted in GraphPad Prism using Non-linear 

















































































































































Supplementary Figure 4.2 MDA Toxicity dose-response (inhibition) curves plotted in GraphPad Prism using Non-linear 

















































































































































Supplementary Figure 4.3 HeLa Toxicity dose-response (inhibition) curves plotted in GraphPad Prism using Non-linear 




















































































































































Errors AB logIC50 MCF7 (𝜇g ml-1)  24 hr 48 hr 4 day 7 day 
N5 8.80 1.65 0.45 0.16 
C5 - 0.05 0.12 0.12 
LT5 5.30 - 0.44 2.45 











Errors Calcein logIC50 MCF-7 (𝜇g ml-1)  24 hr 48 hr 4 day 7 day 
N5 0.33 0.41 0.29 0.15 
C5 0.05 0.14 0.10 0.26 
LT5 10 - 3.19 0.33 
Dox 0.04 0.09 0.12 0.16 
Errors AB logIC50 MDA (𝜇g ml-1) 24 hr 48 hr 4 day 7 day 
N5 1.32 0.33 0.20 0.14 
C5 0.20 0.15 0.07 0.07 
LT5 - 1.1 0.14 0.14 
Dox 4.0 0.1 0.07 0.08 
Errors Calcein logIC50 MDA (𝜇g ml-1) 24 hr 48 hr 4 day 7 day 
N5 - - 0.37 0.11 
C5 1.0 - 0.24 0.10 
LT5 - - - 0.74 
Dox 1.1 - 0.35 0.04 
Errors AB logIC50 HeLa (𝜇g ml-1) 24 hr 48 hr 4 day 7 day 
N5 0.18 0.24 0.06 0.28 
C5 0.40 0.16 0.08 0.15 
LT5 - 1.16 0.14 0.11 
Dox 0.05 0.15 0.06 0.12 
Errors Calcein logIC50 HeLa (𝜇g ml-1) 24 hr 48 hr 4 day 7 day 
N5 0.09 1.3 3.1 3.6 
C5 0.21 1.4 2.4 3.0 
LT5 - 7.8 0.6 1.8 
Dox 0.06 1.6 2.5 3.7 
Supplementary Figure 4.4 Standard errors of cytotoxicity data presented in table 4.4 (of main chapter text). Log IC50  values 
shown as this is most appropriate for this data set.  
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5. Green fluorescent Carbon Dots for PTT 
5.1 Photothermal therapy  
 
Photothermal therapy (PTT) treatments have been explored over the last 10 years (Figure 5.1). These 
types of therapy are based on using the lower energies (biologically compatible) of the 
electromagnetic spectrum (400-1350 nm) for biomedical applications.225 The technology often works 
in combination with nanoparticle agents or small molecules which due to their size and 
physiochemical properties are able to target or accumulate in a particular tissue or cell (e.g. cancer) 
and upon activation elicit local heating, which can lead to a therapeutic response.225,226  
 
  
Figure 5.1 Publications with the word "phototherapy" included between 2009-2019 
 
The application of PTT has been exemplified both in vitro / in vivo.226 Commonly the energy used for 
these type of applications is in the UV-visible-near infrared (NIR) range (700-1100 nm), with a variety 
of nanoparticle types being used, metallic nanoparticles including gold, silver, palladium, copper, iron 
oxide, and molybdenum oxide227, as well as carbon nanotubes (CNTs) and single layer graphene 
nanotubes (GNTs) and polymer nanoparticles226. These nanomaterials can also act in a multimodal 
way including drug or DNA delivery, imaging agent or MRI contrast agent. The energy applied in the 
form of a photon of light is absorbed and can then be emitted spectroscopically in a number of ways, 
however, a high conversion to heat is required for inducing hyperthermia and delivering photothermal 









































Figure 5.2 UV-visible-NIR irradiation of a nanoparticle energy conversion.227 
 
PPTs can induce local hyperthermia with detrimental effect on the target cell. Hyperthermia is 
categorised into primary and a secondary effects. Primary effects refer to the local effects seen in the 
immediate context of a nanoparticle i.e. causing intracellular protein denaturation (between 48-60 
oC) also known as thermal ablation. While secondary effects elicit the general biological homeostatic 
responses observed in surrounding tissue which occur at temperatures around 41-48 oC 226 and require 
longer treatment times of 15-60 minutes for cytotoxicity compared to 4-6 minutes for primary.228 
Primary effects induce more severe toxicity; hence, nanoparticles have been widely studied for PTT as 
they are able to induce higher local temperature increase.  
 
PPTs can be induced by a wide range of wavelengths, however, one important consideration is the 
effect of each therapy on a biological sample. In the context of cancer, tumours can be up to 
centimetres below the skin surface and therefore wavelength penetration depth must be 
considered(Figure 5.3). Furthermore, the healthy tissue must not absorb too much energy such that 
necrosis of cells is induced. Hence, through NIR irradiation in combination with a nanoparticle 
conferring efficient NIR to heat conversion, targeted PTT becomes viable. However, as these 
wavelengths are lower energy than UV and visible wavelength, longer treatment times are required 
for the same therapeutic effect. NIR-I and NIR-II refer to the 2 biological windows which PTTs are 
generally targeted towards, with the NIR-II providing greater therapeutic potential in terms of depth 





Figure 5.3 UV-Visible-NIR wavelengths and tissue penetration depth. 226,228 
 
Achieving nanoparticle based targeted anti-cancer treatments has been of particular interest. New 
technologies are moving away from magnetic field induced metallic nanoparticle-based treatments 
developed in the 1950’s, which are limited to superparamagnetic ferromagnetic nanoparticles such as 
iron oxide nanoparticles. These offer useful properties in that they have good light to heat conversion, 
magnetism and NIR absorption. However, this PTT is only able to raise intracellular temperature to 
42-45 oC, and often have toxicity issues associated229.  
 
Other nanomaterials have also been used for photothermal therapy, common to all is a good 
photoluminescence and biocompatibility. Nanogold is a popular option due to its surface plasmon 
resonance (SPR) properties, which confers excellent light to heat conversion. This is due to efficient 
absorption, good photostability, low luminescence yield and rapid relaxation of surface plasmon 
resonance230. For nanogold-based applications, visible or IR wavelengths are readily absorbed and the 
emitted light profile changes depending on the size, shape and local environment of the nanoparticle 
which allows for sensing applications.231 
 
Graphene also has good photothermal properties and has been used in conjunction with IR irradiation 
to induce hyperthermia in cancer cells. Graphene’s aromatic lattice is a good scaffold for drug loading 
through hydrophobic and pi-pi interactions offering potential for dual treatment232. Single-walled 
carbon nanotubes (CNTs) are able to absorb in the NIR and emit between 1100-1400 nm in the NIR 
region also due to strong absorption, allowing for PTT and deep tissue imaging. Their PTT potential 
was first compared to gold nanorods where a 10 times lower dose was observed to elicit the same 
tumour elimination through local heating233. In addition being able to drug load via 𝜋 − 𝜋 stacking,234 
CNTs also have a hollow cavity which is suitable for drug sequestering and through PEG coating their 
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associated toxicity can be addressed235. Associated toxicity is known to come from their high aspect 
ratio, meaning they can pierce cells236. 
 
Upconverting nanoparticles (UCNPs)237 provide a novel way to deliver high energy UV and visible 
wavelength energy in a targeted way using relatively benign NIR irradiation. As NIR has good 
penetration of biological material they are able to interact with UCNPs deep within tissue. These 
nanoparticles act as optical centres and often contain an absorbing metal antenna such as Erbium 
(Er3+) and photon upconverting ion such as Ytterbium (Yb3+). The upconverting lanthanide metal ion 
has the ability to absorb two photons sequentially with an intermediate electronic state which in an 
anti-stoke shift, produces a photon in an energy conserving manner. Up conversion is 5 orders of 
magnitude more efficient compared to multiphoton (two photon) irradiation which requires 
coincident photon irradiation for high energy emission238.  
 
Another material that has found applications in PTT are carbon dots due to their photostability, facile 
synthesis and low toxicity properties as well as non-bleaching properties allowing for their use in 
bioimaging, drug delivery and other therapeutic purpose. Achieving NIR wavelength absorbing CDs 
within the biological transparency window between 650 – 1350 nm where tissue is most penetrable 
by light, is particularly difficult. Hence, deep tissue penetration limitations exist currently for CD 
photothermal therapy. Furthermore, due to poor IR absorption, CD irradiation requires high power 
densities which are energy intensive to produce. However, efforts to red-shift the carbon dot 
spectroscopic profile have been explored through p-type doping or with small organic molecules 
containing a variety of heteroatoms72. 
 
5.1.1 Carbon dots for PTT 
 
Recent efforts have been directed to modifying the synthesis of CDs to yield nanomaterials that are 
amenable to IR absorption. This has been achieved via the addition of known IR absorbing small 
molecules such as ureas within the synthesis and optimising the number of nitrogen containing pyrrole 
groups on the CD surface which are generated by careful control of the reaction conditions such as 
starting material ratios, reaction time and temperature.239 
 
For instance, Permatasari et al.239 synthesised carbon dots through a 30 minute microwave assisted 
methodology at 140 oC using a range of ratios of citric acid:urea (between 1:1 and 1:10). A ratio of 1:5 
w/w citric acid:urea was found to be optimal in order to achieve the most red-shifted and most 
pronounced absorbance peak at 650 nm. Secondly, the temperature during formation was optimised 
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to 140 oC. Initial efforts to reduce the temperature to 130 oC changed the absorbance shape to 
broaden across the visible and NIR range (400-700 nm). This suggests sufficient energy is provided 
above 140 oC to form these pyrrolic structures. Increasing the temperature above 140 oC marginally 
improved the absorbance at 650 nm but the material was less stable after 5 days. Finally, the reaction 
time was optimised to 240 minutes based on the intensity of the absorbance peak at 650 nm. Physical 
characterisation including FTIR and XPS was carried out on three of the CD materials produced from 
these experiments which had varying degrees of NIR absorption to determine that pyrrolic structures 
were the basis of the NIR absorbance observed. Evidence included FTIR stretching vibrations at 1350 
cm-1 and 1630 cm-1 corresponding to nitrogen containing functional groups C-N and C=N/C=O 
respectively. XPS is able to measure nitrogen content and can be deconvoluted to show the proportion 
of nitrogen in the pyrrolic-N form which was highest at 70.9 % for the best NIR emitter. Overall 
optimisation produced carbon dots with high 54.3 % photothermal conversion.  
  
Bao et al.240 conducted in vivo (mice) experiments with a 655 nm laser with NIR-absorbing CDs with 
excellent photothermal conversion of 59.2 %. After 3 hr incubation the CD accumulation was assessed 
in the tumour and the subject’s organs. Accumulation was greatest in the tumour compared to any of 
the excised organs. Furthermore, thermographic measurements observed temperatures of 59-71 oC 
at the tumour site with CD present after 5 min irradiation (655 nm laser,  1 W cm-2) compared to 
control where no CDs were present.240 Hence, this material offers great potential for NIR induced 
cellular ablation and targeted tumour treatment. Interestingly, the starting materials used by Bao et 
al. were the same as those conducted by Permatasari et al.239 consisting of only citric acid and urea at 
a 1:3 ratio w/w, but conducted under different solvothermal method, at 160 oC for 240 minutes. 
Fluorescence and absorption profiles were almost identical in shape to Permatasari et al. with a peak 
absorption between 600-700 nm and fluorescence peak at 720 nm. They claim that the dimethyl 
sulfoxide (DMSO) sulfur containing solvent is a doping agent in their synthesis and they report an 
improved photothermal conversion of 59%. XPS data revealed pyrrolic-N as expected but also 1.2% 
sulfur composition. Both nitrogen and sulphur are known carbon dot doping agents which red-shift 
spectral properties by passivating the trapped states so that lower energies can escape75. 
Furthermore, the lower band gap energy associated with these surface states means that the 
photoluminescence profile is more red-shifted than non-pyrrolic-N containing carbon dots.   
  
Alternatively, passivation with highly branched bis-MPA polyester hydroxyl polymer was shown to 
improve carbon dot QY within the NIR region compared to equivalent oxygen content seen with linear 
PEGylation. Oxygen content was improved through increased hydroxyl content in this new started 
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material which was added into the commercial grade honey carbon dot synthesis. Honey:polymer was 
microwaved for 10 minutes at a 1:8 w/w ratio. Post synthesis hydroxyl groups were more highly 
presented on the CD surface. NIR emission at 820 nm (𝜆ex 745 nm) was considerably enhanced 
dependent on increasing hydroxyl terminated hyperbranching241. These materials showed excitation 
dependent emission between the ranges 𝜆ex 350-700 and 𝜆em 521 -751 nm, but passivation with 
sequential generations of hyperbranching did not red-shift these profiles, rather improved quantum 
yield at the NIR of the emission spectra. This indicated better surface passivation of trapped surface 
states with greater levels of branching but no new associated surface states introduced by these 
hydroxyl groups.  
 
Doping carbon dots with metals has been explored as a means for improving quantum yield whilst 
avoiding the inherent toxicity effects of the metal. After doping with Ga, Sn, Ag, Zn, and Au through a 
sonochemical synthetic method, CD toxicity was determined to be low in all materials242. Furthermore, 
evidence has been shown that metallic nanoparticles have good optical properties and photothermal 
conversion and hence promise as PTT agents. Rare earth metals have poor quantum yield but good 
photothermal conversion upon NIR irradiation243. They have many energy levels which when used as 
a doping agent, can exist within the band gap of the bulk material.  Nd3+ doped LaF3 nanocrystals show 
excellent photothermal properties, allowing for sensitive thermal detection applications226. Hence, 
using lanthanides as a means to introduce energy levels within the carbon dot band gap could improve 
their photothermal properties. However, research into PTT applications of metal doped carbon dots 
is fairly new and literature has scope to develop in this area.  
 
The majority of carbon dots are within a UV-light spectral window which is less amenable to more 
biologically penetrating treatments. However, within the visible absorption region between  440 – 560 
nm up to 2.5 mm depth penetration through the dermis can be still achieved, which is suited to 
treating surface and sub-cutaneous tumours244. These wavelengths are usually associated with ROS 
production from either direct radical formation or through triplet to singlet O2 conversion. This process 
is termed photo dynamic therapy (PDT) and is distinctly different from the thermal method seen in 
PTT. Carbon dots which are able to achieve PTT are highly sought after.  
 
Furthering the efficacy of PTTs against tumours can be achieved through combining it with a secondary 
treatment in a two-pronged attack. For example, sequestering a secondary treatment on the surface 
of a nanoparticle means drug delivery is achieved. If the nanoparticle is delivered to the tumour 
through the ERP effect or targeted through a targeting molecule, then targeted drug delivery can be 
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combined with PTT. Many groups have looked to combine photothermal treatment with a secondary 
mechanism such as drug release225 or immunoadjuvant activation245 through local acidic pH at the 
target site246. Often times the irradiation forms an in-situ activation step. Work by Hu at el. shows that 
using a graphene-PEG-doxorubicin proteinosome, doxorubicin release can be induced intracellularly 
by NIR irradiation in doxorubicin resistant MCF-7 cell line. Zhou et al. used Copper sulfide (CuS) 
nanoparticles containing radioactive copper salts which upon irradiation emitted radiation which 
caused secondary tissue damage in conjunction with hyperthermia225. Other examples include having 
small molecule dyes such as indocyanine green, associated with a nanoparticle which enhances the 
photothermal effect225. One important prerequisite for all of these therapies is that the nanomaterial 
is non-toxic to healthy cells. Carbon dots are reported as low in toxicity and biocompatible248, lending 
their use for PTT. Their facile synthesis also means they are an easily accessible material to work with.  
 
5.1.2 Doping carbon dots with small molecules for PTT 
 
5.1.2.1 Phenylenediamine carbon dot doping for PTT 
Literature precedent shows phenylene diamine can be used in carbon dot syntheses to produce 
materials fluorescent between the green-red visible range depending on the synthesis (Figure 5.4). A 
number of studies explore phenylene diamine isomers as starting materials in carbon dot syntheses. 
Jiang et al. carried out CD synthesis with o-, m- and p- of phenylene diamine in ethanol in a 12 hr 
thermal reaction at 180 oC to afford green/yellow (𝜆em 535 nm), blue (𝜆em 435 nm) and red (𝜆em 604 
nm) fluorescent CDs (under 𝜆ex 365 nm) respectively249. FTIR data revealed that these particles shared 
common chemical functional groups on the surface, however the nitrogen content measured by XPS 
was 7.32 %, 3.69 % and 15.57 % for o-, m- and p- phenylene diamine starting material CDs respectively. 
Furthermore, the average carbon dot size were 8.2 nm 6.0 nm and 10 nm for o-, m-, p- phenylene 
diamine derived CDs. These results support that nitrogen doping red-shifts fluorescence and is likely 
due to a greater amount of pyrrolic-N groups on the surface of p-phenylene diamine containing CDs 
allowing for improved trapped state emission and also direct excitation of these groups.  
 
Furthermore, Jiang et al. then took CD synthesis using o- and m- phenylene diamine and added tartaric 
acid under the same conditions of 12 hr solvothermal reaction at 180 oC in ethanol which allowed 
them to red-shift the CD fluorescence profile. Spectra shift for m-phenylenediamine (under 𝜆ex 365 
nm) went from blue (𝜆em 435 nm) to (𝜆em 510 nm) green and for o-phenylenediamine from 
green/yellow (𝜆em 535 nm) to a multipeaked red-NIR shape. They suggest that the surface groups 




Interestingly, yellow fluorescent (𝜆ex. 400 nm, 𝜆em 573 nm) CDs were also synthesised from o-
phenylenediamine in a twenty-minute microwave assisted reaction by Song et al.251 This reaction was 
in water rather than ethanol, and FTIR data indicates surface groups are composed of unsaturated 
C=O, C=C, C-N= and C-O/C-O-C groups and XPS indicates 14.93 % nitrogen content. They hypothesise 
that o-phenylene forms a polymer in the carbonisation process which incorporates oxygen and 
explains the poly unsaturated bond peaks in FTIR251. 
 
Ding et al.252 took p-phenylenediamine and added urea into the synthesis with the aim of improving 
the QY of the red fluorescent carbon dots produced by Jiang et al.249 through increased nitrogen 
doping. Optimal conditions were selected as 1:1 w/w ratio at 160 oC for 10 hr in a hydrothermal 
synthesis. Upon purification using silica gel chromatography they separated 8 fractions of CDs which 
had distinct fluorescence peaks from 440 – 625 nm. Interestingly, the size distribution of these 
nanoparticles was similar but they differed in the degree of surface oxidation which conferred a 




Figure 5.4 Phenylenediamine carbon dot syntheses summary including diameter by DLS (unless indicated), Quantum yield 
(QY), photoluminescence excitation and emission peak (excitation independent emission). Jiang et al. 2015249, Jiang et al. 
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Separation: Silica column DCM/MeOH

































The results presented in this chapter are published253. The work presented in this chapter was carried 
out by myself, Stephen Andrew Hill and David Benito-Alifonso (indicated in the text of the results 
chapter). Stephen Andrew Hill and I share joint first authorship of this publication. Section 5.2 previous 
work, covers work carried out by Stephen Andrew Hill and are presented in his thesis83. All the work 
in results section 5.4 was carried out by myself. 
5.2 Previous work  
 
Previous work carried out by Stephen Andrew Hill83 in the Galan group looked to modify the blue 
carbon dot synthesis from section 2.2.1.1  to achieve carbon dots with a more red-shifted spectral 
profile. This should allow bioimaging to be conducted and intracellular targeting to be observed. 
Beginning with the material in hand synthesised from glucosamine hydrochloride and TTDDA in a facile 
domestic microwave synthesis, the protocol was adapted. Following literature president showing 
phenylenediamine as a good nitrogen doping source, its three isomers were incorporated into the 
established glucosamine hydrochloride 3-minute microwave assisted carbon dot synthesis (as 
outlined in chapter 2) instead of TTDDA. The same protocol was followed with a 1:1 w/w glucosamine 
to phenylenediamine ratio in 20 ml H2O in a 3-minute microwave assisted reaction. For o- and p-
phenylenediamine a blue fluorescent material was afforded which had excitation dependent 
properties. This suggested poor incorporation of these materials into the nanoparticle as the spectral 
profile had not been red shifted compared to the original material. The m-phenylenediamine and 
glucosamine synthesis produced a fluorescence peak at 525 nm with excitation independent 
properties. A green fluorescent carbon dot was afforded (FCD-3) from this synthesis. Stephen Andrew 
Hill carried out initial characterisation of FCD-3 as described in section 4.2.1. However, further 
characterisation revealed that FCD-3 was made up of mostly two distinct materials termed 4 and FCD-
5. These materials were characterised separately by myself in the results section 4.4. 
5.2.1 Characterisation  
 
Characterising this new CD termed FCD-3, dynamic light scattering (DLS) showed a hydrodynamic 
diameter of 6-9 nm Fig.S5.2 and a zeta potential (𝜁) of 12.05 mV Fig.S5.3. High resolution TEM shows 
that these carbon dots have an amorphous internal structure, as no lattice patterns can be seen at 
high-magnification. TEM also reported a core diameter distribution between 1.8-3 nm Fig.S51. 
Quantum yield measurements using fluorescein a standard dye (QY = 0.95) showed that FCD-3 has a 
QY of 0.33 which is relatively high compared to other syntheses from m-phenylenediamine. FCD-3 
FTIR data shows key features at 3338 cm-1 (O-H/N-H), 1629 cm-1 (amide C=O) 1016 cm-1 (C-O/C-N), and 
612 cm-1 (C-Cl). XPS data showed nitrogen was predominantely in the amine/N-heteroatom (3.99.69 
eV) form, and carbon in the C-C/aromatic C-C (285.07 eV) form and the C-OH/C-O-/C-N (286.46 eV) 
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form. Fluorescence data shows FCD-3 have excitation independent emission peak at 525 nm with 𝜆ex 
450 nm (Fig.S5.6). Thermogravimetric analysis found that 50% of mass was lost upon heating to 650 
oC, whilst the remaining 50% was able to withstand extreme heating. 
 
The fluorescence spectrum of FCD-3, showed flavin like molecules which share a similar profile with a 
peak at 525 nm. Furthermore, pyrazine and hydroxyl motifs found shown to be present in FCD-3 
through NMR and fluorescence are found in riboflavin. These molecules may be formed during the 
synthesis reaction and presented on the CD surface. This is supported by the excitation indepenedent 
fluroescence mechanism of these carbon dots. Riboflavin-like chromophores formed from the 
reaction between glucosamine and m-phenylenediamine would then be incorporated into the core as 
well as presented on the surface of the nanoparticle. Furthermore, the basis of FCD-3 cytotoxicity 
could be down to ROS generation coinciding with known photosensitiser properties of riboflavin254 
and fructosazine255 in the literature. They are known photooxidising agents which destroy cellular 
material. Bhattacherjee et al.255 show that UV-B irradiation combined with either riboflavin, 
fructosazine or glucoseamine caramel show a greater bacteriocidal effect on E.coil than each 
individually through an ROS mechanism.  
 
Furthermore, results indicating nuclear localisation and DNA targeting offer promise for a novel ROS 
mediated PDT. Owing to their potential for PDT, FCD-3 used in combination with cheap and accessible 
light emitting dioides (LEDs), with 460 nm excitation, were explored for in vitro cancer cell toxicity. 
The literature mechanism of glucoseamine self condensation to form fructosazine and 2,5-
deoxyfructosazine likely occurs in this reaction. Fructosazine could then incorporated into the carbon 














5.2.2 Cell studies 
 





Figure 5.5 FCD-3 Toxicity and reductive metabolism data in HeLa and HDF cells treated with FCD-3 for 2 hrs after 1hr, 1day 
and 3 days. 
 
This material named FCD-3 was assessed for its cytotoxicity and potential for bio-application in cancer 
cell line HeLa and healthy cell line HDF. FCD-3 was incubated with HeLa and HDF for 1 hour, 1 day and 
3 days before toxicity experiments were performed. Figure 5.5 shows that FCD-3 is more toxic to HeLa 
than HDF, likely due to the greater uptake rate and nuclear localisation. However, FCD-3 is relatively 
non-toxic considering the high dosage >100 ug ml-1 requried at 3 days to induce cell death in both cell 
lines. The starting material m-phenylenediamine has associated toxicity which when incorporated into 
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5.2.2.2 Selective uptake  
 
Comparing the cellular uptake of FCD-3 in HeLa and HDF showed that these particles are taken up 
more quickly by cancer cells 67% than the healthy HDF cell line 20% possibly passively. Interestingly 
FCD-3 was observed in the nucleus of HeLa after 1 minute, and was localised there for up to 30 minutes 
before fluorescence in this area decreased. This fast nuclear targeting was not seen in HDF either 
through passive or active uptake. Furthermore, over a 2 hour period FCD-3 was observed not to 
localise in any other organelles, observed through co-localisation experiments and confirmed with 
Pearson Correlation values indicating no corrolation. Values were, Mitotracker -0.0979, Late 
Endosome -0.0915, Early Endosome -0.0828, Golgi -0.0608, Lysosome 0.461, whilst Nucleus was 
0.743. These results suggest FCD-3 as a specific nuclear, cancer cell line targeting particle.  
 
5.2.2.3 Localisation  
 
Flow cytometry was used to detect FRET interaction between FCD-3 and DNA dyes in vitro to assess 
FCD-3 potential for nuclear targeting. FCD-3 was again incubated for 2 hours in HeLa and HDF before 
nuclear permeating DNA dyes Enzo NuclearID-Red or DRAQ-5 were added to the cells and FRET was 
measured in vitro. The donor fluorescence was used as an indicator of FRET efficiency. The percentage 
decrease in donor signal was greater in HeLa then HDF, 82% compared 50% (Enzo) and 60% compared 
with 44% (DRAQ-5). This confirms results that FCD-3 targets cancer cells and the nucelus over healthy 
cells and shows promise as a DNA drug delivery agent. 
 
5.2.2.4 Killing mechanism  
 
The ROS generated upon the treatment with FCD-3 were first assessed to determine if this mechanism 
is the basis for cytotoxicity and hence PDT. If this is not the case then the hypothesis that FCD-3 acts 
as a strong photothermal converter should be investigated through temperature experiments and its 
potential for PTT explored. Hypothesised local temperature heating effect should be investigated in 
the context of LED irradiation as this could be an accessible therapy treatment.  
 
Measuring intracellular temperature increase is practically very difficult, so experimentally a number 
of markers such as ATP depletion, ROS generation and metabolite production can be measured 
alongside cytotoxicity to help give a better overview of the potential mechanism of action. 
Furthermore, in practice the local temperature around cells is measured as an indication of 
intracellular temperature increase240. To assess the killing mechanism of LED-irradiated FCD-3 treated 
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cells, three experiments were conducted. Anaylsis of the reactive oxygen species (ROS) levels using 
dihydroethidium (DHE) in section 4.2.2.5, FCD-3 metabolite production effects (5.2.2.6) and ATP 
depletion studies in a luciferase-luciferin based assay in 5.2.2.7. 
 
5.2.2.5 ROS levels 
 
ROS levels in vitro were detected through the loss in fluorescence of DHE and conducted under the 
same conditions as toxicity experiments in sectionn 4.2.2.1. FCD-3 concentration of 1, 10, 50, 100 and 
500 µg ml-1 were assessed after LED irradiation times of 30, 60 and 90 min and compared to controls 
(untreated cells and cells exposed to FCD-3 but without LED irradiation), ROS levels were assessed 
after 1hr and compared to control. In HeLa, only at 500 µg ml-1 after 90 min was a reduction of 50% 
fluorescence measured after 1 hr, which does not corrolate with the toxicity data. Toxicity data shows 
that even with irradiation times of 30 & 60 min, cell viability decreased by 50% and 60% after 1 hr 
which was not supported by ROS levels (Figure 5.7). In HDF, similarly a lack of ROS levels at the 
harshest condition did not produce a significant reduction in DHE fluorescence, supporting a lack of 
ROS associated killing.    
 
  
Figure 5.6 DHE fluorescence as a measure of ROS in HeLa and HDF cells treated with FCD-3 and LED irradiation for 30, 60 
and 90 mins after 1hr.  
5.2.2.6 Metabolite production 
 
To ascertain if metabolic products of FCD-3 were causing toxicity upon LED-irradiation, the cell lysate 
post irradation was reintroduced to naïve HeLa and HDF cells and the toxicty measured. Again, under 
the same experimental conditions (including LED-irradiation) toxicity after 1hr on HeLa was lower, 
40% than without lysate 60%. HDF showed negligable toxicty compared to control upon lysate 
incubation. Therefore, no additional cytotoxicty was induced by the lysate or FCD-3 metabolites after 
1 hr. NMR studies of FCD-3 post LED-irradiation observed no structural changes supporting this.   
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5.2.2.7 ATP depletion assay 
 
Indicating cancer cell growth and metabolic activity, high levels of HeLa cellular ATP can be observed 
through a depletion assay. Through a luciferase-luciferin assay the amount of cellular ATP was 
measured at 1hr, 1 day, 3 days. In this assay, luciferin is catalysed to oxyluciferin using one molecule 
of ATP in a visbile light (510 nm) producing reaction. At concentrations of 1, 10, 50, 100 and 500 µg 
ml-1, FDC-3 treated HeLa cells were irradiated for 90 mins before cell lysis and the assay was carried 
out. Relative to control, treatment with 1 µg ml-1 induced a 20% ATP level drop after 1 hr post 
irradiation. Furthermore, a decrease of 65 and 75 % after 1 day and 3 days respectively was observred 
after treatment with 1 µg ml-1 FCD-3. This trend of FCD-3 concentration dependent ATP depletion 
coincides with reductive metabolism and cytotoxicity assay results under the same conditions (Figure 
5.7). This result confers that FCD-3 treatment combined with LED-irradiation results in cytotoxicity as 
a function of ATP depletion.  
 
5.2.2.8 LED-irradiation cytotoxicity  
 
Toxicity of FCD-3 was assessed using Calcein AM and Alamar blue (AB) assays and this data was 
compared with toxicity data post LED-irradiation to assess FCD-3 capability for photothermal therapy. 
For LED-irradiation studies, under the same conditions toxicity was assessed in the same way having 
introduced a 30, 60 or 90 minute LED-irradiation ( λex 420 nm) step. Directly after this step, the media 
was exchanged to remove non-internalised material before an incubation period and cytotoxicity 
assays were conducted.   
 
For HeLa, 30 minute LED-irradiation had a toxic effect with an IC50 of 10 µg ml-1 after 1 day compared 
to  250 µg ml-1 without irradiation. Upon longer irradiation time the toxicity effect was increased and 
as before longer exposure up to 3 days had greater toxicity effect. Reductive metabolism followed 
similar trends. However, for HDF this was not the case, under even the longest LED-irradiation time 
(90 minutes) the toxicity did not exhibit a dose-resposnse curve within the concentration range 
measured (up to 500 µg ml-1). Furthermore, with any of 30, 60 or 90 minute LED-irradiation, after 3 
days the viability is greater than control showing cell population survival similar to non-irradiated 
controls. This is likely due to the lower uptake of FCD-3 by HDF and illustrates the non-harmful effect 
of the LED-irradation by itself. These results show that that FCD-3 has a cancer cell selective toxic 








Figure 5.7 Toxicity and reductive metabolism data for HeLa and HDF cells treated with FCD-3 for 2 hrs and LED-irradiation 
for 90 mins after 1hr, 1day and 3 days. A) HeLa reductive metabolism B) HeLa viability C) HDF reductive metabolism D) HDF 
viability. 
5.3 Aims  
 
Having outlined the results conducted by Stephen Andrew Hill, we aim to understand the effects 
observed in more detail and the underlying key features of the CD responsible for the different 
intracellular uptake and killing mechanism, which is not observed with the blue emissive long linker 
CDs (Chapter 2).  
 
Initial experiments involved size exclusion chromatography (SEC) to investigate if there were carbon 
dots with distinct spectral profiles within a heterogeneous population. This would be supported by 
Ding et al. where they were able to isolate 8 carbon dots synthesised from p-phenylenediamine with 
distinct spectral profiles from one reaction mixture252. Furthermore, Jiang et al. saw larger 
nanoparticle diameter (6-10 nm) correlated with a more red-shifted fluorescence profile in carbon 
dots synthesised from the 3 isomers of phenylenediamine250. Hence, our material having a diameter 
distribution between 6-9 nm could feasibly be composed of CDs with differing fluorescence profiles 
which together produce a fluorescence peak at 525 nm. 
 
Initial SEC interestingly fractionated our material into 2 main fractions: the small molecule 2,5-
deoxyfructosazine termed 4 and a carbon dot termed FCD-5. Thermogravimetric analysis (TGA) data 
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suggested that there is organic material (around 50%) of the nanoparticle which can be destroyed by 
heating to 650 oC which is not incorporated in the core, supporting a core/corona model as is common 
with carbon dot structure with a tuneable surface. Hence, we aimed to characterise further the 
surface groups, determining structure and hopefully being able to correlate it to the LED induced 
toxicity observed.  
 
In our work, we explored the importance of 2,5-deoxyfructosazine and its photothermal therapeutic 
effect when associated with a carbon dot having been synthesised in-situ as part of a facile carbon dot 
microwave reaction. Literature evidence suggests that passivating the surface of carbon dots leads to 
improved quantum yield and in some cases more red-shifted spectral properties. 2,5-
deoxyfructosazine is thought to act as a passivating agent and in our system we aim to assess the 
fluorescence profile of our carbon dot with and without the surface associated small molecule. 
Furthermore, we aim to explore the implications of the surface functionality on the cytotoxicity of this 
material. Isolating the small molecule from the surface of the carbon dot, we were able to assess the 
toxicity of each component separately.  
 
By understanding the mechanism of killing of FCD-3 we aim to determine if our system is working 
through a PDT or PTT pathway or a combination of both. The fluorescence window of our material 
would suggest PDT methods, generating ROS as the basis for cytotoxicity. However, literature 
evidence also supports the idea that 2,5-deoxyfructosazine can provide energy levels within the 
spectral band gap of the carbon dot, facilitating energy release in the form of heat which would 
support a PTT pathway. Furthermore, results by Stephen Andrew Hill256 indicate that ROS weren’t 
generated and thus it suggests this mechanism might not be the basis for toxicity suggesting the 
nanoparticle confers good photothermal conversion and offers potential for PTT which would be novel 












5.4 Results and discussion. 
5.4.1 FCD-3 Synthesis  
 
Carbon dots were synthesised according to the protocol developed in the Galan group previously as 
described in Stephen Andrew Hill’s thesis83, as seen in scheme 5.1. Glucosamine.HCl and m-
phenylenediamine starting materials were combined in a 1:1 H2O:EtOH solvent mixture and heated in 
a domestic microwave reaction for 3 mins. A brown viscous oily material was afforded, which was 
green fluorescent under UV light. The glucosamine.HCl was included in this synthesis as work from 
our group and others62  was shown to be a good starting material for carbon dot formation as also 
seen when accessing AmCD 16 synthesis in chapter 2 (section 2.2.1.1). The m-phenylenediamine 
component was added as it has known doping effects attributed to its nitrogen content and has been 
used in other literature carbon dot syntheses. Initial purification of FCD-3 entailed dialysis purification 
of the crude mixture using a 10,000 MWCO cellulose membrane in H2O overnight. FCD-3 was freeze 
dried before further use. FCD-3 was functionalised with succinic anhydride to afford acid functional 
groups on the surface, followed by amide coupling with 1-amino mannose in an analogous manner to 
that carried out with AmCD 16 as shown in chapter 2 (section 2.2.1.1 and 2.2.1.5 respectively)1.  
 
 




Scheme 5.1 FCD-3 synthesis  
 
Further purification was carried out of FCD-3 to better understand the composition of the green CD. 
To that end, FCD-3 was eluted through a sephadex G15 size exclusion column (eluting MeOH) and two 
main fractions were observed with numerous other smaller fractions (Scheme 5.2). The two main 
fractions were collected. The first was a material weakly bluish-green fluorescent by eye under UV 
light. The second was a green fluorescent (under UV light) material. Both fractions were further 
characterised by NMR and the first fraction was termed FCD-5.  
 
From our initial evaluation and purication of FCD-3 , it became apparent that the nanomaterial was 
comprised of an amorphous core with a small molecule or molecules coating the surface. Size 
exclusion choromatography (G15 Sephadex) was then used to purified  the small surface molecules 
from bigger fragments and the core. This afforded two fractions, a green fluorescent fraction which 
upon further NMR characterisation was assigned to 2,5-deoxyfructosazine (4) and a blue fluorescent 
fraction which from DLS measurements gave similar size distribution 9-11 nm to the original FCD-3, 




5.4.2 FCD-3, 4 & FCD-5 Characterisation  
 
4.4.2.1 Surface group determination  
 
FCD-3, FCD-5 and 4 were further characterised using a battery of techniques. 
1H NMR was used to identify 4 (Scheme 5.2) as 2,5-deoxyfructosazine which had identical NMR shifts 
as a commercial sample (Figure 5.9a). Hence, the main component in FCD-3 1H NMR spectra (Scheme 
5.2) is 2,5-deoxyfructosazine. Compound 4 appears to be also present on the surface of FCD-5 in trace 
amounts compared to that present on the surface of  FCD-3.  
 
 















































































































































































































































































































































































































































































5.4.2.2 Proposed Mechanism of 2,5-deoxyfructosazine formation 
 
As previously mentioned, carbohydrates such as glucosamine have been used as a precursor for a 
number of carbon dot syntheses to date (section 1.4.2.2). Bhattacherjee et al257. showed that in a self-
condensation reaction fructosazine is formed from glucosamine (Scheme 5.3). The reaction between 
an amine group and carbohydrates to form heterocyclic molecules which are known as advanced 
Maillard reaction products255 such as fructosazine and 2,5-deoxyfructosazine. Both fructosazine and 
deoxyfructosazine have been found in foods including roasted peanuts and caramel255, while the use 
of 2,5-deoxyfructosazine in beer production has been patented as a colourless flavour additive and is 
made in a controlled reaction of glucosamine258.   
 
The family of advanced Maillard reaction products are known to act as photosensitizing molecules in 
combination with UVA and UVB light to either produce free radicals or form singlet state 1O2 which 
reacts locally with proteins and lipids in the cell. This is thought to be the basis for bactericidal toxicity 






showed that heat resistant E. Coli can be killed using fructosazine, which is an important consideration 
as strains with both virulence and heat-resistance could evolve259. 
 
Furthermore, studies in mammalian Caco-2 cell line from the intestine showed that fructosazine was 
readily taken across the epithelial barrier facilitated by natural hexose transporters GLUT1 GLUT2 and 
SGLT. Glucose transport via GLUT1 is known to rely on the hydroxyl groups and hydrophobic pyranose 
ring interacting in the protein in a non-specific way. Hence, it is proposed that fructosazine navigates 
the channel via the same interactions due to similar structural motifs257.  
 
 
Scheme 5.3 Mechanism of fructosazine and 2,5-deoxyfructosazine formation from glucosamine. 
 
 
Using 1H NMR with an internal standard, the amount of 2,5-deoxyfructosazine on the surface of FCD-
3 and in the sample 4, was calculated comparing with commercial 2,5-deoxyfructosazine. For each mg 
of 2,5-deoxyfructosazine in FCD-3, 4 had 2.14 mg. For FCD-5, in NMR the 2,5-deoxyfructosazine peaks 
were not visible. Hence the concentration was assumed to be negligable. FTIR data showed that FCD-
3 contained a peak at 3338 cm-1 which correspond to O-H and N-H bonds. These peaks were not 
present in FCD-5. This suggested amine functional groups on the surface could be present on the 
surface of FCD-3 as seen with AmCD 16.   
 
5.4.2.3 DOSY of FCD-3, 4 and FCD-5 
 
Having isolated and identified the structure of 4 from the surface of FCD-3 further characterisation 
was carried out in the form of DOSY to investigate how 2,5-deoxyfructosazine was associated to the 
carbon dot or if it was a separate molecule. Diffusion ordered spectroscopy (DOSY) can be used to 
determine the diffusion coefficient of a molecule or particle in solution. The diffusion coefficient 
describes the molecules translational movement and hence the coefficient describes the speed of the 
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molecule. If a molecule or particle is bound to another particle or molecule in solution, then the 
diffusion coefficient will be retarded. This is therefore useful to investigate binding to nanoparticle. 
DOSY has been used in this way for AuNPs labelled with dye to observe whether conjugation has 
occurred260. DOSY was shown to be used to measure AuNPs 2.7 nm and 4.6 nm in size through a 
thiolate group261. Polymers up to 100 nm have been studied by DOSY, but for metallic and 
semiconductor particles they should be within the 1-5 nm range262. The diffusion coefficient of 2,5-
deoxyfructosazine in the samples FCD-3 and 4 were compared to observe if the presence of carbon 
dot in FCD-3 retarded the diffusion coefficient compared to 4.  
 
DOSY experiment a FCD-3 showed that 2,5-deoxyfructosazine 4 was associated with the core in 
solution as the core and 2,5-deoxyfructosazine shared the same diffusion coefficient of 3.83 x10-6 cm2 
s-1 in FCD-3 (Table 5.1). 2,5-deoxyfructosazine was monitored by H1 peak at 8.53 and 8.71 ppm and CD 
was monitored by the peak at 3.22 ppm (Figure A.38). Diffusion coefficients which indicate no 
interaction between a nanoparticle and small molecule would be expected to be greater than an order 
of magnitude different form each other.  
 
Commercial 2,5-deoxyfructosazine and peaks corresponding to 2,5-deoxyfructosazine in the sample 4 
had diffusion coefficients of 3.56 x10-6 cm2 s-1 and 4.11 x10-6 cm2 s-1 respectively. These values are not 
an order of magnitude faster that seen in FCD-3 suggesting that the smaller molecule independently 
diffuses at a similar speed as the NP associated form. The commercial 2,5-deoxyfructosazine diffuses 
slightly faster than the 2,5-deoxyfructosazine in 4 which reflects the small amount of CD remaining in 
this sample with which it would interact. Overall, the DOSY data was not conclusive, and further 
experiments are needed to confirm this interaction. 
 
 







Sample Diffusion coefficients / x 10-6 cm2 s-1 Water diffusion coefficient/ x 
10-6cm2 s-1 
2,5deoxyfructosazine 3.56 1.63 
FCD-3 Fructosazine: 3.83      CD: 3.83 1.63  
FCD-5   5.50  1.52 





Transmission electron microscopy (TEM) was carried out on a batch of FCD-3 different to that used 
for the work carried out by Stephen Andrew Hill83 and at lower resolution (1200 kV). A new batch was 
synthesised to confirm synthesis reproducibility and TEM allowed CD size property to be assessed 
between batches. Mean dimeter by TEM is 7.1 ± 4.8 nm standard deviation (SD) (a bandpass filter and 
thresholding were applied before diameter was determined using Fiji software) as measured from 
images in figure 5.9. This diameter is larger than that measured by Stephen Andrew Hill83, perhaps in 
part owing to the resolution, the variation in purification, TEM sample preparation and the way the 
diameter was measured in Fiji. TEM therefore shows some slight difference in particle size. However, 
NMR data matched indicating the same material was synthesised between batches. 
 
 
5.4.2.5 DLS & Zeta potential 
 
DLS (number %) measurements show 4 and FCD-5 as aggregated with hydrodynamic diameters of 27.2 
± 0.9 nm and 159 ± 9 nm respectively (Fig 5.10a). These values are all much larger than 8.5 ± 4.2 nm 
observed for FCD-3. This value supports TEM determined diameter of 7.14 nm ± 4.76 nm (SD) as it is 
the same order of magnitude but a large value due to the hydration layer observed in DLS. FCD-5 and 
4 are likely to self-aggregate in H2O once separated from the nanoparticle FCD-3. Zeta potential 
measurements of FCD-3, 4 and FCD-5 are  8.53 ± 0.79 mV, 14.2 ± 1.9 mV and -3.52 ± 1.5 mV. The 
surface charge of FCD-3 reflects the measured charge of 4 and FCD-5 in H2O, i.e. it has a zeta potential 
  
Figure 5.9 TEM characterisation of FCD-3. A)&B) TEM images of FCD-3 (1200 kV). Mean diameter 7.14 ± 4.76 nm (SD). 




in between the two, meaning the charge of both FCD-5 and 4 likely contribute to the surface charge 
of FCD-3 (Fig 5.10b). The hydrodynamic diameter measured for FCD-3 8.523 ± 4.21 nm, in this batch 
is within the range 6-9 nm as measured by Stephen Andrew Hill in a different batch. The zeta potential 
8.53 ± 0.79 mV and that for the Stephen Andrew Hill batch 12.05 mV are similar in that they are 
positive and large. However, the difference indicates difference between batches which may reflect 
the amount of 2,5-deoxyfructosazine on the surface which is controlled by the reaction conditions.  
 
  
 Figure 5.10 a) DLS and b) Zeta potential of FCD-3,4 and FCD-5. 
 
5.4.2.6 UV-Vis & Fluorescence spectra  
 
  
Figure 5.11 a) UV-vis absorption spectra for FCD-3, 4 and FCD-5. b) Fluorescence excitation and emission spectra of 4. Peak 
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UV-vis absorption spectra Figure 9 presents data for FCD-3, 4 and FCD-5. FCD-3 shows a peak at 280 
nm corresponding to 𝜋 → 	𝜋 ∗ transitions from C=C/C=N bonds and 𝑛 → 	𝜋 ∗ transitions from 
C=O/C=N. These features are common to many carbon dots found in the literature.239,241 Furthermore, 
there is a tail toward 600 nm which corresponds to multiple optical states found in CD’s. 4 shows a 
similar spectrum to that of 2,5-deoxyfructosazine (Figure. 5.11) owing to the 2,5-deoxyfructosazine in 
the sample, with a peak at 280 nm whilst CD associated peaks are not observed. FCD-5 does not absorb 
much within the range 250-600 nm. All spectra show a strong absorption band < 230 nm indicating 
some surface aromaticity on the CD and from the fructosazine.  
 
Fluorescence spectra of 4 seen in figure 5.11, reveals a similar excitation and emission profile to that 
of FCD-3, with an excitation peak at 250 nm and emission peak at 525 nm. This reflects that there is 
some CD core remaining in 4 and the fluorescence profile is made up of both 2,5-deoxyfructosazine 




FTIR was carried out on FCD-3, 4 and FCD-5 to investigate the surface functional groups present on 
the carbon dot surface and differentiate which peaks are from 2,5-deoxyfructosazine and the core 
(Figure 5.12). FCD-3 had peaks at 3338 cm-1 (O-H stretch/N-H bend), 1629 cm-1 (O-H stretch/N-H 
stretch), 1016 (C=O stretch) cm-1 and 612 cm-1 (C-Cl stretch). 4 has peaks at 3323 cm-1 (O-H stretch/N-
H bend), 1634 cm-1 (C=C stretch),1434 cm-1(O-H bend), 1040 cm-1 (CO-O-CO stretch), 567 cm-1 (C-Cl 
stretch). FCD-5 has peaks at 1614 cm-1 (C=C stretch/C=N stretch), 1326 cm-1, 987 cm-1, 832 cm-1 and 
695 cm-1 (C-Cl stretch).  
 
Surface quantification through fluorine NMR (section 5.4.2.1.1) shows that FCD-3 has amine groups 
on the surface which are attributed to the 3338 cm-1 peak. FCD-5 does not have this peak suggesting 
the core does not have amines on the surface. The same peak is present in 4, however, this is likely 
due to O-H groups of the molecule. The peak at 1324 cm-1 unique to FCD-5 could be aromatic amine 
(C-N) or phenol (O-H) which are both possibilities as carbon dots are known to have both sp2 and sp3 

















































5.4.3 Cell studies  
 
5.4.3.1 Cytotoxicity  
 
Having identified 2 major isolated components  (4 & FCD-5) of FCD-3. Cell cytotoxicity studies were 
carried out where each individual component and FCD-3 were evaluated in the absence and presence 
of LED ilumination and evaluated for their ability to induced cytotoxicity. These experiments would be 
able to help us identify which components were responsible for the bioactvity previously observed. 
 
FCD-3, 4 and FCD-5 were incubated with HeLa and toxicity was assessed at 1 hr, 8 hr and 24 hr as 
previously done in section 5.2.2.8 and results compared. For these experiments concentration of 
nanomaterial was corrected using the known mass of 2,5-deoxyfructosazine in each sample to be 
made consistent between FCD-3 and 4. FCD-5 had negligible 2,5-deoxyfuctosazine present by NMR, 
so in each case the mass concentration used was the same as FCD-3 (Fig.5.8).  
 
3323 cm-1 (O-H/N-H) 












Similar toxicity for FCD-3 was observed in these results as those carried out by Stephen Andrew Hill 
(Figure 5.8), toxicity began emerging in both sets of data after 24 hr with 50 𝜇g ml-1 FCD-3 treatment 
and similar trends continue at higher concentration. Comparing the toxicity of 4 and FCD-5 shows a 
similar concentration dependant effect to FCD-3 at 24hrs. FCD-5 interestingly shows comparatively 






Figure 5.13 Toxicity data of FCD-3, 4 and FCD-5 in HeLa cells using Calcein and AB as indicators of viability and reductive 
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5.4.3.2 LED-irradiation cytotoxicity  
 
Working with CDs which absorb in the UV-visible region we were able to conduct photothermal cell 
experiments with cheap and easy to use LED lights (𝜆&' 460 nm). Following the protocol previously 
developed, FCD-3, 4 and FCD-5 were assessed as toxic agents when combined with LED irradiation. 
Furthermore, experiments were carried out to evidence the localised heating effect we hypothesised 
was the mechanism by which FCD-3 exerts toxicity. The global temperature rise of the cell media 
(without cells) over time upon LED irradiation was measured as a function of concentration of FCD-3, 
4 and FCD-5.  
 
Toxicity and reductive metabolism assays were measured after treatment with FCD-3, 4 and FCD-5 
after 60 minutes of  LED-irradiation to determine which components cause the toxic effect observed 
previously with FCD-3. Concentrations of 50 and 100 𝜇g ml-1 were chosen as good concentrations with 
which to see differences in toxicity between FCD-3, 4 and FCD-5 (Figure 5.14). As there appeared 
differences in toxicity at these concentrations at 24 hr compared to control in figure 5.15. After 1 hr, 
1 day and 3 days calcein and alamar blue assays were conducted. Toxicity data after 1 day and 3 day 
clearly show a marked decrease in cell viability compared to control for FCD-3 only. At 50 𝜇g ml-1 20% 
viability is observed and 10 % at 100 𝜇g ml-1. After 3 days viability is < 10 % for both concentrations. 
Comparatively, 4 and FCD-5 show no significant viability decrease at any of these concentrations or 





















Figure 5.14 Toxicity data of HeLa cells upon LED irradiation. Data from Calcein and AB assays assessing viability and reductive 
metabolism respectively are presented as % of control data. Time points 1 hr, 24 hr and 72 hr were observed. Blue bars 
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Figure 5.15 Toxicity data of HeLa cells without LED irradiation. Data from Calcein and AB assays assessing viability and 
reductive metabolism respectively are presented as % of control data. Time points 1 hr, 24 hr and 72 hr were observed. Blue 
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5.4.3.3 Control experiments  
 
Control experiments aimed to determine whether the media (or H2O) alone showed the same 
temperature change as when cells or nanomaterial were present. Control experiments were carried 
out under the same conditions as previous LED-irradiation experiments. FCD-3, 4 and FCD-5 were 
maintained at 50 𝜇g ml-1 and irradiation time was 60 minutes. Temperature change maxima of 12-15 
oC was observed for both DMEM high cell culture media and H2O. FCD-3 in both media and H2O had a 
steeper gradient and greater temperature change then 4, FCD-5 or solution without nanomaterial 
(Figure 5.16).  
 
Figure 5.16 Control experiment measuring the temperature change of H2O and DMEM high cell culture media with 
nanomaterial FCD-3, 4 and FCD-5 in a 96-well plate without cells present. Starting temperature was room temperature of 
21.4 oC in each case and temperature was recorded over 90 minutes. Blue points: Control H2O or DMEM cell culture media 
only, red with FCD-3, green with 4 and purple with FCD-5. 
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Treatment with FCD-3 combined with LED irradiation was thought to create a localised heating effect 
at the nuclear accumulation site, inducing cytotoxicity. Control experiments were carried out with 
HeLa cells and FCD-3, 4 and FCD-5 to observe if the temperature of the local media changed as a 
function of UV-irradation and nanoparticle.  
 
HeLa cells seeded in a 96-well plate were treated with FCD-3, 4 or FCD-5 at concentrations of 1, 50, 
100 and 500 ug ml-1, at 37 oC for 2 hours and then the temperature was measured over a 90-minute 
period of LED irradiation at room temperature. The temperature change was plotted as a function of 
time. All non-irradiated experiments show a decrease in temperature as the wells cooled to room 
temperature over the first 10 minutes then maintained the same temperature over the remaining 
eighty minutes. All LED irradiated experiments showed a similar decrease before an increase in 
temperature up to 7 oC greater than that at the start of the experiment and up to 12 oC greater than 
room temperature. FCD-3 and 4 both show a positive concentration dependent heating effect (figure 
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Figure 5.17 Temperature change observed with and without LED-irradiation of DMEM media incubating HeLa cells. HeLa cells 
were treated with either FCD-3,4 or FCD-5 prior to recording and incubated at 37 oC for 2 hrs before temperature was recorded 
over 90 minutes of LED irradiation. Blue line: 0 ug ml-1, red 1 ug ml-1 , green 50 ug ml-1 , purple 100 ug ml-1 , orange 500 ug ml-
1 . 
 
5.4.3.4 Confocal microscopy 
 
Confocal microscopy was used to visualise 4 in HeLa cells having been incubated with nanomaterial 
for 6 hrs at 10 𝜇g ml-1 of 4 (figure 5.18). Grey values per treated cell were 20.7 ± 1.11 (SEM) compared 
to control of 7.0 ± 0.31 grey values per cell which were significantly different (P < 0.0001). The material 
4 was fluorescent however, the 2,5-deoxyfructosazine alone is not. This suggests that the FCD-5 CD 
remaining in 4 is crucial for its fluorescent property. Riboflavin molecules with known fluorescence254 
could be present in 4 could be one explanation for the fluorescence, or an interaction between the 
CD and 2,5-deoxyfructosazine. More work needs to be conducted to determine this. 
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Figure 5.18 A1) Confocal fluorescence image of 4 in HeLa cells, A2) brightfield A3) fluorescence and brightfield overlaid. B1) 
Confocal fluorescence image of control HeLa cells, B2) brightfield B3) fluorescence and brightfield overlaid. C) Bar chart of 





Correlative light and electron microscopy (CLEM) combines the advantages of light and electron 
microscopy to identify novel molecular information263. Light microscopy (LM) provides a wide field of 
view of a population of cells for high-throughput analysis. Most usefully confocal microscopy can 
provide sub-cellular fluorescence information. Electron microscopy (EM) provides high resolution – 
down to an atomic level – imaging but at the cost of the field of view. In this way LM acts as a live cell 
imaging honing technique before cells of interest are fixed and sectioned into 70 -140 nm slices for 
ultrastructural imaging by EM. At this resolution nanoparticles with high electron density such as 
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CLEM was carried out to visualise FCD-3 localisation in cells. Fluorescence evidence from confocal 
indicates that FCD-3 localises in both the nucleus and cytoplasm (Figure 5.19 B1). Average grey values 
per cell is 94 ± 62 (SEM) whilst control has 27 ± 0.33 grey values per cell which were significantly 
different (P < 0.0001). Cells used for quantification were those within the focal plane. Cells were 
incubated with 33.3 𝜇g ml-1 FCD-3 for 6 hrs.  
 
   
   
                   
 
                                                  
Figure 5.19 Confocal tiled images of FCD-3 in HeLa cells for CLEM. A1) Confocal fluorescence tiles images of control HeLa cells 
A2) brightfield A3) fluorescence and brightfield overlaid. B1) Confocal fluorescence image of FCD-3 treated HeLa cells B2) 
brightfield B3) fluorescence and brightfield overlaid. C) Bar chart of fluorescence in grey values per cell measured between 



















































   
Figure 5.20 CLEM image of control HeLa cell 1 generated from confocal and EM image of the same cell overlaid. A) EM image 
of healthy control HeLa cell 1 B) Confocal image of healthy control HeLa cell 1. C) CLEM overlaid image of A&B. D) Magnified 







Looking at these cells at higher resolution through TEM we aimed to generate further evidence for 
their uptake and localisation at the nucleus. Areas of high fluorescence in both FCD-3 and control 
samples were imaged via EM up to 200,000x magnification. Features tens of nanometres large were 
observed, but all were common between control (Figure 5.20 e and S.8g&h) and FCD-3 treated cell 
(Figure S.10g) suggesting them as native features such as ribosomes (~20 nm). On the nano and micron 
scale, features were seen which were not natural to the intracellular environment, but clearly 
identified as stain within certain organelles due to the very heavy contrast. Most images show this but 
this is well illustrated in figures S5.7 a&b, S5.8 a (control cell) and 5.20f, 5.22a and S 5.10b,c&d (treated 
cell). Furthermore, there were larger micron sized features which were loose pieces of stained 
material which were also observed covering the Formvar grid membrane in places, figure S5.8 a,g&h 
(control cell) and 5.22a (treated cell). Furthermore, some organelles likely golgi body or endoplasmic 
reticulum looked to be stained heavily, figure S 5.8f (control cell) and 5.20f, 5.22b,c&d and S5.10f 
(treated cell). 
 
CLEM images of FCD-3 treated cells were produced to identify intracellular areas from which high 
relative fluorescence originated. Magnified EM were then produced of these areas to observe FCD-3 
as well as imaging the nucleus at higher magnification to see if FCD-3 could be seen, which would 
support FRET experiment data (section 5.2.2.3) that FCD-3 enters the nucleus.  
 
Figure S5.9 shows 3 cells which were all of HeLa cells incubated with FCD-3, 2 of which are shown at 
further magnification in figures 5.21 and S5.9. From all images of these cells it can be said that 
treatment with FCD-3 at 33.3 𝜇g ml-1 for 6hrs did not diminish the health of the cells. Cellular 
membrane and organelles maintain their integrity to the same degree as control HeLa cells. This 
supports the non-toxicity of these nanomaterials observed through cytotoxicity assays under these 
same conditions.  
 
From figure 5.21, fluorescence can clearly be observed localised at high concentration at the 
perinuclear region, whilst also diffuse throughout the cell. EM images were taken of these areas of 
high fluorescence; however, no features were observed different from control cells. Figure 5.22 shows 
one cell with 3 regions marked in 5.22a which are magnified in 5.22b,c&d. In 5.22b,c&d organelles 
around the vacuole corresponding to areas of high fluorescence are stained darker in EM. Within these 
regions no features not found in control samples can be identified. Similar to control samples, 
organelles are stained heavily, and larger micron and nano sized particles are observed – which do not 
correlate with regions of fluorescence. Figure S5.10 shows a second HeLa cell treated with FCD-3. 
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CLEM figure S5.10 shows the same perinuclear fluorescence seen in the figure 5.21, likely due to FCD-
3 fluorescence. EM images similar to the cell in figure S5.10 a-g, only shows features also observed in 
control cells such as staining (Figure S5.8 a and S5.7a&b), nor does fluorescence correlate with any 
structures observed. Looking at the nucleus of this cell did not reveal novel features compared to 





Figure 5.21 CLEM image of HeLa cell 2 incubated with FCD-3. A) EM image of HeLa cell 2 incubated with FCD-3 B) Confocal 
image of HeLa cell 2 incubated with FCD-3. C) CLEM overlap of EM and fluorescence images A&B. Areas of high fluorescence 










Figure 5.22 EM images of HeLa cell 2 treated with FCD-3. A) Whole cell image B,C&D) areas magnified areas from A.  
 
Looking at confocal microscopy images of FCD-3 treated HeLa in figure 5.22 c and S 5.10 h shows that 
FCD-3 has clearly been internalised. This is evidenced by significant fluorescence observed in FCD-3 
treated cells compared to control. Fluorescence is both diffuse throughout the cytosol but also areas 
of high fluorescence are localised at the perinuclear region. However, no features could be identified 
using the high-resolution technique of EM correlating to these regions of higher fluorescence. 
 
Working with low density carbon dots and the stained cellular background provides a challenging 
sample in which to observe FCD-3 nanoparticles. This was due to uranyl acetate stain, osmium 
tetroxide contrast enhancing stain and resin density. Furthermore, considering the relative heavy 










detect in TEM within the cellular environment. Literature evidence assessed through Web of Science 
does not report carbon dot CLEM to date (as of 11th March 2020). 
 
An abundance of fluorescence from FCD-3 intracellularly suggests that nanoparticles in those areas 
are not aggregated to a degree that induced quenching. This supports the conclusion that larger 
features observed were stain and debris rather than aggregated nanomaterial. In order to better 
visualise single FCD-3 nanoparticles an experiment using unstained cellular material with dark-field 
energy filtered TEM (EFTEM) could provide better contrast between the nanoparticles and cell. For 
example fluorescent nanodiamond of 62.7 nm diameter was observed through EFTEM which was not 
possible with CLEM and standard TEM.265 
 
5.5 Conclusions and Future work  
 
Owing to the low toxicity of our FCD-3 nanoparticle to both healthy and cancerous cells without 
external stimulus, tight control can be exerted over cancer cell cytotoxicity through LED irradiation. 
Toxic effect is only present when both 4 and FCD-5 are present in the form of FCD-3 upon LED 
irradiation. The toxic effect observed in a cancerous cell line, HeLa, for this combination, is greater 
than the toxic effect observed for 4 or FCD-5 alone. Through confocal microscopy we observe 
significant FCD-3 uptake compared to control, suggesting that the combined CD core and 2,5-
deoxyfructosazine is readily up taken by cancer cells. Furthermore, we suggest a local heating effect 
induced by LED irradiation when the CD core is present intracellularly which is responsible for the 
marked cytotoxic effect we observe after 24 hr. The LED dependent cytotoxicity is supported by 
general cell media temperature increase of 12 oC which agrees with previous data (section 5.4.3.4), 
showing a lack of correlation with ROS or metabolite production but increased ATP production. ROS 
production is an energy consumptive process and indicates worse photothermal conversion. The lack 
of ROS production and the increase in cell media temperature corroborates the idea that primary PTT 
effects, with high temperatures of 48-60 oC, can be achieved with FCD-3.  
 
Confocal microscopy provides evidence for the uptake of FCD-3 and 4 by the cancerous cell line HeLa.  
Perinuclear localisation can be seen through areas of high fluorescence intensity in confocal images. 
Without organelles trackers it is difficult to identify where carbon dots maybe localising. Overlaying 
these confocal images with EM allowed for high-resolution imaging of these areas of high fluorescence 
with the aim of observing FCD-3 material. However, this did not reveal any sub-micron structures 




Figure 5.19 depicts the uptake of 4 into HeLa cells. 2,5-deoxyfructosazine is a non-fluorescent 
molecule (confirmed with commercial 2,5-deoxyfructosazine), hence the green fluorescence that we 
observe must be due to the residual carbon dots in 4 which we know are present from NMR. 
Compared to FCD-3, 4 had 2.4 times more 2,5-deoxyfructosazine present confirmed by NMR Figure 
5.8. 
 
The CD component still present in 4 is therefore important for the fluorescence peak at 525 nm (Figure 
5.11 and S5.6). The emission spectra of FCD-3 and 4 are identical and the excitation spectra both peak 
at 450 nm. However, the excitation spectra differ in shape reflecting the amount of CD present in the 
sample (Figure 5.11). DOSY shows that CD peaks and 2,5-deoxyfructosazine share a similar diffusion 
coefficient suggesting they at physically associated in solution. This interaction is likely the basis for 
the fluorescence observed when both components are present. 
 
The significant uptake of FCD-3 compared to control cell line (as found by SAH) could be explained 
through consideration of the requirements of cancer cells. In cancer cell lines including HeLa glucose 
uptake is upregulated to meet metabolic demand due to fast growth and high proliferation. In HeLa 
this is mediated by overexpressed GLUT transporters 1 & 3266. Hence, the 2,5-deoxyfructosazine 
coated FCD-3 which contains hydroxyl groups similar to carbohydrates could promote uptake through 
these channels.257 This could be tested through active versus passive cell uptake experiments at 4 oC.   
 
Further work which could be conducted is as follows. Improving the NIR (650 – 950 nm) absorption of 
our nanoparticle by including new materials into the synthesis such as NIR absorbing molecules or 
exploring the synthesis reaction parameters such as reagent ratios and reaction time may produce a 
material with the cytotoxic properties of 2,5-deoxyfructosazine and allow for absorption in the NIR 
region. This would facilitate in vivo studies to be carried out, and organ and tumour localisation studies 
to be investigated. Furthermore, known anti-microbial properties could be explored with FCD-3 (2,5-
deoxyfructosazine containing) and LED-irradiated before comparison to work by Bhattacharjee et 
al.267 with fructosazine.  
 
Further exploration of cancer cell targeting could be though functionalisation of the FCD-5 core and 
recombination with 4 to form modified FCD-3 variants with differing targeting capabilities. Following 
previous work in the Galan group where lactose can be used as a means to promote nanoparticle 








































5.6 Chapter 5 Experimental  
5.6.1 Synthesis  
 
1) Synthesis of FCD-3  
 
To a solution of Glucosamine.HCl (1 g, 4.63 mmol) in deionised water (20 mL), was added m-
phenylenediamine (0.55 g, 5.1 mmol) as a solution in MeOH (10 mL). The solution was agitated by 
sonication until the mixture was homogeneous and then transferred to a 250 ml Erlenmeyer flask 
before microwave synthesis for 3 minutes at the centre of a domestic microwave (800 W, 80 % power 
setting). A viscous brown solid was afforded which was then solubilised in distilled H2O before filtering 
using a 10,000 MWCO Vivaspin 20 spin concentrating falcon. The bulk solution was then lyophilised 
to yield FCD-3, a brown oil-like material (1 g) before further use. 
 
5.6.2 NMR characterisation of synthetic FCDs  
 
FCD-3 and 4 1H NMR (500 MHz) spectra match the commercial 2,5-deoxyfructosazine spectra (all 
presented in figure 5.9). 
 
FCD-3  
(2,5-deoxyfructosazine structure):  
1H NMR (500 MHz, Deuterium Oxide) δ 8.58 (d, J = 1.4 Hz, 1H, 1a), 8.40 (d, J = 1.4 Hz, 1H, 1b), 5.02 (d, 
J = 2.3 Hz, 1H, 4), 3.90 (ddd, J = 9.7, 6.2, 3.3 Hz, 1H 10,2,3,1a,12a), 3.80 – 3.65 (m, 4H, 2,3,1a,12a), 3.63 
– 3.48 (m, 4H, 11,1b,12b), 3.09 (dd, J = 14.3, 3.3 Hz, 1H, 9a), 2.85 (dd, J = 14.3, 9.8 Hz, 1H, 9b).  
13C NMR (126 MHz, Deuterium Oxide) δ 153.95 (C5) 153.18 (C7), 144.06 (C8) 142.15 (C6), 74.39 (C11), 
73.36 (C2), 71.31 (C4), 71.26 (C10), 70.99 (C3), 62.90 (C1), 62.43 (C12) , 37.49 (C9). See figures S.11 
and S.12 for spectra and 2,5-deoxyfructosazine structure which the peaks here are assigned to.  
 
4) Isolation of 4 & FCD-5 from FCD-3 
FCD-3 were subjected to G15-Sephadex size exclusion column (35 x 1.7 cm) chromatography in 




5.6.2 Cell studies experimental  
 
Confocal 
1x104 HeLa cells (100 𝜇L) were plated in a 96 well plate and left for 16 hr to adhere at 37 oC. The next 
day 4 was incubated with HeLa cells for 2 hrs at 10 𝜇g ml-1. Live cells were imaged using Multi-laser 
CLSM Leica SP8 AOBS attached to a DM I6000 inverted epifluorescence microscope at 40x 




Confocal imaging was carried out on live HeLa cells before fixing and sectioning for electron 
microscopy. 2.5x104 HeLa cells (250 𝜇L) were plated in gridded confocal dishes and left overnight to 
adhere at 37oC. The next day FCD-3 was incubated with the cells for 6 hrs at 33.3 𝜇g ml-1 (300	𝜇L). Live 
cells were imaged in a 50x50 𝜇M area using Multi-laser CLSM Leica SP8 AOBS attached to a DM I6000 
inverted epifluorescence microscope at 40x magnification in buffered live imaging media (65 mW Ar 
laser, λex 488 nm at 5.44% power, λem 500-600 nm).  
 
Fixing cells  
Cells were fixed using sodium cacodylate solution (1 mL, 0.1 M pH 7.2 plus 2.5% glutaraldehyde) for 5 
mins. Cells were then rinsed with distilled H2O. before staining with 4% Osmium Tetroxide in H2O (0.5 
mL), for 30 mins. Cells were then stained with 0.5% uranyl acetate in H2O (0.5 mL) for 30 mins. Samples 
were then dehydrated over 25 mins, with 5 mins at increasing concentration of ethanol at 70, 80 90, 
96 and 100%. Epon solution (1 mL) was added to each sample and cured for 2 days using an oven.  
Liquid nitrogen was used to freeze and break off the confocal dish from the cured sample.  
 
Sectioning samples  
Samples were sectioned into 70 nm thick slices using a glass knife in preparation for electron 
microscopy. Areas chosen for each sample which were identifiable in corresponding confocal 
microscopy images for correlation purposes. Sections were floated on water and mounted onto 
Formvar/Copper TEM grids and dried overnight before imaging. TEM was carried out using a FEI Tecnai 
12 120kV BioTwin Spirit TEM. Images were then correlated in Fiji image processing package. Sodium 
cacodylate solution was purchased from Sigma Aldrich. Uranyl acetate and osmium tetroxide were 





HeLa cells were plated at 1x104 cells per well (100 𝜇L) in a 96-well plate and incubated overnight. The 
next day cells were incubated with either 3, 4 or 5 in triplicate at concentrations between the range 
500 𝜇g ml-1 and 0.01 𝜇g ml-1. After incubation with nanomaterial for either 1 hr, 8 hrs or 24 hrs cells 
were washed thrice with PBS and then Calcein AM and Alamar blue toxicity assays were carried out. 
 
LED irradiation toxicity experiments  
In a 96-well plate 1x104 HeLa cells (100 𝜇L) per well, were treated with FCD-3, 4 or FCD-5 in triplicate 
for 2 hrs at 37oC. For FCD-3 and FCD-5, 50 and 100 𝜇g ml-1 were used. For 4, 23.8 and 47.6 𝜇g ml-1 
were used in place respectively. Following 2 hr exposure, plates were irradiated with LEDs for 60 mins. 
LED lights (𝜆&' 460 nm) were purchased from LightingEVER ~4100057-BLUE, 12 V, 24 W. At room 
temperature LED lights were mounted onto a black carboard platform upon which clear 96-well plates 
containing cells, were stilted on Eppendorf lids with an opaque covering placed over the top. Control 
experiments were conducted under the same conditions in the dark without LED lights present. Post 
irradiation cell media was exchanged for fresh media not containing any nanomaterial and maintained 
at 37oC. After F1 h, 24 hr and 72 hr toxicity was determined using Calcein and AB assays.  
 
LED irradiation temperature experiments 
Temperature assays upon LED irradiation followed a similar protocol as above with HeLa cells and with 
a non-irradiated control run in parallel. Post irradiation, cell media was not exchanged and instead the 
temperature of the media bathing the cells was recorded over 90 mins at a time interval of 5 mins 
between 0 – 40 mins and every 10 mins between 40 and 90 mins. A Thermocouple (type K from Fisher 
Scientific) was used to record temperature to 1 decimal place.   
 
A second set of control temperature assays, without cells present using a similar protocol was carried 
out in both H2O and DMEM cell culture media. Per well of a 96-well plate, 100 𝜇L of media or H2O with 
either FCD-3, 4 or FCD-5 was placed at room temperature. Upon LED irradiation the temperature was 
measured over 90 mins at 1 min intervals between 0 – 15 min and every 5 min from 15 – 40 min and 







Supplementary Figure 5.1 Histogram of TEM image of FCD-3 carbon dots in figure 3. 
 
Supplementary Figure 5.2 Dynamic light scattering average hydrodynamic diameter of FCD-3 (% number) data. Peak 
between 6-9 nm. 
 
 
Supplementary Figure 5.3 Zeta potential average charge of 12.05 mV of FCD-3. 





























Supplementary Figure 5.6 Fluorescence spectra of FCD-3. Excitation independent emission at 525 nm. 
 
 

















2,5-deoxyfructosazine UV-vis absorption 
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Supplementary Figure 5.7 Healthy control HeLa cell 1 a) white box identifying the cell within amongst others on the grid. b) 












Supplementary Figure 5.8 EM of a healthy control HeLa cell 2. A) Shows HeLa cell in surrounding context B) Magnification of 








Supplementary Figure 5.9 EM image of three FCD-3 treated HeLa cells. Each of these cells were imaged further at higher 

















Supplementary Figure 5.10 CLEM of a second HeLa cell 3 treated with FCD-3. i) shows HeLa cell EM and confocal images 
overlaid in a CLEM image. A) TEM image of HeLa cell 3 B) Shows a magnification of HeLa cell 3 C,D,E,F,G) Show magnified 































6. General Experimental  
 
UV-Vis  
UV-vis was carried out using a Carys UV-Vis 50 spectrometer (Agilent) using a 1 cm path length quartz 
cuvette (Thor Labs). 
 
DLS and Zeta potential  
Dynamic light scattering and Zeta potential measurements were carried out using Malvern 
Instrument, Zetasizer Nano-S90 ZEN1690 and Nano-Z ZEN 2600 respectively. Samples were prepared 
in distilled water or 0.1 M HEPES buffer with 5 mM MnCl2 and 5 mM CaCl2 as specified. 70 𝜇L volume 
disposable micro cuvettes were used for DLS and disposable folded capillary cells DST 1070 for Zeta 
potential, both purchased from Malvern Panalytical.  
 
Fluorometer 
Fluorescence measurements were conducted on a PerkinElmer Fluorescence Spectrophotometer 
LS50B). The voltage was maintained at 700 V, whilst a 700 𝜇L quartz cuvette was used with pathlength 
1 cm for all measurements.  
 
NMR 
NMR measurements were carried out on either a Varian 500 MHz or Bruker 400 MHz machine as 
detailed for each spectrum in the appendix. Samples were made up to ~ 1 mg ml-1 in deuterated water 
before 1H, 13C or HSQC experiments were conducted. 
 
DOSY  
Diffusion ordered spectroscopy was carried out on a 500 MHz NMR machine with a relaxation delay 
of 2 second and samples were prepared in D2O. Data was processed using MestReNova software, 
Bernstein polynomial fitting and phasing were carried out on all spectra before peak fit model was 
used to plot data. Diffusion coefficients from different spectra were corrected against the water peak 
diffusion coefficient before comparing. 
 
Cell culture 
HeLa and MDA cells (ECACC, Public Health England) were maintained in Dulbecco’s Modified Eagle’s 
medium (DMEM) with 4.5 g glucose/L. MCF-7 cells were maintained in Minimal Essential Medium 
(MEM). All cell lines were kept at 37oC in antibiotic-antimycotic and Foetal Bovine Serum (FBS) at 10 




Calcein AM and Alamar blue (AB) toxicity assays 
These toxicity assays were carried out in tandem in all cases. Experiments were carried out in 96-well 
plate, post treatment cells were incubated for 1 hour in media containing 5% v/v Alamar blue, at 1 μM 
concentration Calcein and without FBS, total well volume 1 ml. Calcein is a measure of cell viability 
using Calcein AM which is reduced to Calcein (λex 483 nm, λem 530 nm) in live cells. The alamar blue 
assay active ingredient is resazurin which is reduced inside live cells to fluorescent resorufin (λex 555 
nm, λem 590 nm).  The amount of resazurin turnover positively correlates with cell metabolism. Dye 
fluorescence emission was measured using a Clariostar microplate reader. All cell culture and assay 
media and reagents were purchased from Invitrogen, Life Technologies (Thermo-Fisher).  




Resazurin is the non-fluorescent active ingredient in the commercially available cell metabolism test 
Alamar Blue. Upon incubation with cultured cells it diffuses across the cell plasma membrane where 
it can be reduced by cellular components to the red fluorescent Resorufin. Detecting the fluorescence 
of Resorufin at 590 nm allows quantification of the intracellular metabolism through a positive 
correlation. Increased cell metabolic activity is an indicator of cellular proliferation rather than a cell 
viability test.  
 
Cancer cells proliferate more than healthy cells, meaning that they grow and divide at a faster rate. 
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energy currencies such as NADPH, NADH, FADH. These molecules are responsible for reducing 
Reszurin to Resorufin during the Alamar Blue assay. Hence, living cancer cells exhibit a higher 
metabolic activity compared to healthy cells in the assay.  
 
Other methods of probing this include MTT, MTT/XTT and WST assays. Commonly used is the 
colorimetric MTT assay which similarly involves reduction by mitochondrial reductases of the 
tetrazolium salt MTT to formazan. However, this requires solubilisation before its absorbance can be 
read.  
 
Calcein AM is used as a means to test cell viability. Calcein AM can also cross the cell membrane and 
in the case of live cells, esterases present in the cytosol cleave the ester bond to produce Calcein which 
is green fluorescent. After this, calcein cannot cross the plasma membrane and leave the cell. 
Measuring fluorescence at 530 nm allows quantification of the number of live cells.  
 




Transmission Electron Microscopy (TEM) involves an electron beam interacting with a sample to 
produce a contrast image of ultra-high resolution. This technique supersedes light microscopy in terms 
of resolution due to the De Broglie wavelength of electrons being much smaller than light and allowing 
for atomic resolution imaging.  
 
An electron beam is produced from an emission source using high voltages commonly between 120 
and 200 kV, in a vacuum. Electrons interact and pass through the sample at points of low density and 
are unscattered, whilst areas of higher density scatter electrons and create dark areas on the detector. 
The sample must be less than 100 nm thin to allow for electron transmission. In the case of carbon 
dot imaging; because carbon is a relatively light element, the carbon film should be made thin enough 
to allow for contrast with the carbon-based nanoparticles.  
 
Scanning Transmission Electron Microscopy (STEM) is a type of TEM which has a more focused ion 
beam than standard methods which rasters across the sample. STEM can involve collecting only the 
scattered electrons from the sample using an annular dark-field detector. Combining this signal with, 
the dark-field image confers greater resolution. Furthermore, using STEM the elemental composition 
of a sample to be mapped through energy dispersive X-rays (EDX). When irradiated with electrons 
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elements emit characteristic x-rays which can be detected with a spectrometer. Combined with the 
high-resolution electron beam in STEM, a high-resolution elemental map can be made of the sample.  
 
 
7.2.2 AFM  
 
Atomic force microscopy (AFM) involves the physical probing of a sample using a scanning probe to 
provide atomic structural information. Resolution is much greater than with light microscopy, down 
to 0.1 nm. Most commonly AFM works via tapping mode to probe the surface of a sample using Van 
der Waal interactions between the sample and probe as the basis of signal detection. Tapping mode 
is an intermittent contact-based method with low level sample adhesion and friction. The AFM probe 
is commonly made of silicon with a high aspect ratio tip on the end with a diameter of ~ 40 nm. This 
large diameter means that the lateral resolution is low (~ 40 nm reflecting the tip diameter in the work 
presented in this thesis). However, in the height dimension, sub-nanometer resolution is detected.  
 
The cantilever is vibrated near its resonant frequency above the sample surface using a piezoelectric 
modulator. As it interacts with the surface intermittently, the oscillation amplitude changes which is 
used to calculate the tip to surface distance, via the z-feedback loop. In order to know the height of 
the probe itself, a laser is reflected off the back of the cantilever, which is detected by a photodiode. 
This all happens as the probe is rastering back and forth across the sample to build up an image of the 
surface. Tapping mode also allows for phase imaging to be conducted as the tip comes into contact 
with the sample surface. The difference in oscillation expected (from the piezoelectric modulator 
input) and measured can be converted into information about the material’s physical stiffness.   
7.2.3 Quantum yield (Qy) 
 
In order to assess the fluorescence potential of the singlet excited state of our carbon dots we 








For each carbon dot the quantum yield was determined by comparing against the widely used 
standard quinine sulfate. This dye is suitable for excitation in the range 310 – 360 nm and emission 
between 400 – 600 nm268, similar to the spectral features of our carbon dots. This dye has a quantum 




The absorbance of quinine sulfate is measured when < 0.1 a.u. to create a linear calibration curve and 
to minimise self-absorption effects and plotted against integrated fluorescence (400 – 560 nm). Using 
this we determined the percentage quantum yield values of our CD’s in table 2.5 according to the 
equation46:  







The integrated fluorescence (𝐼()) of the CD and quinine sulfate (𝐼+,) at the same absorbance (< 0.1 
a.u.) were determined experimentally over the linear portion of the absorbance v. integrated 
fluorescence relationship. The refractive index (𝜂()	&	𝜂+,) is η = 1.33 for aqueous media and the Qy 








The quantum yield for each CD-saccharide can be calculated from either a single integrated 
fluorescence point against absorption or for more reliable values, by plotting a line of linear regression 
from multiple measurements of integrated fluorescence against absorption.  
Then using the gradient of absorption against integrated area under the fluorescence intensity (400-
560 nm) for each CD-saccharide can be standardised against the gradient of the quinine sulfate 
reference curve to determine the Qy269.  











Dynamic light scattering uses the detected scattered light from a nanoparticle to determine the 
hydrodynamic size of said particle. Particles in solution move due to Brownian motion which is 
measured in DLS using a laser (633 nm) and detecting the backscatter from the particle, usually at 
173o to the angle of incidence. This allows for the diffusion coefficient to be measured from which the 





Where Dh = Translational diffusion coefficient (m2 s-1), kB = Boltzmann constant (m2kg Ks-2), T = 




 As particles diffuse and the detector records signals a trace is created. The frequency of fluctuations 
in the trace reflects the frequency of signal coming from the particles in solution. Hence smaller, faster 
moving particles create a trace with more fluctuations over time. This data is used to create an 
autocorrelation function which quantifies the time taken from a monodispersed sample signal to 
decay so that the signal no longer relates to the signal at time 0, which looks like a single exponential 
decay over time. This time taken is used to determine the translational diffusion coefficient (Dh) in the 
Stokes-Einstein equation, which is used to determine the hydrodynamic diameter.  
 
When looking for monodispersion, the poly dispersity index (PDI) can indicate whether you are seeing 
aggregation. The PDI is a measure of the broadness of the size distribution, the larger the value the 
more polydispersed the sample. Between 0.05 and 0.7 size data collected is reliable. Looking at the 
size distribution information, number, intensity and volume can provide further information on the 
populations of species in a sample.  
 
7.2.4.1 Volume, Number and Intensity distribution 
 
Each of intensity, number and volume distribution values reported are drawn from the same 
correlation function and interpret the scatter signal differently. Intensity data shows the raw 
scattering signal observed for each peak. Larger particles which scatter more (d6 according to Rayleigh 
scattering theory) will have a greater signal than the same number of particles of a smaller diameter. 
Hence, describing the proportion of sample making up each peak. The Z-average value reported is the 
mean of the intensity peaks and is best suited to describing monodispersed samples. 
 
Number and Volume data use Mie Theory to interpret scattering data. This takes into account the 
scattering potential of a particle of a certain size (from the correlation function) and composition 
(refractive index). Number distribution represents the number of particles of that size corrected for 
the scattering they produce. It describes the number of each type of species in solution. The volume 
distribution considers the size and number of species in solution and reports the volume of space they 
take up based on particles being spherical. Number and volume data contain more errors than 
intensity data as they contain added assumptions. However, being able to look at number data can 
reveal smaller aggregates or monodispersed CDs which may otherwise be occluded by larger 





When investigating an aggregating population and looking at the shift from monodispersed to 
aggregated number data allows smaller particles to be picked up when they may be missed in 
intensity-based measurements. Furthermore, when looking at a titration involving 2 components such 
as carbon dot and lectin, comparing like for like species removes certain errors associated with 
number measurements.   
 
7.2.5 Zeta potential  
 
Zeta potential (z ) refers to the electrochemical potential between the surface of a colloidal 
suspension and the dispersant it is in. The surface is usually referring to the slipping plane of the 
particle, where the free-flowing dispersant meets the stationary layer of dispersant associated with 
the particle (which is made up of an electrical double layer). The zeta potential value gained describes 
the net charge at the surface of a particle in a particular solution. This provides information on the 
colloidal stability of a particle, the higher the value the more stable it is.  
 
Upon the introduction of an electric field (E), particles which have a net charge will move. Using light 
scattering, the velocity (V) of these particles is measured and the electrophoretic mobility (μe) which 
is calculated according to: 
V = 	𝜇&E 




Where e is the dielectric constant, 𝜂 is the absolute zero-shear viscosity of the diluent and f(𝑘𝛼)	is 
Henry’s function. In the case of polar aqueous diluent f(𝑘𝛼) = 1.5 and in the case of non-polar diluent 
f(𝑘𝛼) = 1. 
 
For z measurements the dispersant is required to be conductive but below 5 mS/cm, for which 0.1 M 
HEPES (5 mM CaCl2 and 5 mM MnCl2) buffer is suited with a conductivity of 4.39 ± 0.41 mS/cm. This 
allows for an electrical current to be applied across the cell but not too high that the electrodes 
overheat and blacken. As a general rule higher z	 values correspond to more monodispersed particles. 
However, the zeta potential value indicating aggregation is particle dependent and should be 




7.2.6 UV-Vis  
 
Carbon dots have certain absorption characteristics seen through UV-Vis spectroscopy. Looking at this 
spectra can help characterise the origin of absorption, a peak between 200-250 nm can be assigned 
to 𝜋 − 𝜋* electronic transitions in C=C and C=N aromatic domains and a peak between 250 – 350 nm 
can be assigned to 𝑛 − 	𝜋* electronic transitions in C=O and C=N sp2 conjugation as well as carboxyl 
and amine groups in the edge states. The edge states refer to hybridised groups at the edge of 
graphene sp2 or crystalline domains270. Often a tail into the visible region (up to 800 nm) is seen 
reflecting the variety of surface states that exist on CDs. Each state could be seen as imposing its own 
small peak which when overlaid represent the CD surface whilst the peaks at 200 – 270 nm represent 
the core absorption and 280 – 350 nm represent the edge states between the core and surface271.  
                 
                                        
Analytical technique  1 Example UV-visible spectroscopy spectra. 
 
7.2.7 Photoluminescence  
 
Photoluminescence describes the light emitted following absorption of a photon by a molecule or 
material such as carbon dots. Multiple fluorescence centres exist in carbon dots reflecting their 
multiple absorption bands coming from any of the core, edge or surface states. Fluorescence resulting 
from core absorption, when the CD is well passivated, is excitation independent as it emits at one 
discrete wavelength. This is because the CD core often is similar in structure to a highly conjugated 
graphene molecule. Upon irradiating with higher wavelengths, the surface and edge states are 
excited, and they can fluorescence at a range of wavelengths red-shifted with respect to the excitation 
wavelength. The range of emissions reflect the range of hybridised groups and band gaps belonging 
to the CD.  
 
The energy in the LUMO band will relax (vibrational relaxation) to the lowest orbital before relaxing 
to the HOMO band where it can fluoresce. Hence, the surface state controls the final PL properties of 
the CD. Overall, depending on their structure and PL origin carbon dots can exhibit excitation 
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dependent or independent emission. Small surface molecules on the surface of the CD can have their 
own PL spectra, which is excitation independent. Solvent and pH can affect the surface group PL 











2.2.8 FTIR  
 
Fourier transformed infrared (FTIR) spectroscopy collects information on a samples IR absorption over 
a range of wavelengths 600-4000 cm-1. Different bonds absorb light of different frequencies over this 
range, hence FTIR is diagnostic of bonds and therefore functional groups presence in a material. 
Spectra shows peaks which dip downwards when light of that particular wavelength has been 
absorbed, and the fingerprint region unique to a sample is below 1500 cm-1. FTIR can be used in 
collaboration with other techniques as a means to identify a molecule. With carbon dots, it is used to 
identify the surface functional groups as they are accessible and able to absorb IR photons. Some CD 






































































































        
 



























































                              
 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A.38 DOSY of commercial 2,5-deoxyfructosazine  
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